# NATIONAL CARDIOVASCULAR DISEASE DATABASE (NCVD)

# Annual Report of the Percutaneous Coronary Intervention (PCI) Registry

# 2013 - 2014

Editors:

Wan Azman Wan Ahmad Liew Houng Bang

A publication of the National Heart Association of Malaysia (NHAM) and the Ministry of Health Malaysia

#### July 2016 © National Cardiovascular Disease Database (NCVD)

**Publisher:** 

Jointly published by the National Heart Association of Malaysia (NHAM) and the Clinical Research Centre, Ministry of Health Malaysia

#### National Cardiovascular Disease Database

c/o National Heart Association of Malaysia Heart House, Level 1, Medical Academies of Malaysia 210 Jalan Tun Razak 50400 Kuala Lumpur MALAYSIA

 Tel
 : (603) 4023 1500

 Fax
 : (603) 4023 9400

 Email
 : ncvd@acrm.org.my

 Website
 : http://www.acrm.org.my/ncvd

This report is copyrighted. It may, however, be freely reproduced without the permission of the National Cardiovascular Disease Database. Acknowledgement would be appreciated.

*Suggested citation:* W.A Wan Ahmad, H.B. Liew (Eds). Annual Report of the NCVD-PCI Registry, Year 2013 – 2014. Kuala Lumpur, Malaysia: National Cardiovascular Disease Database, 2016

#### Electronic version

The electronic version of this report may be downloaded at <u>http://www.acrm.org.my/ncvd</u>

#### Funding

The National Cardiovascular Disease Database (NCVD) - Percutaneous Coronary Intervention (PCI) Registry is funded with grants from the National Heart Association of Malaysia (NHAM) and the Ministry of Health Malaysia (MOH)

ISSN Number: ISSN 1394-0635

## **ACKNOWLEDGEMENTS**

The National Cardiovascular Disease Database (NCVD) – Percutaneous Coronary Intervention (PCI) Registry would like to extend its appreciation to everyone who had helped to make this report possible.

We would especially like to thank the following:

- National Heart Association of Malaysia (NHAM)
- Health Informatics Centre, Ministry of Health Malaysia
- Clinical Research Centre (CRC), Ministry of Health Malaysia
- The members of various expert panels
- Our source data providers

### PREFACE

The 2013 – 2014 PCI Registry is the fourth report since the inception of the Registry in 2007. This report provides information on not only the interventional cardiology practice in major cardiac centres in Malaysia but also the patients who underwent the interventional procedures. Such data is crucial as it represents facts rather than the usual estimates generated for the practicing healthcare professionals, private and public hospital administrators, policy makers, patients advocates, as well as the pharmaceutical and insurance industries. In addition to being an academic reference, the report can be used to improve quality of care, delivery of services, and healthcare planning.

A vast amount of data was collected, and this was only made possible with the countless hours the medical and nursing staff from individual sites throughout Malaysia spent uploading the information online. I thank them for their effort, commitment, perseverance, and enthusiasm for the last eight years; they have truly gone beyond the call of duty. Our sincere gratitude to the writing committee headed by Prof Dr Wan Azman Wan Ahmad, which devoted many weekends pouring through the data, analysing the figures, and transforming the data into meaningful information. I thank them for the effort and commitment, which truly showcased their passion for this project.

Our thanks also to the NCVD secretariat staffs in the Heart House, who quietly worked behind the scene, consistently following through and coordinating with the site investigators, the sub-investigators, the writing committee, the statisticians, etc. Without them, the registry and report would not have come together.

We strongly encourage everyone involved in the registry to fully utilise its immense data and to publish in medical journals so that the information can be shared worldwide; enabling Malaysia to truly contribute to the practice of cardiology globally.

Lastly, we would like to thank the National Heart Association of Malaysia, Clinical Research Centre of the Ministry of Health Malaysia, Health Informatics Centre of the Ministry of Health Malaysia, and the medical industries for the unrestricted grant to make this costly registry a reality.

Thank you

**Datuk Dr Rosli Mohd Ali** Chairman NCVD Governance Board

### FOREWORD

Greetings and Salam!

Ten years ago, on 9<sup>th</sup> August 2006, we started this national multicentre NCVD PCI registry. Today, we are proud to see this registry grown and starting to bear fruits! This latest report accumulates our PCI experience involving 38,595 patients, 41,997 procedures and 54,202 coronary lesions since 2007 to 2014.

We hope the registry will provide a "real-world" database of contemporary PCI practice in Malaysia. We began this registry with the objectives to evaluate the outcomes of PCI based on selected performance measures, to determine the cost-effectiveness of PCI, to determine the level of adherence to practice guideline, to stimulate research, to facilitate quality improvement activities, to act as a reference for future studies, to facilitate research and development, and to benchmark against other national/regional PCI registries. e.g. ASPECT, ASEAN.

Much has been achieved, through the commitment and teamwork from everyone! However, there is more to do still. The way forward is to go beyond "output" to "outcome", beyond "quantity" to "quality". With the sizeable number of cases reported, we may now embark on more analysis of trends and subgroups, to determine the factors that contribute to procedural success and long-term patient-centred outcomes. To this end, we may embark to appraise our practice based on both clinical practice guidelines (CPG) and appropriateness use criteria (AUC).

Beyond the value to service improvement, our registry may provide the platform for 'registry-based randomised controlled trials", post-marketing surveillance as required by the recent governance of medical devices in the ever-changing field of interventional cardiology.

The way forward for the next decade and beyond will depend on continual commitment and support in leadership and funding from NHAM. The machinery of the NCVD registry lies with each of us. The NCVD-PCI registry will continue to be a voluntary collaborative group, with shared ownership. Participating sites will continue to have free access to their 'own' institutional database to facilitate local quality-assurance activities. We continue to uphold the 'code of honour', *Together everyone achieves more*.

We would also like to take this opportunity to thank Dr Rosli Mohd Ali, for his leadership, dedication and perseverance.

Happy Reading. We welcome feedback and comments.

**Dr Liew Houng Bang** Chairman NCVD-Percutaneous Coronary Intervention (PCI) Registry

### NOTE FROM THE WRITING COMMITTEE CHAIRMAN

The NCVD is an initiative by Prof Dr Sim Kui Hian established under the Ministry of Health Malaysia. Its aim is to collect information about cardiovascular disease (CVD) in Malaysia which will enable us to estimate disease incidence, and evaluate risk factors and treatment. These data and information will be useful in planning and evaluating strategies for CVD prevention and control.

The NCVD Governance Board was established in year 2006. Its role is to oversee the operations of the NCVD to ensure that the NCVD stays focused on its objectives, and its continuing relevance and justification.

Currently we have successfully set up two registries; the NCVD-Acute Coronary Syndrome (ACS) registry and the NCVD Percutaneous Coronary Intervention (PCI) registry. Each registry has its own steering committee which comprises individuals who were subject matter experts, representatives from Ministry of Health, Universities, National Heart Institute, and Private Hospital. The committee establishes policy and procedures for the running of the registry, encourages the continuous participation of source data providers (SDP), disseminates information about the registry, communicates results at local and international levels, approves and validates statistical analysis, and ensures the quality control of the reported data.

We also have the medical writing committee, which has the crucial roles of preparing the registry's regular or interim report and subsequently the manuscript for journal submission. So far, we have completed four reports for the NCVD-ACS and three reports for NCVD PCI registries:

- 1. Annual Report of the NCVD-ACS Registry 2006
- 2. Annual Report of the NCVD-ACS Registry 2007 and 2008
- 3. Annual Report of the NCVD-ACS Registry 2009 and 2010
- 4. Annual Report of the NCVD-ACS Registry 2011 and 2013
- 5. Annual Report of the NCVD-PCI Registry 2007
- 6. Annual Report of the NCVD-PCI Registry 2007 2009
- 7. Annual Report of the NCVD-PCI Registry 2010 2012

These reports are available at NHAM websites. We also have 13 other publications:

- 1. The foundation of NCVD PCI Registry: The Malaysia's first multi-centre interventional cardiology project (Medical Journal of Malaysia 2008)
- 2. Acute Coronary Syndrome (ACS) registry Leading the charge for National Cardiovascular Disease (NCVD) database (Medical Journal of Malaysia 2008)
- 3. Highlight of the first Malaysian NCVD-PCI registry (CVD Prevention and Control Journal 2011)
- 4. Malaysian NCVD registry: How are we different? (CVD Prevention and Control Journal 2011)
- 5. Acute coronary syndrome in women of reproductive age. (International Journal of Women's Health 2011)
- 6. The journey of Malaysian NCVD-PCI registry: A summary of three years report (International Journal of Cardiology 2013)

- 7. An Asian validation of the TIMI risk score for ST-segment elevation myocardial infarction: Results and implications for cardiac care in a developing country (PLOS ONE 2012)
- 8. Impact of cardiac care variation on ST-elevation myocardial infarction outcomes in Malaysia (The American Journal of Cardiology 2013)
- 9. Are there gender differences in coronary artery disease? The Malaysian National Cardiovascular Disease Database Percutaneous Coronary Intervention (NCVD-PCI) registry (PLOS One 2013)
- 10. Young coronary artery disease in patients undergoing percutaneous coronary intervention (Annals of Saudi Medicine 2013)
- 11. The Asia-Pacific evaluation of cardiovascular therapies (ASPECT) Improving the quality of cardiovascular care in the Asia Pacific region (International Journal of Cardiology 2014)
- 12. Gender differences in acute coronary syndrome in a multiethnic Asian population: Results of the Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome (NCVD-ACS) registry. (Global Heart Journal 2014)
- 13. The elderly in acute coronary syndrome: The Malaysian National Cardiovascular Database Acute Coronary Syndrome (NCVD-ACS) registry (Singapore Medical Journal 2016)

Many abstracts had been presented locally in the form of posters and oral presentations. Many of the data had also been presented international conferences. At the moment, we are working on several more papers for publication. We are also hoping to collaborate with other international registries.

I would like to welcome the newly appointed Writing Committee Members into our team and I am definitely looking forward to working hard and fruitfully together. Finally, we would like to thank all involved for their tireless effort and unwavering determination as well as for sacrificing their invaluable time to provide these data. Despite all of the challenges and shortcomings, we can at least be proud to have our own database which provides a yardstick on how we have performed and give us guidance for further improvement. We hope more hospitals particularly the private institutions will come forward and participate in this registry. We also encourage all young cardiologists to be actively involved in this registry. This project is, without a doubt, an asset towards realising the long-term national goal to create new, impeccable medical histories through cardiology.

Yours sincerely

**Prof Dr Wan Azman Wan Ahmad** Chairman NCVD Writing Committee

## ABBREVIATIONS

ACE	Angiotensin Converting Enzyme
ACS	Acute Coronary Syndrome
BMI	Body Mass Index
CABG	Coronary Artery Bypass Graft
CAD	Coronary Artery Disease
CCU	Coronary Care Unit
СК	Creatinine Kinase
CK-MB	Creatinine Kinase, MB Isoenzyme
CRC	Clinical Research Centre
CRF	Case Report Form
CVD	Cardiovascular Disease
DBMS	Database Management System
EDC	Electronic Data Capture
GFR	Glomerular filtration rate
GP	Glycoprotein
HDL	High Density Lipoprotein
HDU	High Dependency Unit
HIC	Health Informatics Centre
ICT	Information and Communication Technology
ICU	Intensive Care Unit
IJN	Institut Jantung Negara
IT/IS	Information Technology and Information System
JPN	Jabatan Pendaftaran Negara
LDL	Low Density Lipoprotein
LVEF	Left Ventricular Ejection Fraction
MDRD	Modification of Diet in Renal Disease
MOH	Ministry of Health
NCVD	National Cardiovascular Disease Database
NHAM	National Heart Association of Malaysia
NSTEMI	Non-ST-Elevation Myocardial Infarction
PMP	Per Million Population
RCC	Registry Coordinating Centre
SAP	Statistical Analysis Plan
SD	Standard Deviation
SDP	Source Data Provider
STEMI	ST-Elevation Myocardial Infarction
TIMI	Thrombolysis In Myocardial Infarction
TnI	Troponin I
TnT	Troponin T
UA	Unstable Angina

## NCVD-PERCUTANEOUS CORONARY INTERVENTION (PCI) REGISTRY

### Governance Board (2016 - 2018)

Advisor Chairman Committee : Dr Robaayah Zambahari
: Dr Rosli Mohd Ali
: Dr Choo Gim Hooi
Dr Goh Pik Pin
Dr Md Khadzir Sheikh Hj Ahmad
Dr Omar Ismail
Dr Sim Kui Hian
Dr Wan Azman Wan Ahmad

## Steering Committee (2016 – 2018)

Chairman	: Dr Liew Houng Bang
Committee	: Dr Asri Ranga Abdullah Ramaiah
	Dr Chee Kok Han
	Dr Choo Gim Hooi
	Dr Mohd Sapawi Mohamed
	Dr Shaiful Azmi Yahaya
	Dr Zubin Othman Ibrahim

Writing Committee	
Chairman	: Dr Wan Azman Wan Ahmad
Committee	: Dr Abdul Kahar Abdul Ghapar
	Dr Abdul Muizz Abd Malek
	Dr Ahmad Syadi Mahmood Zuhdi
	Dr Alan Fong Yean Yip
	Dr Al Fazir Omar
	Dr Aslannif Roslan
	Dr Chee Kok Han
	Dr Liew Houng Bang
	Dr Muhamad Ali SK Abdul Kader
	Dr Omar Ismail
	Dr Prem Nathan Arumuganathan
	Dr Sazzli Shahlan Kasim
	Dr Sridhar Ganiga Srinivasaiah
	Dr Tan Kin Leong

Dr Zubin Othman Ibrahim

## CONTENTS

ACKNOWLEDGEMENTS	3
PREFACE	4
FOREWORD	5
NOTE FROM THE WRITING COMMITTEE CHAIRMAN	6
ABBREVIATIONS	8
NCVD-PERCUTANEOUS CORONARY INTERVENTION (PCI) REGISTRY	9
CONTENTS	10
LIST OF TABLES	11
PATIENT CHARACTERISTICS	15
CLINICAL PRESENTATIONS AND INVESTIGATIONS	
PROCEDURAL SETTINGS	62
LESION CHARACTERISTICS	74
OUTCOME	106
APPENDIX A: DATA MANAGEMENT	
APPENDIX B: STATISTICAL METHODS	141
APPENDIX C: PARTICIPATING CENTRE DIRECTORY	143
APPENDIX D: NOTE OF APPRECIATION	144
APPENDIX E: GLOSSARY	147
APPENDIX F: CASE REPORT FORM	

## LIST OF TABLES

## PATIENT CHARACTERISTICS

Table 1.1 Characteristics of patients who underwent PCI, NCVD-PCI Registry, 2007 – 201417
Table 1.2 Distribution of patients by number of procedures, NCVD-PCI Registry, 2007 – 2014 22
Table 1.3.1 Distribution of patients who underwent PCI, by SDP, NCVD-PCI Registry, 2007 – 2014*
Table 1.3.2 Distribution of PCI procedures performed by Source Data Providers (SDPs), NCVD-PCI         Registry, 2007 – 2014*
Table 1.4.1 Age-gender distribution of patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014         24
Table 1.4.2 Age-gender distribution of patients who underwent PCI, by ethnic group, NCVD-PCIRegistry, 2007 – 2014
Table 1.4.3 Age-gender distribution of patients who underwent PCI, by pre-morbid diabetes, NCVD-PCI Registry, 2007 – 2014       27
Table 1.4.4 Age-gender distribution of patients who underwent PCI, by pre-morbid hypertension,NCVD-PCI Registry, 2007 – 2014
Table 1.4.5 Age-gender distribution of patients who underwent PCI, by pre-morbid dyslipidaemia,NCVD-PCI Registry, 2007 – 2014
Table 1.4.6 Age-gender distribution of patients who underwent PCI, by family history of premature cardiovascular disease, NCVD-PCI Registry, 2007 – 2014         33
Table 1.5.1 Presence of cumulative risk factors, NCVD-PCI Registry, 2007 – 2014
Table 1.5.2 Presence of cumulative risk factors by gender, NCVD-PCI Registry, 2007 – 2014
CLINICAL PRESENTATIONS AND INVESTIGATIONS
Table 2.1 Patient clinical status at the time of PCI procedure, NCVD-PCI Registry, 2007 – 201440
Table 2.2.1 Time to treatment for STEMI, with transfer, NCVD-PCI Registry, 2007 – 2014^45
Table 2.2.2 Time to treatment for STEMI, without transfer, NCVD-PCI Registry, 2007 – 2014 <sup>^</sup>
Table 2.3 Comparison of heart rate according to PCI status, NCVD-PCI Registry, 2007 – 2014
Table 2.4 Comparison of heart rate according to ACS subtypes, NCVD-PCI Registry, 2007 – 201448
Table 2.5 Comparison of systolic blood pressure according to PCI status, NCVD-PCI Registry, 2007 –         2014
Table 2.6 Comparison of arterial blood pressure according to PCI status, NCVD–PCI Registry, 2007 –         2014
Table 2.7 Comparison of TIMI risk index according to PCI status, NCVD-PCI Registry, 2007 – 2014
Table 2.8 Comparison of ejection fraction according to PCI status, NCVD-PCI Registry, 2007 – 2014         52

Table 2.9 Comparison of NYHA according to PCI status among patients with heart failure, NCVD–         PCI Registry, 2007 – 2014         53
Table 2.10 Comparison of previous PCI according to PCI status, NCVD-PCI Registry, 2007 – 2014.54
Table 2.11 Comparison of HbA1c according to PCI status, NCVD-PCI Registry, 2007 – 2014
Table 2.12 Comparison of baseline creatinine according to PCI status, NCVD-PCI Registry, 2007 –         2014
Table 2.13 Comparison of GFR according to PCI status, NCVD-PCI Registry, 2007 – 201456
Table 2.14 Comparison of TC according to PCI status, NCVD-PCI Registry, 2007 – 2014
Table 2.15 Comparison of LDL according to PCI status, NCVD-PCI Registry, 2007 – 2014
Table 2.16 Comparison of functional ischaemia according to PCI status, NCVD-PCI Registry, 2007 –         2014
Table 2.17 Comparison of ECG according to ACS subtypes, NCVD-PCI Registry, 2007 – 2014 60
Table 2.18 Comparison of IABP use according to ACS subtypes, NCVD-PCI Registry, 2007 – 2014.61
PROCEDURAL SETTINGS
Table 3.1 PCI status of patients who underwent procedures, NCVD-PCI Registry, 2007 – 2014
Table 3.2 Duration of thienopyridine in patients who underwent PCI, NCVD-PCI Registry, 2007 –         2014
Table 3.3 Access site of patients who underwent procedures, by PCI status, NCVD-PCI Registry, 2007         - 2014
LESION CHARACTERISTICS
Table 4.1 Summary of location of lesions treated with percutaneous coronary intervention, NCVD-PCI         Registry, 2007 – 2014
Table 4.1.1 Comparison between 2007 – 2012 and 2013 – 2014 results
Table 4.2 Characteristics of lesions treated by PCI, NCVD-PCI Registry, 2007 – 2014
Table 4.3 Prevalence of lesions according to the American College of Cardiology (ACC)         classifications, NCVD-PCI Registry, 2007 – 2014         77
Table 4.4 Prevalence of high risk lesion type, NCVD-PCI Registry, 2007 – 2014
Table 4.5 Comparison of TIMI flow grade by pre- and post-procedure, NCVD-PCI Registry, 2007 –         2014
Table 4.6 Types of stents used, NCVD-PCI Registry, 2007 – 2014
Table 4.7 Lesion characteristics for patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014.79
Table 4.8 Types of devices used during percutaneous coronary intervention, NCVD-PCI Registry, 2007         - 2014
Table 4.9 Types of post-procedure complications, NCVD-PCI Registry, 2007 – 2014
Table 4.10 Acute coronary syndrome status of in-stent restenosis percutaneous coronary intervention,         NCVD-PCI Registry, 2007 – 2014

Table 4.11 Types of stents used in the in-stent restenosis, NCVD-PCI Registry, 2007 – 2014
Table 4.12 Types of devices used in the in-stent restenosis, NCVD-PCI Registry, 2007 – 2014
Table 4.13 Types of complications in post in-stent restenosis, NCVD-PCI Registry, 2007 – 2014 84
Table 4.14 Types of lesions in left main stem procedure, NCVD-PCI Registry, 2007 – 2014
Table 4.15 Clinical presentation of left main stem, NCVD-PCI Registry, 2007 – 2014
Table 4.16 TIMI flow prior to intervention in left main stem procedure, NCVD-PCI Registry, 2007 –         2014
Table 4.17 Types of stents used in left main stem procedure, NCVD-PCI Registry, 2007 – 201490
Table 4.18 Types of devices used in left main stem procedure, NCVD-PCI Registry, 2007 – 2014 90
Table 4.19 Types of complications in post left main stem, NCVD-PCI Registry, 2007 – 2014
Table 4.20 Planned duration of dual antiplatelet therapy in left main stem procedure, NCVD-PCI         Registry, 2007 – 2014
Table 4.21 Lesion types in graft PCI, NCVD-PCI Registry, 2007 – 2014
Table 4.22 Clinical presentation of graft PCI, NCVD-PCI Registry, 2007 – 2014
Table 4.23 Types of stents used in graft PCI, NCVD-PCI Registry, 2007 – 2014
Table 4.24 Types of complications in graft PCI, NCVD-PCI Registry, 2007 – 2014
Table 4.25 Planned duration of dual antiplatelet therapy in graft PCI, NCVD-PCI Registry, 2007 –      2014
Table 4.26 Summary of location of lesions treated with percutaneous coronary intervention and for lesion with description of $CTO > 3$ months only, NCVD-PCI Registry, $2007 - 2014$
Table 4.27 Characteristics of PCI procedures performed for lesion with description of CTO > 3 months only, NCVD-PCI Registry, 2007 – 2014
Table 4.28 Types of stents used for lesion with description of CTO > 3 months only, NCVD-PCI         Registry, 2007 – 2014
Table 4.29 Types of devices used during percutaneous coronary intervention for lesion with description of $CTO > 3$ months only, NCVD-PCI Registry, $2007 - 2014$
Table 4.30 Types of post procedure complications for lesion with description of CTO > 3 months only,         NCVD-PCI Registry, 2007 – 2014
Table 4.31 Duration of thienopyridine in patients who underwent PCI and lesion with description of CTO > 3 months only, NCVD-PCI Registry, 2007 – 2014
OUTCOME
Table 5.1 Summary of in-hospital outcomes for patients who underwent PCI, NCVD-PCI Registry,         2007 – 2014         107
Table 5.2 Overall outcome of patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014 110
Table 5.3 Overall outcome for patients who underwent PCI, by age group (years), NCVD-PCIRegistry, 2007 – 2014

Table 5.4 Overall outcome of patients who underwent PCI, by gender, NCVD-PCI Registry, 2007 –         2014
Table 5.5 Overall outcome of patients who underwent PCI, by pre-morbid diabetes, NCVD-PCI         Registry, 2007 – 2014
Table 5.6 Overall outcome of patients who underwent PCI, by pre-morbid hypertension, NCVD-PCI         Registry, 2007 – 2014
Table 5.7 Overall outcome of patients who underwent PCI, by pre-morbid dyslipidaemia, NCVD-PCIRegistry, 2007 – 2014
Table 5.8 Overall outcome of patients who underwent PCI, by PCI status, NCVD-PCI Registry, 2007 –      2014
Table 5.9 Overall outcome of patients who underwent PCI, by acute coronary syndrome, NCVD-PCIRegistry, 2007 – 2014
Table 5.10 Medication for patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014
Table 5.11 Cause of death of patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014
Table 5.12 Location of death of patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014125
Table 5.13 Outcome at discharge of patients who developed cardiogenic shock peri-procedure, NCVD-PCI Registry, 2007 – 2014
Table 5.14 Outcome at discharge, by post PCI TIMI flow, NCVD-PCI Registry, 2007 – 2014
Table 5.15 Outcome at discharge, by contrast volume used, NCVD-PCI Registry, 2007 – 2014 127
Table 5.16 Summary of 30-day readmission status of patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014 (N = total no. of procedures for 30-day follow- up)
Table 5.17 Procedural complications and clinical outcomes, according to PCI status, NCVD-PCI      Registry, 2007 – 2014
Table 5.18 Heart rate at presentation versus outcome, NCVD-PCI Registry, 2007 – 2014
Table 5.19 Heart rate at presentation versus length of stay, NCVD-PCI Registry, 2007 – 2014
Table 5.20 Prognostic factors for in-hospital mortality among patients who underwent PCI, NCVD-PCI      Registry, 2007 – 2014
Table 5.21a Prognostic factors for 30-days mortality among patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014 (Multivariate analysis)
Table 5.21b Prognostic factors for 30-days mortality among patients who underwent PCI, NCVD-PCI         Registry, 2007 – 2014 (Forced model analysis)

## PATIENT CHARACTERISTICS

Prem Nathan Arumuganathan<sup>1</sup>, Alan Fong Yean Yip<sup>2</sup>, Liew Houng Bang<sup>1</sup>, Ong Tiong Kiam<sup>2</sup> and Sim Kui Hian<sup>3</sup>

<sup>1</sup>Hospital Queen Elizabeth II, Kota Kinabalu, <sup>2</sup>Pusat Jantung Hospital Umum Sarawak, Kota Samarahan, <sup>3</sup>National Heart Association of Malaysia

#### Summary

- 1. Patient characteristics remained similar between the periods of 2007 2012 and 2013 2014.
- 2. Nearly all patients had at least one known cardiovascular risk factor (97.2%); however, compared to 2007 2012, the trend was lower: dyslipidemia (71.9% vs. 59.4%), hypertension (73.0% vs. 66.8%), and diabetes (45.7% vs. 43.3%). Compared with the SCAAR registry (17.5%), the prevalence of diabetes mellitus was much higher.
- 3. To improve outcomes of PCI, patients' risk factors should be optimally treated post procedure.
- 4. Malaysian patients were younger with a mean age of 57.7 (SD 10.4) years, which is 10 years younger than patients in the SCAAR registry, 67.1 (SD 11.2) years.
- 5. Twenty-two percent (22.2%) of patients were below the age of 50 years. More Malay and Indian patients, compared to Chinese patients were under the age of 50 years.

Data from 14,136 patients obtained from 15 centres was analysed. The main source data providers were Institut Jantung Negara, Pusat Jantung Hospital Umum Sarawak, Hospital Queen Elizabeth II, Hospital Sultanah Bahiyah, Hospital Pulau Pinang, Pusat Perubatan Universiti Malaya and Hospital Sultanah Aminah. [Table 1.3.1]

The data on patient characteristics will be reported in two periods: between the years 2007 - 2012 and 2013 - 2014. This was because the main finding from 2007 - 2012 had been published, and the subsequent data from 2013 - 2014 would be compared to the former.

In total, of the 14,136 patients, 91.1 % had a single PCI procedure while the remaining had two or more. [Table 1.2]

The mean ages of patients were 57.4 (SD 10.3) years for 2007 - 2012, and 57.7 (SD 10.4) years for 2013 - 2014. The largest group of patients in 2007 - 2012 and 2013 - 2014 were aged between 50 (35.8%) and 60 years old (36.6%), respectively. Patients below the age of 50 years comprised 23.4% in 2007 - 2012 vs. 22.2% in 2013 - 2014. [Table 1.1]

Relatively more males than females underwent PCI; 82.0% in 2007 - 2012 and 83.6% in 2013 - 2014. [Table 1.1]

The distributions of patients from the major ethnic groups in 2007 - 2012 were similar for Malays (48.4% vs. 49.7%), Chinese (23.1% vs. 21.9%), and Indians (21.7% vs. 19.4%). The next major ethnic group was Iban. [Table 1.1]

#### Cardiovascular risk factors

In total, 98.1% of patients in 2007 - 2012 and 97.2 % in 2013 - 2014 had at least one cardiovascular risk factor. [Table 1.5.1]

In terms of active smokers, there was a 6% increase; 21.1% in 2007 - 2012 vs. 27.8% in 2013 - 2014. Seventeen percent of patients had a family history of premature cardiovascular disease in 2007 - 2012 and 10.6% in 2013 - 2014. The mean body index was similar in 2007 - 2012 and 2013 - 2014, with  $26.6 \text{ kgm}^{-2}$  (SD 4.3) and  $26.6 \text{ kgm}^{-2}$  (SD 4.4), respectively. [Table 1.1] There was a decreased trend for dyslipidaemia (71.8% in 2007 – 2012 vs. 59.4% in 2013 – 2014), hypertension (73.0% in 2007 – 2012 vs. 66.8% in 2013 – 2014), and diabetes (45.7% in 2007 – 2012 vs. 43.3 % in 2013 – 2014). Forty-four percent had a previous history of myocardial infarction in 2007 – 2012 and 38.2% in 2013 – 2014. Fifty-five percent had a previous history of known coronary artery disease in 2007 – 2012 and 40.2% in 2013 – 2014. [Table 1.1]

There was an increased trend for PCI among patients with new onset angina (23.7% in 2007 - 2012 vs. 28.6% in 2013 - 2014) and chronic cardiac failure (CCF) (3.6% in 2007 - 2012 vs. 4.2% in 2012 - 2014). [Table 1.1]

There were 5.8% patients with chronic renal failure (CRF) in 2007 - 2012 and 4.8% in 2012 - 2014. There were 20.3% patients with a previous history of percutaneous coronary intervention (PCI) in 2007 – 2012 and 16.2% in 2012 - 2014. [Table 1.1]

Finally, there were 4.0% patients with a previous history of CABG in 2007 - 2012 and 3.2% in 2012 - 2014. [Table 1.1]

#### Age, gender and ethnicity, in 2007 – 2012

Males under the age of 50 years: Malays (27.9%), followed by Indians (25.6%), and Chinese (19.7%). Females under the age of 50 years: Malays (14.0%), followed by Indians (13.5%), and Chinese (5.5%). [Table 1.4.2]

#### Age, gender and ethnicity, in 2013 – 2014

Males under the age of 50 years: Malays (25.6%), followed by Indians (23.7%), and Chinese (19.0%). Females under the age of 50 years: Malays (12.4%), followed by Indians (12.7%), and Chinese (5.0%). Chinese male and female patients tend to have PCI at an older age. [Table 1.4.2]

### Comparative analysis with published data from the region on cardiovascular risk factors

These findings were compared with the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) which recruited 25,143 patients from 2009 to 2010. It is apparent that the mean age of patients proceeding with angioplasty was much higher at 67.1 years. Around 51.4% had hypertension, and the prevalence of dyslipidaemia was almost similar to our own population at 39.8%. Interestingly, the prevalence of diabetes mellitus is comparatively much lower at 17.5%, and about a fifth of patients were smokers.<sup>2</sup>

Based on the Mayo Clinic Percutaneous Coronary Intervention Registry which recruited 7251 patients from 2002 to 2010, the prevalence of diabetes mellitus was 29.0%, hypertension was 21.0% and dyslipidaemia was 85.0%. The mean age of patients was 67.2 years old.<sup>3</sup>

Based on the comparisons with these other registries, it can be deduced that our patients requiring angioplasty were younger by ten years and also had a markedly higher prevalence of diabetes mellitus. In light of this, it is important that the management of cardiovascular risk factors be carried out more effectively with special emphasis on diabetes mellitus.

#### References

- 1. Wan Ahmad WA, Sim KH. (Eds). Annual report of the NCVD-PCI registry, 2010 2012. Kuala Lumpur, Malaysia: National Cardiovascular Disease Database, 2014.
- 2. Fokkema ML, James SK, Albertsson P, et al. Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). *J Am Coll Cardiol.* 2013;61(12):1222–30.
- Lee MS, Flammer AJ, Li J, et al. Comparison of time trends of cardiovascular disease risk factors and Framingham risk score between patients with and without acute coronary syndrome undergoing percutaneous intervention over the last 17 years: From the Mayo Clinic Percutaneous Coronary Intervention Registry. *Clin Cardiol.* 2015;38: 747–56.

Year	2007 - 2012		2013		20	14	2013 - 2014	
Total no. of patients	24459		6353		7783		14136	
	No.	%	No.	%	No.	%	No.	%
Demographics								
Age, Years								
N	244	459	63	53	77	83	14	136
Mean (SD)	57.4	(10.3)	57.6	(10.4)	57.8	(10.5)	57.7	(10.4)
Median (min, max)	57.3 (21	.1, 97.7)	57.6 (23	.6, 91.5)	57.9 (20	.1, 96.0)	57.8 (20	.1, 96.0)
Age group, No. (%)								
20 - < 30	89	0.4	29	0.4	33	0.4	62	0.4
30 - < 40	955	4.0	290	4.6	379	4.8	669	4.8
40 - < 50	4658	19.0	1111	17.4	1289	16.6	2400	17.0
50-<60	8774	35.8	2355	37.0	2816	36.2	5171	36.6
60-<70	6995	28.6	1767	27.8	2269	29.2	4036	28.6
70-<80	2757	11.2	731	11.6	892	11.4	1623	11.4
$\geq 80$	231	1.0	70	1.2	105	1.4	175	1.2
Gender, No. (%)								
Male	20073	82.0	5290	83.2	6528	83.8	11818	83.6
Female	4386	18.0	1063	16.8	1255	16.2	2318	16.4
Ethnic group, No. (%)								
Malay	11841	48.4	3122	49.3	3896	50.0	7018	49.7
Chinese	5650	23.1	1413	22.3	1663	21.4	3076	21.9
Indian	5298	21.7	1187	18.6	1547	19.8	2734	19.4
Orang asli	2	0.0	5	0.0	4	0.0	9	0.0
Kadazan Dusun	191	0.8	116	1.8	103	1.4	219	1.6
Melanau	16	0.0	5	0.0	9	0.2	14	0.0
Murut	8	0.0	6	0.0	6	0.0	12	0.0
Bajau	102	0.4	61	1.0	74	1.0	135	1.0
Bidayuh	108	0.4	49	0.8	15	0.2	64	0.4
Iban	641	2.7	171	2.6	187	2.4	358	2.6
Punjabi	214	0.8	34	0.6	45	0.6	79	0.6
Other Malaysian	228	1.0	121	2.0	168	2.2	289	2.0
Foreigner	135	0.7	58	1.0	63	0.8	121	0.8
Not available	22	0.0	5	0.0	3	0.0	8	0.0
Missing	3	0.0	0	0	0	0	0	0

 Table 1.1 Characteristics of patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014

Year	2007 - 2012		2013		2014		2013 - 2014	
Total no. of patients	244	24459 6353 7783		83	14136			
	No.	%	No.	%	No.	%	No.	%
Other coronary risk factors								
Smoking, No. (%)								
Never	8883	36.3	2035	32.0	2789	35.8	4824	34.2
Former (quit > 30 days)	6844	28.0	1335	21.0	1744	22.4	3079	21.8
Current (any tobacco use within last 30 days)	5177	21.1	1842	29.0	2100	27.0	3942	27.8
Not available	3519	14.4	1141	18.0	1150	14.8	2291	16.2
Missing	36	0.2	0	0	0	0	0	0
Family history of premature cardiovascular disease, No. (%)								
Yes	4151	17.0	710	11.2	784	10.0	1494	10.6
No	17416	71.2	4349	68.4	5427	69.8	9776	69.2
Not known	2858	11.6	1294	20.4	1572	20.2	2866	20.2
Missing	34	0.2	0	0	0	0	0	0
Body mass index (BMI), kgm <sup>-2</sup>								
N	19606		4639		6019		10658	
Mean (SD)	26.6	(4.3)	26.6 (4.4)		26.6 (4.4)		26.6 (4.4)	
Median (min, max)	26.1 (14	.0, 49.9)	26.2 (14	.0, 49.7)	26.1 (14	.0, 49.8)	26.1 (14.0, 49.8)	
Missing, No. (%)	4853	19.8	1714	27.0	1764	22.6	3478	24.6
BMI, kg/m <sup>2</sup> , No. (%)								
< 18.5	289	1.2	69	1.0	88	1.2	157	1.2
18.5 – 23	3470	14.2	822	13.0	1087	13.9	1909	13.5
> 23 - < 25	3726	15.2	902	14.2	1177	15.1	2079	14.7
25 - < 30	8327	34.0	1946	30.6	2514	32.4	4460	31.5
30 - < 35	3000	12.3	695	11.0	894	11.4	1589	11.1
35 - < 40	629	2.6	157	2.4	201	2.6	358	2.6
$\geq$ 40	165	0.7	48	0.8	58	0.8	106	0.8
Missing	4853	19.8	1714	27.0	1764	22.6	3478	24.6
Co-morbidities								
Dyslipidaemia, No. (%)								
Yes	17582	71.8	3811	60.0	4579	58.8	8390	59.4
No	5678	23.2	1950	30.6	2472	31.8	4422	31.2
Not known	1162	4.8	592	9.4	732	9.4	1324	9.4
Missing	37	0.2	0	0	0	0	0	0

Year	2007 - 2012		2013		2014		2013 - 2014	
Total no. of patients	244	159	63	53	77	83	14136	
	No.	%	No.	%	No.	%	No.	%
Hypertension, No. (%)								
Yes	17878	73.0	4275	67.3	5162	66.4	9437	66.8
No	6046	24.8	1745	27.5	2155	27.6	3900	27.6
Not known	517	2.2	333	5.2	466	6.0	799	5.6
Missing	18	0.0	0	0	0	0	0	0
Diabetes, No. (%)								
Yes	11165	45.7	2734	43.0	3394	43.7	6128	43.3
No	12645	51.6	3222	50.8	3837	49.3	7059	49.9
Not known	628	2.7	397	6.2	552	7.0	949	6.8
Missing	21	0.0	0	0	0	0	0	0
Type of diabetes treatment, No. $(\%)$								
OHA	8395	34.4	1785	28.0	1997	25.6	3782	26.8
Insulin	1219	5.0	390	6.2	583	7.4	973	6.8
OHA + insulin	579	2.4	279	4.4	354	4.6	633	4.4
Non-pharmacology therapy	312	1.2	168	2.6	214	2.8	382	2.8
Myocardial infarction history, No. (%)								
Yes	10749	44.0	2557	40.2	2845	36.6	5402	38.2
No	12814	52.3	3330	52.4	4271	54.8	7601	53.8
Not known	867	3.5	466	7.4	667	8.6	1133	8.0
Missing	29	0.2	0	0	0	0	0	0
Documented coronary artery disease, No. (%)								
Yes	13464	55.0	2702	42.6	2976	38.2	5678	40.2
No	10487	42.8	3309	52.0	4324	55.6	7633	54.0
Not known	481	2.0	342	5.4	483	6.2	825	5.8
Missing	27	0.2	0	0	0	0	0	0
New onset angina (< 2 weeks),								
Yes	5780	23.7	1881	29.6	2169	27.8	4050	28.6
No	18168	74.3	4144	65.2	5130	66.0	9274	65.6
Not known	487	2.0	328	5.2	484	6.2	812	5.8
Missing	24	0.0	0	0	0	0	0	0
Congestive heart failure (2 weeks prior), No. (%)								
Yes	898	3.6	228	3.6	359	4.6	587	4.2
No	23049	94.2	5890	92.8	7002	90.0	12892	91.2
Not known	481	2.0	235	3.6	422	5.4	657	4.6
Missing	31	0.2	0	0	0	0	0	0

Year	2007 - 2012		2013		2014		2013 - 2014	
Total no. of patients	24459		6353		7783		14136	
	No.	%	No.	%	No.	%	No.	%
Cerebrovascular disease, No. (%)								
Yes	352	1.5	152	2.4	247	3.2	399	2.8
No	23675	96.8	5949	93.6	7117	91.4	13066	92.4
Not known	410	1.7	252	4.0	419	5.4	671	4.8
Missing	22	0.0	0	0	0	0	0	0
Peripheral vascular disease, No. (%)								
Yes	205	0.8	59	1.0	60	0.8	119	0.8
No	23822	97.4	6036	95.0	7294	93.7	13330	94.3
Not known	407	1.6	258	4.0	429	5.5	687	4.9
Missing	25	0.2	0	0	0	0	0	0
Chronic renal failure								
Yes	1441	5.8	320	5.1	357	4.6	677	4.8
No	22589	92.4	5786	91.1	7025	90.2	12811	90.6
Not known	401	1.6	247	3.8	401	5.2	648	4.6
Missing	28	0.2	0	0	0	0	0	0
*Coronary artery disease, No. (%)								
Yes	19590	80.1	4765	75.1	5445	70.0	10210	72.2
No	4365	17.8	1264	19.9	1813	23.2	3077	21.8
Not known	504	2.1	324	5.0	525	6.8	849	6.0
Baseline investigation								
Baseline creatinine, mmol/L								
Ν	222	221	53	70	66	47	120	)17
Mean (SD)	116.9 (	(121.7)	116.0 (117.2)		116.1 (117.5)		116.0 (117.4)	
Median (min, max)	93.0 (44.0	), 6500.0)	92.0 (44.0	), 1510.0)	91.0 (44.0, 1632.0)		92.0 (44.0, 1632.0)	
Not available, No. (%)	903	3.7	398	6.2	638	8.2	1036	7.4
Missing, No. (%)	1335	5.4	585	9.2	498	6.4	1083	7.6
Baseline creatinine, mmol/L, No. (%)								
< 100	13407	54.8	3275	51.6	4133	53.2	7408	52.4
100 – 199	7669	31.4	1811	28.6	2168	27.8	3979	28.2
$\geq$ 200	1145	4.7	284	4.4	346	4.4	630	4.4
Not available	903	3.7	398	6.2	638	8.2	1036	7.4
Missing	1335	5.4	585	9.2	498	6.4	1083	7.6

Year	2007 -	- 2012	20	13	20	14	2013 -	- 2014
Total no. of patients	24,	459	6,3	353	7,7	783	14,	136
	No.	%	No.	%	No.	%	No.	%
**Glomerular filtration rate (GFR), MDRD								
Ν	222	206	53	70	66	47	120	017
Mean (SD)	74.0	(25.2)	75.4 (	(25.9)	75.6	(25.9)	75.5	(25.9)
Median (min, max)	75.0 (0.0	5, 212.5)	75.6 (2.9	9, 179.2)	76.7 (2.)	7, 200.5)	76.0 (2.7	7, 200.5)
Missing, No. (%)	2253	9.2	983	15.5	1136	14.6	2119	15.0
**Glomerular filtration rate								
(GFR), MDRD, NO. (%)	710	29	166	26	217	2.8	383	2.7
15 - < 30	488	2.9	120	1.8	136	1.7	256	1.8
30 - < 45	1186	4.8	272	4.3	344	4.4	616	4.4
45 - < 60	3180	13.0	685	10.8	816	10.5	1501	10.6
> 60	16642	68.0	4127	65.0	5134	66.0	9261	65.5
Missing	2253	9.2	983	15.5	1136	14.6	2119	15.0
missing	2233	7.2	705	15.5	1150	14.0	2117	15.0
***Total cholesterol, mmol/L								
N	92	13	15	96	17	05	33	01
Mean (SD)	4.5	(1.2)	4.4 (	(1.3)	4.3	(1.3)	4.4	(1.3)
Median (min, max)	4.3 (2.0	), 24.2)	4.2 (2.0	), 25.0)	4.1 (2.2	2, 23.0)	4.1 (2.0	), 25.0)
Not available, No. (%)	3221	24.0	696	25.8	893	30.0	1589	28.0
Missing, No. (%)	1030	7.6	410	15.2	378	12.8	788	13.8
***LDL levels, mmol/L								
Ν	91	01	15	55	16	68	32	23
Mean (SD)	2.6	(1.1)	2.5 (	(1.1)	2.5	(1.1)	2.5	(1.1)
Median (min, max)	2.4 (0.7	7, 20.0)	2.3 (0.8	8, 14.0)	2.2 (0.	8, 16.0)	2.2 (0.8	8, 16.0)
Not available, No. (%)	3323	24.6	725	26.8	937	31.4	1662	29.2
Missing, No. (%)	1040	7.8	422	15.6	371	12.4	793	14.0
Previous intervention								
Previous PCI, No. (%)								
Yes	4953	20.3	997	15.6	1284	16.4	2281	16.2
No	19488	79.7	5356	84.4	6499	83.6	11855	83.8
Missing	18	0.0	0	0	0	0	0	0
Pravious CAPC No. (0/)								
Vas	072	4.0	021	26	220	2.0	160	2.0
No	713	4.0	6122	06 A	7551	07.0	13676	06.8
Missing	23402	90.0	0122	90.4 0	0	97.0	13070	90.0
wiissing	24	0.0	0	U	U	U	U	U

\*Coronary artery disease is defined as "Yes" for any of the following co-morbidities: 1) History of myocardial infarction, 2) Documented CAD > 50% stenosis, 3) New onset angina (less than 2 weeks) \*\*Glomerular filtration rate calculated based on MDRD formula \*\*\*Mean (SD) of Total Cholesterol, mmol/L and LDL levels, mmol/L is of patients who had documented coronary artery disease

Note: 'Not known' for coronary artery disease includes patients who do not know their co-morbidities as well as missing data

				No. o	f patients				
Vear		2007 -	- 2012	20	13	20	14	2013 -	- 2014
		Ν	%	Ν	%	Ν	%	Ν	%
	1	24459	92.4	6353	91.7	7783	90.6	14136	91.1
f ires	2	1932	7.3	545	7.9	758	8.8	1303	8.4
lo. o cedu	3	85	0.3	27	0.4	40	0.5	67	0.4
Pro N	4	7	0.0	3	0	5	0.1	8	0.1
	Total	26483	100.0	6928	100.0	8586	100.0	15514	100.0

 Table 1.2 Distribution of patients by number of procedures, NCVD-PCI Registry, 2007 – 2014

## Table 1.3.1 Distribution of patients who underwent PCI, by SDP, NCVD-PCI Registry, 2007 – 2014\*

No.	Source data provider	2007 - Total patients	- 2012 no. of = 24459	20 Total patients	13 no. of s = 6353	20 Total patients	14 no. of s = 7783	2013 - Total patients	- 2014 no. of = 14136
		No.	%	No.	%	No.	%	No.	%
1	Pusat Perubatan Universiti Malaya, Kuala Lumpur	1184	4.8	55	0.8	810	10.4	865	6.2
2	Institut Jantung Negara, Kuala Lumpur	14183	58.1	2651	41.8	2834	36.4	5485	38.8
3	Hospital Pulau Pinang, Pulau Pinang	2099	8.7	432	6.8	480	6.2	912	6.4
4	Hospital Umum Sarawak, Sarawak	2723	11.3	687	10.8	665	8.6	1352	9.6
5	Hospital Sultanah Aminah, Johor	1777	7.3	434	6.8	445	5.8	879	6.2
6	Hospital Sultanah Bahiyah, Kedah	1042	4.2	393	6.2	531	6.8	924	6.6
7	Hospital Queen Elizabeth, Sabah	445	1.8						
8	Hospital Pakar KPJ Selangor, Selangor	70	0.2						
9	Hospital Serdang, Selangor	148	0.6	454	7.2	247	3.2	701	5.0
10	Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur	20	0.0						
11	Pusat Perubatan Mahkota, Melaka	12	0.0						
12	Hospital Sultanah Nur Zahirah, Terengganu	110	0.4	129	2.0	151	2.0	280	2.0
13	Hospital Tengku Ampuan Afzan, Pahang	28	0.2	197	3.2	261	3.4	458	3.2
14	Pusat Perubatan Subang Jaya, Selangor	91	0.4	83	1.4	127	1.6	210	1.4
15	Hospital Queen Elizabeth 2, Sabah	508	2.0	542	8.5	521	6.5	1063	7.5
16	Hospital Pantai Ipoh, Perak	19	0.0	82	1.2	9	0.2	91	0.6
17	Hospital Raja Permaisuri Bainun, Perak			176	2.7	419	5.3	595	4.1
18	Hospital Raja Perempuan Zainab II, Kelantan			2	0.0	15	0.2	17	0.2
19	UiTM Sg Buloh, Selangor			36	0.6	268	3.4	304	2.2
	Total	24459	100.0	6353	100.0	7783	100.0	14136	100.0

\*Each SDP started contributing data at different time periods

No.	Source data provider	2007 - Total patients	- 2012 no. of = 26483	20 Total patients	13 no. of s = 6928	20 Total patients	14 no. of s = 8586	2013 - Total patients	- 2014 no. of = 15514
		No.	%	No.	%	No.	%	No.	%
1	Pusat Perubatan Universiti Malaya, Kuala Lumpur	1293	4.8	55	0.8	990	11.6	1045	6.8
2	Institut Jantung Negara, Kuala Lumpur	15375	58.0	2941	42.4	3114	36.2	6055	39.0
3	Hospital Pulau Pinang, Pulau Pinang	2369	9.0	484	7.0	546	6.4	1030	6.6
4	Hospital Umum Sarawak, Sarawak	2952	11.2	747	10.8	716	8.4	1463	9.4
5	Hospital Sultanah Aminah, Johor	1902	7.2	477	6.8	470	5.4	947	6.2
6	Hospital Sultanah Bahiyah, Kedah	1118	4.2	425	6.2	570	6.6	995	6.4
7	Hospital Queen Elizabeth, Sabah	453	1.8						
8	Hospital Pakar KPJ Selangor, Selangor	72	0.2						
9	Hospital Serdang, Selangor	148	0.6	475	6.8	253	3.0	728	4.6
10	Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur	20	0.0						
11	Pusat Perubatan Mahkota, Melaka	12	0.0						
12	Hospital Sultanah Nur Zahirah, Terengganu	111	0.4	138	2.0	158	1.8	296	2.0
13	Hospital Tengku Ampuan Afzan, Pahang	29	0.2	213	3.0	282	3.2	495	3.2
14	Pusat Perubatan Subang Jaya, Selangor	92	0.4	83	1.2	129	1.5	212	1.3
15	Hospital Queen Elizabeth 2, Sabah	518	2.0	587	8.5	581	6.7	1168	7.5
16	Hospital Pantai Ipoh, Perak	19	0.0	82	1.3	9	0.2	91	0.6
17	Hospital Raja Permaisuri Bainun, Perak			182	2.6	466	5.4	648	4.2
18	Hospital Raja Perempuan Zainab II, Kelantan			2	0.0	16	0.2	18	0.2
19	UiTM Hospital Sg Buloh, Selangor			37	0.6	286	3.4	323	2.0
	Total	26483	100.0	6928	100.0	8586	100.0	15514	100.0

Table 1.3.2 Distribution of PCI procedures performed by Source Data Providers (SDPs), NCVD-PCI Registry, 2007 – 2014\*

\*Each SDP started contributing data at different time periods

	2007 -	- 2012	20	13	20	14	2013 -	- 2014
group	Total no. of	f patients =						
	244	459	63	53	77	83	141	136
Age	Male	Female	Male	Female	Male	Female	Male	Female
7	No. (%)							
20 - < 30	81	8	28	1	30	3	58	4
	(0.4)	(0.2)	(0.6)	(0.0)	(0.4)	(0.2)	(0.4)	(0.2)
30 - < 40	892	63	277	13	368	11	645	24
	(4.4)	(1.4)	(5.2)	(1.2)	(5.6)	(0.8)	(5.4)	(1.0)
40 - < 50	4212	446	1001	110	1176	113	2177	223
	(21.0)	(10.2)	(19.0)	(10.4)	(18.0)	(9.0)	(18.4)	(9.6)
50 - < 60	7485	1289	2025	330	2446	370	4471	700
	(37.3)	(29.4)	(38.2)	(31.0)	(37.5)	(29.5)	(37.9)	(30.2)
60 - < 70	5354	1641	1399	368	1789	480	3188	848
	(26.7)	(37.4)	(26.5)	(34.6)	(27.5)	(38.3)	(27.1)	(36.6)
70 - < 80	1887	870	513	218	649	243	1162	461
	(9.4)	(19.8)	(9.7)	(20.6)	(10.0)	(19.4)	(9.8)	(19.8)
≥ 80	162	69	47	23	70	35	117	58
	(0.8)	(1.6)	(0.8)	(2.2)	(1.0)	(2.8)	(1.0)	(2.6)
Total	20073	4386	5290	1063	6528	1255	11818	2318
	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)

Table 1.4.1 Age-gender distribution of patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014

				2013					2014		
			Total no	. of patien	ts = 6353			Total no	. of patien	ts = 7783	
Gender	Age group	Malay	Chinese	Indian	Others	Not Available	Malay	Chinese	Indian	Others*	Not Available
		No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)
	20 -	15	3	8	2	0	18	1	9	2	0
	< 30	(0.7)	(0.2)	(0.9)	(0.3)	(0)	(0.6)	(0.0)	(0.8)	(0.4)	(0)
	30 -	158	38	42	38	1	215	44	60	48	1
	< 40	(5.9)	(3.4)	(4.5)	(7.3)	(33.3)	(6.4)	(3.2)	(4.7)	(8.1)	(33.3)
	40 -	524	194	165	117	1	605	195	234	142	0
	< 50	(19.6)	(17.0)	(17.4)	(22.6)	(33.3)	(18.2)	(14.3)	(18.7)	(23.9)	(0)
ale	50 -	1039	386	392	207	1	1311	442	478	214	1
	< 60	(38.8)	(33.8)	(41.4)	(40.0)	(33.4)	(39.4)	(32.5)	(38.2)	(36.2)	(33.3)
W	60 –	692	351	246	110	0	870	450	344	125	0
	< 70	(25.8)	(30.6)	(26.0)	(21.2)	(0)	(26.2)	(33.0)	(27.6)	(21.2)	(0)
	70 –	232	159	82	40	0	271	211	113	53	1
	< 80	(8.6)	(13.8)	(8.6)	(7.8)	(0)	(8.2)	(15.4)	(9.0)	(9.0)	(33.4)
	≥ 80	18 (0.6)	13 (1.2)	12 (1.2)	4 (0.8)	0 (0)	30 (1.0)	21 (1.6)	12 (1.0)	7 (1.2)	0 (0)
	Total	2678 (100.0)	1144 (100.0)	947 (100.0)	518 (100.0)	3 (100.0)	3320 (100.0)	1364 (100.0)	1250 (100.0)	591 (100.0)	3 (100.0)
	20 -	1	0	0	0	0	2	1	0	0	0
	< 30	(0.2)	(0)	(0)	(0)	(0)	(0.4)	(0.4)	(0)	(0)	(0)
	30 -	7	2	2	2	0	7	1	3	0	0
	< 40	(1.6)	(0.7)	(0.8)	(1.8)	(0)	(1.2)	(0.4)	(1.0)	(0)	(0)
	40 -	56	10	28	16	0	54	14	35	10	0
	< 50	(12.6)	(3.7)	(11.6)	(14.9)	(0)	(9.4)	(4.6)	(11.8)	(12.0)	(0)
nale	50 -	156	64	76	32	2	192	58	95	25	0
	< 60	(35.2)	(23.8)	(31.6)	(29.7)	(100.0)	(33.4)	(19.4)	(32.0)	(30.2)	(0)
Fen	60 –	141	109	81	37	0	224	109	114	33	0
	< 70	(31.8)	(40.6)	(33.8)	(34.2)	(0)	(38.8)	(36.4)	(38.4)	(39.8)	(0)
	70 -	81	72	46	19	0	89	98	42	14	0
	< 80	(18.2)	(26.8)	(19.2)	(17.6)	(0)	(15.4)	(32.8)	(14.2)	(16.8)	(0)
	≥ 80	2 (0.4)	12 (4.4)	7 (3.0)	2 (1.8)	0 (0)	8 (1.4)	18 (6.0)	8 (2.6)	1 (1.2)	0 (0)
	Total	444 (100.0)	269 (100.0)	240 (100.0)	108 (100.0)	2 (100.0)	576 (100.0)	299 (100.0)	297 (100.0)	83 (100.0)	0 (0)

Table 1.4.2 Age-gender distribution of patients who underwent PCI, by ethnic group, NCVD-PCI Registry, 2007 – 2014

\*Others include Orang Asli, Kadazan, Melanau, Murut, Bajau, Bidayuh, Iban, Punjabi, Other Malaysian, and Foreigner

			^	2007 – 201	.2			2	2013 - 201	4	
			Total no.	of patient	s = 24459			Total no.	of patient	s = 14136	
Gender	Age group	Malay	Chinese	Indian	Others	**Not Available	Malay	Chinese	Indian	Others*	Not Available
		No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)
	20 - < 30	43 (0.2) (0.4)	11 (0.0) (0.2)	17 (0.0) (0.4)	10 (0.0) (0.8)	0 (0) (0)	33 (0.6)	4 (0.2)	17 (0.8)	4 (0.4)	0 (0)
	30 - < 40	501 (2.4) (5.1)	132 (0.6) (2.9)	176 (0.8) (4.2)	82 (0.4) (6.1)	1 (0.0) (4.8)	373 (6.2)	82 (3.2)	102 (4.6)	86 (7.8)	2 (33.4)
	40 - < 50	2236 (11.2) (22.4)	752 (3.8) (16.6)	879 (4.4) (21.0)	341 (1.7) (25.4)	4 (0.0) (19.0)	1129 (18.8)	389 (15.6)	399 (18.3)	259 (23.3)	1 (16.6)
ıle	50 - < 60	3878 (19.5) (38.9)	1515 (7.6) (33.3)	1632 (8.3) (38.9)	453 (2.3) (33.8)	7 (0.0) (33.3)	2350 (39.2)	828 (32.9)	870 (39.7)	421 (37.9)	2 (33.4)
M	60 - < 70	2446 (12.2) (24.5)	1473 (7.4) (32.4)	1101 (5.5) (26.2)	326 (1.7) (24.3)	8 (0.0) (38.1)	1562 (26.0)	801 (31.9)	590 (26.8)	235 (21.2)	0 (0)
	70 - < 80	811 (4.0) (8.1)	601 (3.0) (13.3)	359 (1.8) (8.6)	115 (0.6) (8.6)	1 (0.0) (4.8)	503 (8.4)	370 (14.8)	195 (8.8)	93 (8.4)	1 (16.6)
	≥ 80	58 (0.2) (0.6)	59 (0.2) (1.3)	31 (0.2) (0.7)	14 (0.0) (1.0)	0 (0) (0)	48 (0.8)	34 (1.4)	24 (1.0)	11 (1.0)	0 (0)
	Total	9973 (49.7) (100.0)	4543 (22.6) (100.0)	4195 (21.0) ( <i>100.0</i> )	1341 (6.7) (100.0)	21 (0.0) (100.0)	5998 (100.0)	2508 (100.0)	2197 (100.0)	1109 (100.0)	6 (100.0)
	20 - < 30	7 (0.2) (0.4)	0 (0) (0)	0 (0) (0)	1 (0.0) (0.3)	0 (0) (0)	3 (0.2)	1 (0.2)	0 (0)	0 (0)	0 (0)
	30 - < 40	37 (0.8) (2.0)	6 (0.2) (0.5)	16 (0.4) (1.5)	3 (0.0) (1.0)	1 (0.0) (25.0)	14 (1.4)	3 (0.6)	5 (1.0)	2 (1.0)	0 (0)
	40 - < 50	217 (5.0) (11.6)	55 (1.2) (5.0)	133 (3.0) (12.1)	40 (1.0) (13.2)	1 (0.0) (25.0)	110 (10.8)	24 (4.2)	63 (11.7)	26 (13.7)	0 (0)
ıale	50 - < 60	627 (14.3) (33.6)	235 (5.4) (21.2)	337 (7.7) (30.6)	90 (2.0) (29.6)	0 (0) (0)	348 (34.2)	122 (21.4)	171 (31.7)	57 (29.9)	2 (100.0)
Fen	60 - < 70	677 (15.5) (36.2)	456 (10.5) (41.2)	405 (9.3) (36.7)	101 (2.5) (33.2)	2 (0.0) (50.0)	365 (35.8)	218 (38.4)	195 (36.4)	70 (36.6)	0 (0)
	70 - < 80	291 (6.6) (15.6)	326 (7.4) (29.5)	188 (4.2) (17.1)	65 (1.4) (21.4)	0 (0) (0)	170 (16.6)	170 (30.0)	88 (16.4)	33 (17.2)	0 (0)
	≥ 80	12 (0.2) (0.6)	29 (0.6) (2.6)	24 (0.6) (2.0)	4 (0.0) (1.3)	0 (0) (0)	10 (1.0)	30 (5.2)	15 (2.8)	3 (1.6)	0 (0)
	Total	1868 (42.6) (100.0)	1107 (25.3) (100.0)	1103 (25.2) (100.0)	304 (6.9) (100.0)	4 (0.0) (100.0)	1020 (100.0)	568 (100.0)	537 (100.0)	191 (100.0)	2 (100.0)

\*Others include Orang Asli, Kadazan, Melanau, Murut, Bajau, Bidayuh, Iban, Punjabi, Other Malaysian, and Foreigner \*\*Missing and Not Available were added together ^Percentage was presented differently in the 2007 – 2012 and 2013 – 2014 results. Percentage within the group was recalculated for 2007 – 2012 data and presented in italic font style

				20	13					20	14		
			Total	no. of p	atients =	6353			Total	no. of p	atients =	7783	
er	dno		Pı	re-morbi	id diabet	es			Pı	re-morbi	d diabet	es	
Gende	Age gr	D: 1 - 41 -	Diabeuc	Non-	Diabetic	Not	known		DIADEUC	Non-	Diabetic	Not	known
		No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
	20 - < 30	5	0.2	19	0.6	4	1.2	6	0.2	21	0.6	3	0.6
	30 - < 40	72	3.4	180	6.4	25	7.2	89	3.4	240	7.0	39	8.0
	40 - < 50	326	15.4	591	20.9	84	23.8	390	14.7	694	20.5	92	18.6
ale	50 - < 60	834	39.6	1067	37.7	124	35.2	1024	38.7	1234	36.5	188	38.2
W	60 - < 70	635	30.2	681	24	83	23.6	819	31.0	842	24.8	128	26.0
	70 - < 80	215	10.2	269	9.6	29	8.2	289	11.0	322	9.4	38	7.8
	≥ 80	20	1.0	24	0.8	3	0.8	27	1.0	39	1.2	4	0.8
	Total	2107	100.0	2831	100.0	352	100.0	2644	100.0	3392	100.0	492	100.0
	20 - < 30	0	0	1	0.2	0	0	1	0.2	2	0.4	0	0
	30 - < 40	8	1.2	3	0.8	2	4.4	6	0.8	4	0.8	1	1.6
	40 - < 50	62	9.8	43	11.0	5	11.2	63	8.4	44	9.8	6	10.1
nale	50 - < 60	220	35.0	100	25.6	10	22.2	224	29.8	127	28.6	19	31.6
Fen	60 - < 70	222	35.5	130	33.2	16	35.6	300	40.0	159	35.8	21	35.1
	70 - < 80	103	16.5	105	26.8	10	22.2	140	18.6	94	21.2	9	15.0
	≥ 80	12	2.0	9	2.4	2	4.4	16	2.2	15	3.4	4	6.6
	Total	627	100.0	391	100.0	45	100.0	750	100.0	445	100.0	60	100.0

Table 1.4.3 Age-gender distribution of patients who underwent PCI, by pre-morbid diabetes, NCVD-PCI Registry, 2007 – 2014

			^2007	- 2012			2013 - 2014	
			Total no. of pa	tients = 24459		Total n	o. of patients =	= 14136
	đ		Pre-morbi	d diabetes		Pre	-morbid diabe	etes
Gender	Age grou	Diabetic	Non- Diabetic	Not known	Missing	Diabetic	Non- Diabetic	Not known
		No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)
	20 - < 30	10 (0.0) (0.1)	59 (0.2) (0.5)	12 (0.0) (2.2)	0 (0) (0)	11 (0.2)	40 (0.6)	7 (0.8)
	30 - < 40	245 (1.2) (2.9)	616 (3.0) (5.6)	31 (0.2) (5.7)	0 (0) (0)	161 (3.4)	420 (6.9)	64 (7.6)
	40 - < 50	1484 (7.4) (17.5)	2623 (13.0) (23.8)	103 (0.6) (18.9)	2 (0.0) (11.1)	716 (15.0)	1285 (20.7)	176 (20.8)
lle	50 - < 60	3374 (16.8) (39.7)	3906 (19.5) (35.5)	196 (1.1) (35.9)	9 (0.0) (50.0)	1858 (39.2)	2301 (37.0)	312 (37.0)
Ma	60 - < 70	2490 (12.4) (29.3)	2718 (13.7) (24.7)	140 (0.6) (25.6)	6 (0.0) (33.3)	1454 (30.6)	1523 (24.4)	211 (25.0)
	70 - < 80	831 (4.2) (9.8)	997 (5.1) (9.1)	58 (0.2) (10.6)	1 (0.0) (5.6)	504 (10.6)	591 (9.4)	67 (8.0)
	≥80	67 (0.4) (0.7)	89 (0.4) (0.8)	6 (0.0) (1.1)	0 (0) (0)	47 (1.0)	63 (1.0)	7 (0.8)
	Total	8501 (42.4) (100.0)	11008 (54.9) (100.0)	546 (2.7) (100.0)	18 (0.0) (100.0)	4751 (100.0)	6223 (100.0)	844 (100.0)
	20 - < 30	2 (0.0) (0.1)	6 (0.2) (0.4)	0 (0) (0)	0 (0) (0)	1 (0.0)	3 (0.4)	0 (0)
	30 - < 40	38 (0.8) (1.4)	23 (0.6) (1.4)	2 (0.0) (2.4)	0 (0) (0)	14 (1.1)	7 (0.8)	3 (2.8)
	40 - < 50	278 (6.4) (10.4)	154 (3.6) (9.4)	13 (0.2) (15.9)	1 (0.0) (33.3)	125 (9.1)	87 (10.4)	11 (10.5)
ıale	50 - < 60	832 (19.0) ( <i>31.2</i> )	435 (10.0) (26.6)	21 (0.4) (25.6)	1 (0.0) (33.3)	444 (32.2)	227 (27.2)	29 (27.7)
Fem	60 - < 70	1011 (23.1) (38.0)	604 (13.9) ( <i>36.9</i> )	25 (0.6) (30.5)	1 (0.0) (33.4)	522 (38.0)	289 (34.6)	37 (35.2)
	70 - < 80	464 (10.6) (17.4)	387 (8.8) (23.6)	19 (0.4) (23.2)	0 (0) (0)	243 (17.6)	199 (23.8)	19 (18.0)
	≥ 80	39 (0.8) (1.5)	28 (0.6) (1.7)	2 (0.0) (2.4)	0 (0) (0)	28 (2.0)	24 (2.8)	6 (5.8)
	Total	2664 (60.7) (100.0)	1637 (37.7) (100.0)	82 (1.6) (100.0)	3 (0.0) (100.0)	1377 (100.0)	836 (100.0)	105 (100.0)

<sup>^</sup>Percentage was presented differently in the 2007 – 2012 and 2013 – 2014 results. Percentage within the group was recalculated for 2007 – 2012 data and presented in italic font style

				20	13					20	14		
	dr		Total	no. of p	atients =	6353			Total	no. of p	atients =	7783	
ndeı	grou		Pre-	morbid	hyperter	nsion			Pre-	morbid	hyperter	ision	
Ge	Age	Hyper	tensive	No hypert	on- tensive	Not k	nown	Hyper	tensive	No hypert	on- tensive	Not k	nown
		No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
	20 - < 30	7	0.2	17	1.0	4	1.4	7	0.2	18	1.0	5	1.2
	30 - < 40	109	3.2	147	9.4	21	7.2	139	3.4	190	9.8	39	9.4
	40 - < 50	540	15.8	385	24.4	76	25.7	584	14.0	496	25.3	96	23.0
ale	50 - < 60	1318	38.7	597	37.8	110	37.2	1616	38.7	683	34.9	147	35.4
W	60 - < 70	1014	29.7	328	20.8	57	19.3	1265	30.3	421	21.6	103	24.8
	70 - < 80	392	11.4	95	6.0	26	8.8	506	12.2	119	6.2	24	5.8
	≥ 80	35	1.0	11	0.6	1	0.4	46	1.2	22	1.2	2	0.4
	Total	3415	100.0	1580	100.0	295	100.0	4163	100.0	1949	100.0	416	100.0
	20 - < 30	0	0	1	0.6	0	0	1	0.2	2	1.0	0	0
	30 - < 40	9	1.1	2	1.2	2	5.2	9	0.9	1	0.4	1	2.0
	40 - < 50	77	9.1	27	16.4	6	15.8	69	6.9	38	18.4	6	12.0
nale	50 - < 60	250	29.0	70	42.4	10	26.4	284	28.4	74	36.0	12	24.0
Fen	60 - < 70	322	37.4	38	23.0	8	21.0	390	39.0	67	32.6	23	46.0
	70 - < 80	183	21.2	25	15.2	10	26.4	218	21.8	19	9.2	6	12.0
	≥ 80	19	2.2	2	1.2	2	5.2	28	2.8	5	2.4	2	4.0
	Total	860	100.0	165	100.0	38	100.0	999	100.0	206	100.0	50	100.0

Table 1.4.4 Age-gender distribution of patients who underwent PCI, by pre-morbid hypertension, NCVD-PCI Registry, 2007 – 2014

			^2007	- 2012			2013 - 2014	
		1	Total no. of pa	tients = 24459		Total n	o. of patients =	= 14136
			Pre-morbid	hypertension		Pre-n	orbid hyperte	nsion
	đ	e	e,			e	6	
der	rou	siv	sivo	wn	οü	siv	sivo	uw
ene	66	ten	on- ten	ou	sin	ten	on- ten	ou
0	Ag	per	N. N.	ot k	Mis	per	No	ot k
		HyJ	hyl	ž		HyJ	hyl	ž
		 	NT	N	NT		N	NT
		NO.	NO.	NO.	NO.	NO.	NO.	NO.
		(%)	(%)	(%)	(70)	(70)	(70)	(70)
	20 - < 30	(0,0)	(0.2)	(0.0)	(D)	14	35	9
		(0.1)	(1.0)	(2.2)	(0)	(0.2)	(1.0)	(1.2)
		437	419	35	1	249	227	(0
	30 - < 40	(2.2)	(2.0)	(0.2)	(0.0)	(3 2)	(9.6)	(8.4)
		(3.1)	(7.7)	(7.6)	(7.1)	(3.2)	(9.0)	(0.4)
		2545	1567	99	1	1124	881	172
	40 - < 50	(12.7)	(7.8)	(0.4)	(0.0)	(14.9)	(25.0)	(24.2)
		(18.0)	(28.8)	(21.5)	(7.1)			. ,
	50 < 60	2322 (267)	(9.9)	(0.9)	(0,0)	2934	1280	257
e	30-<00	(20.7)	(36.1)	(35.2)	(50.0)	(38.9)	(36.2)	(36.2)
Ial		4143	1103	104	4			
~	60 - < 70	(20.7)	(5.4)	(0.6)	(0.0)	2279	(21.2)	160
		(29.3)	(20.3)	(22.6)	(28.7)	(30.0)	(21.2)	(22.6)
		1531	307	48	1	898	214	50
	70 - < 80	(7.7)	(1.6)	(0.2)	(0.0)	(11.8)	(6.0)	(7.0)
		(10.8)	(5.6)	(10.4)	(7.1)	()	(0.0)	()
	> 00	128	32	2	0	81	33	3
	280	(0.0)	(0.2)	(0.0)	(0)	(1.0)	(1.0)	(0.4)
		14150	(0.3) 5440	(0:5)	(0)			
	Total	(70.6)	(27.1)	(2,3)	(0.0)	7578	3529	711
	Total	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)
		5	3	0	0			
	20 - < 30	(0.2)	(0.0)	(0)	(0)		3	0
		(0.1)	(0.5)	(0)	(0)	(0)	(0.8)	(0)
		39	22	2	0	18	3	3
	30 - < 40	(0.8)	(0.6)	(0.0)	(0)	(1.0)	(0.8)	(3.4)
		(1.1)	(3.6)	(3.5)	(0)			
	10 < 50	338	95 (2-2)	(0,2)	(0,0)	146	65	12
	40 - < 50	(7.8) (9.1)	(2.2) (15.7)	(0.2)	(0.0)	(7.7)	(17.6)	(13.6)
		1069	203	16	(30.0)			
	50 - < 60	(24.4)	(4.6)	(0.4)	(0.0)	534	(28.8)	(25.0)
ale		(28.7)	(33.5)	(28.1)	(25.0)	(28.7)	(38.8)	(23.0)
em		1443	180	17	1	712	105	31
H	60 - < 70	(33.0)	(4.2)	(0.4)	(0.0)	(38.4)	(28.4)	(35.2)
		(38.8)	(29.7)	(29.8)	(25.0)			
	70 < 80	(17.6)	(2.0)	(0,2)	0	401	44	16
	70-< 80	(17.0) (20.7)	(2.0)	(0.2)	(0)	(21.6)	(11.8)	(18.2)
		57	11	1	0			
	≥ 80	(1.2)	(0.2)	(0.0)	(0)	47	7	4
		(1.5)	(1.8)	(1.8)	(0)	(2.6)	(1.8)	(4.6)
		3719	606	57	4	40.50		00
	Total	(85.0)	(13.8)	(1.2)	(0.0)	1859 (100 0)	5/1 (100 0)	88 (100 0)
		(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)

 ^Percentage was presented differently in the 2007 – 2012 and 2013 – 2014 results. Percentage within the group was recalculated for 2007 – 2012 data and presented in italic font style

				20	13					20	14		
er	dno		Total	no. of p	atients =	6353			Total	no. of p	atients =	7783	
end	56		Pre-1	norbid d	lyslipida	emia			Pre-1	norbid d	lyslipida	emia	
G	Age	Y	es	Ν	0	Not k	nown	Y	es	Ň	lo	Not k	nown
		No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
	20 - < 30	12	0.4	10	0.6	6	1.2	14	0.4	9	0.4	7	1.1
	30 - < 40	139	4.4	102	6.2	36	7.2	178	4.8	143	6.8	47	7.3
	40 - < 50	571	18.2	326	19.8	104	21.0	579	15.4	456	21.6	141	21.8
ale	50 - < 60	1197	38.1	641	38.8	187	37.6	1456	38.5	761	36.0	229	35.4
W	60 - < 70	887	28.3	392	23.8	120	24.2	1101	29.1	532	25.2	156	24.2
	70 - < 80	311	9.8	161	9.8	41	8.2	397	10.6	189	9.0	63	9.8
	≥80	28	0.8	16	1.0	3	0.6	45	1.2	22	1.0	3	0.4
	Total	3145	100.0	1648	100.0	497	100.0	3770	100.0	2112	100.0	646	100.0
	20 - < 30	0	0	1	0.4	0	0	0	0	3	0.8	0	0
	30 - < 40	6	0.9	5	1.6	2	2.2	8	1.0	2	0.6	1	1.2
	40 - < 50	60	8.9	41	13.6	9	9.4	66	8.2	38	10.6	9	10.4
nale	50 - < 60	217	32.6	86	28.4	27	28.4	253	31.2	96	26.6	21	24.4
Fen	60 - < 70	234	35.2	104	34.4	30	31.6	301	37.2	139	38.6	40	46.6
	70 - < 80	134	20.2	61	20.2	23	24.2	161	20.0	70	19.4	12	14.0
	≥ 80	15	2.2	4	1.4	4	4.2	20	2.4	12	3.4	3	3.4
	Total	666	100.0	302	100.0	95	100.0	809	100.0	360	100.0	86	100.0

Table 1.4.5 Age-gender distribution of patients who underwent PCI, by pre-morbid dyslipidaemia, NCVD-PCI Registry, 2007 – 2014

			^2007	- 2012			2013 - 2014           I no. of patients = 14136           morbid dyslipidæmia           No         Not known           No.         No.           (%)         (%)           6         19         13           a)         (0.6)         (1.2)           7         245         83           5)         (6.6)         (7.2)           0         782         245           5)         (20.7)         (21.4)           3         1402         416           (a)         (37.1)         (36.4)           8         924         276           3)         1402         416           (a)         (24.6)         (24.2)           8         350         104           (2)         (9.4)         (9.0)           3         38         6           (1.0)         (0.6)         (0)           (1.00.0)         (100.0)         (100.0)           (0         4         7         3           (0)         (4         7         3           (0)         (4         7         3           (1.				
	dr	,	Total no. of pa	ntients = 24459	Total no. of patients = 14136						
nder	groı		Pre-morbid d	lyslipidaemia		Pre-m	orbid dyslipid	aemia			
Gei	Age	Yes	No	Not known	Missing	Yes	No	Not known			
	ł	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		No.	No.						
		(%)	<u>(%)</u> 30	(%)	(%)	(%)	(%)	(%)			
	20 - < 30	(0.2)	(0.2)	(0.0)	0 (0)	26	19	13			
	20 100	(0.3)	(0.6)	(1.4)	(0)	(0.4)	No         Not           No.         (%)           19         (0.6)           245         (6.6)           782         (20.7)           1402         (37.1)           924         (24.6)           350         (9.4)           38         (1.0)           3760         (100.0)           4         (0.6)           7         (1.0)           79         (12.0)           182         (27.4)           243         (36.8)           131         (19.8)	(1.2)			
		592	251	48	1	217	245	92			
	30 - < 40	(3.0)	(1.2)	(0.2)	(0.0)	(4.6)	(6.6)	(72)			
		(4.1)	(5.3)	(4.9)	(3.5)	(4.0)	(0.0)	(7.2)			
	40	2903	1097	205	7	1150	782	245			
	40 - < 50	(14.4)	(5.5)	(1.1)	(0.0)	(16.6)	(20.7)	(21.4)			
		5460	1665	345	(24.1)						
	50 - < 60	(27.2)	(8.3)	(1.9)	(0.0)	2653	1402	416			
le		(38.1)	(35.1)	(35.5)	(51.7)	(38.4)	(37.1)	(36.4)			
Ma		3887	1207	255	5	1099	024	276			
	60 - < 70	(19.4)	(6.1)	(1.3)	(0.0)	(28.8)	(24.6)	(24.2)			
		(27.1)	(25.4)	(26.2)	(17.2)	(20.0)	(24.0)	(24.2)			
	-	1343	443	100	1	708	350	104			
	70 - < 80	(6.6)	(2.2)	(0.4)	(0.0)	(10.2)	924 (24.6) 350 (9.4) 38 (1.0) <b>3760</b> (100.0)	(9.0)			
		(9.4)	(9.3)	(10.3)	(3.3)						
	> 80	(0.6)	(0.2)	(0,0)	(D)	73	(9.4) 38 (1.0) 3760	6			
	200	(0.7)	(1.2)	(0.6)	(0)	(1.0)	(1.0)	(0.6)			
		14327	4744	973	29		782         (20.7)         1402         (37.1)         924         (24.6)         350         (9.4)         38         (1.0)         3760         (100.0)         4         (0.6)         7         (1.0)         79         (12.0)         182				
	Total	(71.4)	(23.7)	(4.9)	(0.0)	6915		1143			
		(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)			
		5	3	0	0	0	4	0			
	20 - < 30	(0.2)	(0.0)	(0)	(0)	0 (0)	(0.6)				
		(0.2)	(0.3)	(0)	(0)	(0)	(0.0)	(0)			
	•••	43	15	5	0	14	7	3			
	30 - < 40	(1.0)	(0.4)	(0.2)	(0)	(1.0)	No         Not           No.         Not           (%)         (%)           6         19           (0.6)         (0.6)           7         245           (5)         (6.6)           0         782           (20.7)         (20.7)           3         1402           (37.1)         (37.1)           8         924           (24.6)         (24.6)           8         350           (2)         (9.4)           3         38           (1.0)         (100.0)           0         4           7         (1.0)           6         79           (5)         (27.4)           5         243           (27.4)         (36.8)           5         131           (19.8)         (24.4)           5         16           (2.4)         (27.4)	(1.6)			
		(1.3)	(1.0)	(2.7)	(0)						
	40 - < 50	(7.4)	(2.0)	(0.6)	$(0,0)^{2}$	126	79	18			
	10 200	(10.1)	(9.4)	(14.8)	(25.0)	(8.6)	924 (24.6)         350 (9.4)         38 (1.0)         3760 (100.0)         4 (0.6)         7 (1.0)         79 (12.0)         182 (27.4)         243 (36.8)         131	(10.0)			
		989	257	40	3	470	192	19			
0	50 - < 60	(22.6)	(5.8)	(1.0)	(0.0)	(31.8)	(27.4)	(26.6)			
lal		(30.4)	(27.5)	(21.2)	(37.5)	(51.0)	(27.4)	(20.0)			
Fen	<0 <b>7</b> 0	1224	344	71	2	535	243	70			
	60 - < 70	(28.0)	(7.8)	(1.6)	(0.0)	(36.2)	(36.8)	(38.6)			
		623	205	(37.0)	(23.0)						
	70 - < 80	(14.2)	(4.6)	(1.0)	(0.0)	295	131	35			
		(19.1)	(22.0)	(21.7)	(12.5)	(20.0)	(19.8)	(19.4)			
		43	22	4	0	35	16	7			
	≥80	(1.0)	(0.6)	(0.0)	(0)	(2.4)	(2.4)	(3.8)			
		(1.3)	(2.4)	(2.0)	(0)	(2)	(2.1)	(3.0)			
		3255	934	189	8	1475	662	181			
	Total	(74.4)	(21.2)	(4.4)	(0.0)	(100.0)	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	(100.0)			
		(100.0)	(100.0)	(100.0)	(100.0)	、 · · · · /		· · · · · · · · · · · · · · · · · · ·			

<sup>^</sup>Percentage was presented differently in 2007 – 2012 and 2013 – 2014 results. Percentage within the group was recalculated for 2007 – 2012 data and presented in italic font style

Gender		2013							2014					
	dn	Total no. of patients = 6353						Total no. of patients = 7783						
	gro	Family history of premature cardiovascular						Family history of premature cardiovascular						
	Age	V	00	No Not known			Vos No			lase	Not known			
	7	No	(0/)	No	(0/)	No	10WII (9/)	No	(9/)	No	(0/)			
		110.	(70)	110.	(70)	110.	(70)	110.	(70)	110.	(70)	110.	(70)	
	20 - < 30	9	1.6	17	0.4	2	0.2	3	0.4	19	0.4	8	0.6	
	30 - < 40	42	7.0	187	5.2	48	4.4	61	9.2	227	5.0	80	6.0	
	40 - < 50	140	23.3	637	17.8	224	20.4	150	22.8	765	16.8	261	19.8	
ale	50 - < 60	262	43.7	1344	37.5	419	38.2	259	39.4	1678	37.0	509	38.4	
M	60 - < 70	114	19.0	992	27.7	293	26.6	141	21.4	1320	29.0	328	24.8	
	70 - < 80	30	5.0	383	10.6	100	9.0	41	6.2	482	10.6	126	9.6	
	≥80	2	0.4	32	0.8	13	1.2	4	0.6	55	1.2	11	0.8	
	Total	599	100.0	3592	100.0	1099	100.0	659	100.0	4546	100.0	1323	100.0	
	20 - < 30	1	1.0	0	0	0	0	0	0	2	0.2	1	0.4	
	30 - < 40	3	2.7	4	0.6	6	3.0	0	0	9	1.0	2	0.8	
	40 - < 50	13	11.7	81	10.7	16	8.2	22	17.6	68	7.9	23	9.2	
nale	50 - < 60	49	44.1	218	28.7	63	32.4	34	27.2	261	29.7	75	30.2	
Fen	60 - < 70	30	27.0	265	35.0	73	37.4	43	34.4	335	38.0	102	41.0	
	70 - < 80	15	13.5	171	22.6	32	16.4	23	18.4	177	20.0	43	17.2	
	≥ 80	0	0	18	2.4	5	2.6	3	2.4	29	3.2	3	1.2	
	Total	111	100.0	757	100.0	195	100.0	125	100.0	881	100.0	249	100.0	

Table 1.4.6 Age-gender distribution of patients who underwent PCI, by family history of premature cardiovascular disease, NCVD-PCI Registry, 2007 – 2014

Gender			^2007	- 2012						
	<u>a</u>	,	Total no. of pa	ntients = 24459	Total no. of patients = 14136					
	grou	Family histo	ory of prematu	ire cardiovasc	ular disease	Family history of premature cardiovascular disease				
	Age	Yes	No	Not known	Missing	Yes	No	Not known		
		No.	No.	No.	No.	No.	No.	No.		
		(%)	(%)	(%)	(%)	(%)	(%)	(%)		
	20 - < 30	(02)	(0.2)	(0 0)	0	12	36	10		
	20-<50	(0.2)	(0.2)	(0.5)	(0)	(1.0)	(0.4)	(0.4)		
		221	590	81	0	102	414	129		
	30 - < 40	(1.2)	(3.0)	(0.4)	(0)	(8.2)	414	(5.2)		
		(6.4)	(4.1)	(3.5)	(0)	(8.2)	(5.0)	(3.2)		
		912	2878	415	7	290	1402	485		
	40 - < 50	(4.6)	(14.4)	(2.0)	(0.0)	(23.0)	(17.3)	(20.0)		
		(20.0)	(20.1)	(18.0)	(20.0)					
	50 - < 60	(6.6)	(26.2)	(4.4)	(0,0)	521	3022	928		
e	50-<00	(38.3)	(36.8)	(38.8)	(41.0)	(41.5)	(37.3)	(38.4)		
Mal		735	3997	615	7	255	2212	(21		
~	60 - < 70	(3.6)	(20.0)	(3.0)	(0.0)	(20.2)	(28.4)	621 (25.6)		
		(21.4)	(28.0)	(26.6)	(26.0)	(20.5)	(28.4)	(23.0)		
		216	1399	270	2	71	865	226		
	70 - < 80	(1.0)	(7.0)	(1.4)	(0.0)	(5.6)	3022         (37.3)         2312         (28.4)         865         (10.6)         8138         (100)         2         (0.2)	(9.4)		
		(6.3)	(9.8)	(11.7)	(7.0)	()	865 (10.6) 87 (1.0) 8138			
	<b>&gt; 80</b>	10	131	(0,2)	0	6	1402         (17.3)         3022         (37.3)         2312         (28.4)         865         (10.6)         87         (1.0)         8138         (100)         2         (0.2)         13         (0.8)	24		
	200	(0.0)	(0.0)	(0.2)	(0)	(0.4)	(1.0)	(1.0)		
		2422	1/301	2312	(0)		865 (10.6)         87 (1.0)         8138 (100)         2 (0.2)			
	Total	(17.2)	(71.4)	(11.4)	(0.0)	1258		2422		
	Total	(100.0)	(100.0)	(100.0)	(100.0)	(100)	(100)	(100)		
		2	6	0	0		_			
	20 - < 30	(0.0)	(0.2)	(0)	(0)		(0,2)			
		(0.3)	(0.2)	(0)	(0)	(0.4)	58         8138 (100)           1         2 (0.2)	(0.2)		
		25	31	7	0	3	13	8		
	30 - < 40	(0.6)	(0.8)	(0.2)	(0)	(1.2)	(0.8)	(1.8)		
		(3.5)	(1.0)	(0.2)	(0)	(112)	No. (%)           36 (0.4)           36 (0.4)           414 (5.0)           1402 (17.3)           3022 (37.3)           2312 (28.4)           865 (10.6)           87 (1.0)           8138 (100)           2 (0.2)           13 (0.8)           149 (9.0)           479 (29.3)           600 (36.7)           348 (21.2)           477 (2.8)           1638 (100)	(110)		
	10 < 50	107	272	66 (1.6)		35	149	39		
	40 - < 50	(2.4)	(0.2)	(1.0) (12.1)	(0.0)	(14.8)	$\begin{array}{c c} (10.6) \\ (10.6) \\ (10.6) \\ (10.6) \\ (1.0) \\ ($	(8.9)		
		240	899	145	5					
	50 - < 60	(5.4)	(20.3)	(3.4)	(0.2)	83	479	138		
ale		(33.4)	(28.9)	(26.6)	(71.4)	(35.2)	(29.3)	(31.1)		
em		246	1192	202	1	73	600	175		
Ĭ.	60 - < 70	(5.5)	(27.1)	(4.5)	(0.0)	(31.0)	(36.7)	(39.4)		
		(34.3)	(38.3)	(37.0)	(14.3)	(0-1.0)	(0000)	(0))		
	70 < 80	(2.2)	663 (15-2)	114	0	38	348	75		
	70-< 80	(2.2)	(13.2) (21.3)	(2.0)	(0)	(16.2)	(21.2)	(16.8)		
		(15.0)	(21.3)	12	(0)					
	≥ 80	(0.2)	(1.2)	(0.2)	(0)	3	47	8		
		(0.5)	(1.6)	(3.2)	(0)	(1.2)	(2.8)	(1.8)		
		718	3115	546	7					
	Total	(16.3)	(71.0)	(12.5)	(0.2)	236	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	444		
		(100.0)	(100.0)	(100.0)	(100.0)	(100)		(100)		

 ^Percentage was presented differently in 2007 – 2012 and 2013 – 2014 results. Percentage within the group was recalculated for 2007 – 2012 data and presented in italic font style

	2007 - 2012 Total no. of patients = 24459		20	13	20	14	2013 - 2014	
Presence of cumulative risk factors*			Total no. of patients = 6353		Total no. = 7	of patients 783	Total no. of patients = 14136	
	No.	%	No.	%	No.	%	No.	%
None	483	2.0	162	2.6	240	3.0	402	2.8
1 risk factor	1798	7.4	719	11.4	948	12.2	1667	11.8
2 risk factors	4389	18.0	1422	22.3	1681	21.6	3103	22.0
3 risk factors	7250	29.6	1955	30.7	2194	28.2	4149	29.4
> 3 risk factors	10539	43.0	2095	33.0	2720	35.0	4815	34.0
Total	24459	100.0	6353	100.0	7783	100.0	14136	100.0

Table 1.5.1 Presence of cumulative risk factors, NCVD-PCI Registry, 2007 – 2014

\* Risk factors were defined as presence of 1) dyslipidaemia, 2) hypertension, 3) diabetes, 4) family history of premature cardiovascular disease, 5) smoking [current smokers and former smokers (quit more than 30 days)], and 6) obesity (BMI >= 23.0)

		2007 - 2012 Total no. of patients = 24459		20	13	20	14	2013 - 2014	
Gender	Presence of cumulative risk factors*			Total no. of patients = 6353		Total no. of patients = 7783		Total no. of patients = 14136	
		No.	%	No.	%	No.	%	No.	%
	None	388	2.0	125	2.4	199	3.0	324	2.8
	1 risk factor	1482	7.4	614	11.6	811	12.4	1425	12.0
Mala	2 risk factors	3503	17.4	1163	22.0	1368	21.0	2531	21.4
Male	3 risk factors	5787	28.8	1569	29.6	1801	27.6	3370	28.6
	> 3 risk factors	8913	44.4	1819	34.4	2349	36.0	4168	35.2
	Total	20073	100.0	5290	100.0	6528	100.0	11818	100.0
	None	95	2.2	37	3.4	41	3.2	78	3.4
	1 risk factor	316	7.2	105	9.8	137	10.9	242	10.4
Famala	2 risk factors	886	20.2	259	24.4	313	24.9	572	24.6
remaie	3 risk factors	1463	33.4	386	36.4	393	31.4	779	33.6
	> 3 risk factors	1626	37.0	276	26.0	371	29.6	647	28.0
	Total	4386	100.0	1063	100.0	1255	100.0	2318	100.0

Table 1.5.2 Presence of cumulative risk factors by gender, NCVD-PCI Registry, 2007 – 2014

\*Risk factors were defined as presence of 1) dyslipidaemia, 2) hypertension, 3) diabetes, 4) family history of premature cardiovascular disease, 5) smoking [included current smokers and former smokers (quit more than 30 days)], and 6) obesity (BMI  $\geq 23.0$ )
# CLINICAL PRESENTATIONS AND INVESTIGATIONS

Zubin Othman Ibrahim and Sazzli Shahlan Kasim Cardiology Unit, UiTM Specialist Centre, Faculty of Medicine, UiTM

# Summary

- 1. Majority of patients (76.0%) had a low TIMI risk index.
- 2. Atrial fibrillation in patients undergoing PCI is 1.2%.
- 3. A rising trend of patients with unstable angina and STEMI-Killip IV undergoing PCI.
- 4. Thirty-five percent (35.0%) of PCIs were performed in patients with ACS and 57.5% of these were STEMI patients. Anterior STEMI (56.2%) remains the predominant presentation of all STEMI PCIs.
- 5. When we compare the data between the 2007 2012 and 2013 2014 periods for STEMI PCIs, we see improvements in all quality indicator times.

This chapter will deal with the clinical presentation and relevant investigations at the time of PCI for patients enrolled in the registry between 2013 - 2014. Overall, there were 15,514 procedures during the years studied (2013 - 2014). In comparison, there were 11,621 in 2007 - 2009 and 14,862 in 2010 - 2012.

Heart rate and blood pressure were recorded at the start of each procedure. The TIMI risk index (TRI) were analysed for low, intermediate, and high (< 30, 30 - 70 and > 70) risks, respectively. This index is predictive of 30-day and long term mortality in ACS. Functional ischaemia relates to information obtained from either stress testing or imaging pre-procedure. Time to treatment follows current practice standards.

Only 10.7% of patients who underwent elective PCI had a functional ischaemic test before the procedure. As there was a large component of missing data in this category, further interpretation cannot be made. We are reminded, however, that many patients undergoing elective PCI could benefit from prior ischaemic testing if the symptoms were atypical, and if the burden of ischaemia was unclear. [Table 2.1]

The mean systolic blood pressure for the years 2013 - 2014 was 136 mmHg (SD 25 mmHg), and mean diastolic blood pressure was 76 mmHg (SD 13 mmHg). Seventy-six percent of all PCI patients in 2013 – 2014 had a TRI < 30. This is a reduction compared to the period of 2007 - 2012, in which 82.2% of all PCI patients had a TRI < 30. [Table 2.1]

Baseline ECG shows that 84.4% of patients were in sinus rhythm compared to 86.4% in 2007 - 2012. In 2013 - 2014, patients undergoing PCI with atrial fibrillation was 1.2% (n = 176). [Table 2.1]

In comparison to the NCVD-PCI data, the prevalence of atrial fibrillation in patients admitted to two large Malaysian hospitals were 2.7% and  $2.8\%^{1,2}$ . Further epidemiological data collected in Malaysia (PURE-REDISCOVER Study) shows that the prevalence of atrial fibrillation in the population was  $0.56\%^2$ . Interestingly, this is much lower than the 6.2 - 7.9% of patients with atrial fibrillation seen in the GRACE registry<sup>3</sup>.

Data shown in the NCVD-PCI registry shows the potential scope of problems PCI operators have in dealing with anticoagulation to prevent stroke in patients requiring DAPT. Although the numbers seem small (1.2%), it is a real problem faced daily by interventionalists and patients. [Table 2.1]

Renal function recorded shows a similar profile with patients from 2007 - 2012. Majority (65.3%) of patients undergoing PCI had a glomerular filtration rate GFR (MDRD) that was more than 60 mls/min/1.73m<sup>2</sup>. This is similar with patients studied during the periods of 2007 - 2012. Mean eGFR did not differ much in patients who underwent elective or emergency PCIs. [Table 2.12]

Total cholesterol (TC) and LDL levels were higher in STEMI PCI patients. During the studied period, median TC was 4.1 mmol/l and 5.2 mmol/l in patients with elective PCI and STEMI PCI, respectively. In elective PCI patients, the median LDL was 2.3 mmol/L and for STEMI-PCI, the LDL was 3.2 mmol/L. Depending on the timing of blood sampling for lipid levels in post STEMI patients, the levels will be falsely low. Thus, the difference will likely be even larger. [Table 2.14 and Table 2.15]

The percentage of PCIs performed in patients who presented with an ACS was 35.0% in 2013 - 2014. In 2007 - 2012, the PCIs performed for ACS was 38.7%. Although the percentage decreased, the absolute numbers per year markedly increased. Of the ACS subtypes, STEMI PCI predominates with an increasing trend, from 55.8% in 2007 - 2012 to 57.5% in 2013 - 2014. Of these, 56.2% were anterior STEMIs. [Table 2.1]

A clear trend is seen throughout the period of NCVD-PCI reporting, as there were more PCIs for UA being performed. The ACS PCI cases were 11.2% (n = 1140) during 2007 – 2012 and this increased to 17.4% (n = 946) in 2013 – 2014. This may just represent the higher number of centres reporting to the NCVD-PCI database, but could possibly be proof of adherence to current guidelines that encourage early invasive strategy for patients with unstable angina. [Table 2.1]

The proportion of STEMI PCI in Killip class IV was 6.2% (n = 358) in 2007 – 2012 compared to 14.9% (n = 395) in 2013 – 2014. The doubling of the percentage of patients getting treated for a STEMI with PCI who present with cardiogenic shock may indicate the readiness of interventionalists in the country to attempt emergency revascularisation in high risk patients. [Table 2.1]

When we compare the data for STEMI PCIs with recorded time to treatment between the 2007 - 2012 and 2013 - 2014 periods, the median symptom-to-door time improved from 175 minutes to 87.5 minutes when presenting to a PCI-capable hospital, and 260 minutes to 107 minutes when presenting to a non-PCI-capable hospital. [Table 2.2.1 and Table 2.2.2] The improvement in these times is encouraging, and could be a reflection of improved awareness of the public and successful health promotion.

An area which also showed improvement was the median door-to-balloon (D2B) time for patients presenting to a PCI-capable hospital. During the 2007 - 2012 period, it was 104 minutes, and this improved to 73 minutes during the 2013 - 2014 period. [Table 2.2.2]

For STEMI patients transferred from a non-PCI-capable hospital, the median transfer time markedly improved from 201 minutes to 65 minutes between the two studied cohorts (2007 - 2012 vs. 2013 - 2014); and between these study periods, the median D2B time in these patients also improved from 74 minutes to 62 minutes. [Table 2.2.1]

In all STEMI PCIs (non-transfer and transfer), the median D2B time was 70 minutes. Compared to the median D2B time of 90 minutes during the 2007 – 2012 periods, this was a tremendous improvement in our reported data. It must be noted, however, that the STEMI-PCI numbers during this earlier period was low, and missing data was not insignificant. [Table 2.1]

The improved quality indicator times were encouraging; however more work need to be done to obtain further outcome benefit for STEMI patients treated with primary PCI. With the MySTEMI network initiative (collaboration between PCI capable centres and non-PCI capable centres for patients presenting with STEMI) commenced in 2016, further improvements are expected.

### References

- 1. Freestone B, Rajaratnam R, Hussain N, Lip GYH. Admissions with atrial fibrillation in a multiracial population in Kuala Lumpur, Malaysia. *Int J Cardiol.* 91:(2003)233–8.
- 2. Goay SE, Lim CW, Tee TY, et al. Prevalence and contemporary management of atrial fibrillation in a single tertiary hospital. Presented as a poster at National Heart Association-Annual Scientific Meeting 2016: 8-10 April 2016, Kuala Lumpur, Malaysia.
- 3. Mehta RH, Dabbous OH, Granger CB, et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. *Am J Cardiol*. 2003;92:1031–6.

	2007 - 2012		20	13	20	14	2013 - 2014		
	Total proced 264	no. of lures = 183	Total proced 69	no. of lures = 28	Total proced 85	no. of lures = 86	Total proced 155	no. of ures = 514	
	No.	%	No.	%	No.	%	No.	%	
Clinical examination									
Heart rate at presentation, beats/minute									
N	241	15	5975		7642		13617		
Mean (SD)	71.3 (	(15.9)	74.3 (17.6)		75.1 (	(18.1)	74.8 (	(17.9)	
Median (min, max)	69.0 (25.0, 193.0)		72.0 (26.	0, 191.0)	72.0 (25.	0, 194.0)	72.0 (25.	0, 194.0)	
Missing, No. (%)	2368	9.0	953 13.8		944	11.0	1897	12.2	
-									
Heart rate at presentation, beats/minute, No. (%)									
< 90	21282	80.4	5058	73.0	6376	74.2	11434	73.8	
$\geq$ 90	2833	10.6	917	13.2	1266	14.8	2183	14.0	
Missing	2368	9.0	953	13.8	944	11.0	1897	12.2	
Systolic blood pressure, mmHg									
Ν	238	337	58	73	75	29	134	402	
Mean (SD)	136.4	(25.2)	135.1	(25.5)	138.0	(26.1)	136.7	(25.9)	
Median (min, max)	134.0 (60	.0, 230.0)	133.0 (60	.0, 230.0)	136.0 (60	.0, 227.0)	135.0 (60	.0, 230.0)	
Missing, No. (%)	2646	10.0	1055	15.2	1057	12.4	2112	13.6	
Systolic blood pressure, mmHg, No. (%)									
< 90	261	1.0	130	1.9	159	1.8	289	1.8	
$\geq$ 90	23576	89.0	5743	82.9	7370	85.8	13113	84.6	
Missing	2646	10.0	1055	15.2	1057	12.4	2112	13.6	
Diastolic blood pressure, mmHg									
N	237	798	58	65	75	13	133	378	
Mean (SD)	76.3 (	(12.8)	75.8 (	(13.5)	77.1 (	(13.7)	76.5 (	(13.6)	
Median (min, max)	76.0 (10	.0, 120.0)	76.0 (10	0.0, 120.0)	78.0 (11	.0, 120.0)	77.0 (10	.0, 120.0)	
Missing, No. (%)	2685	10.2	1063	15.4	1073	12.4	2136	13.8	
TIMI risk index									
N	235	542	58	13	74	10	132	223	
Mean (SD)	18.1	(8.1)	19.4	(9.3)	19.3 (9.3)		19.4 (9.3)		
Median (min, max)	16.6 (2	.1, 105.2)	) 17.5 (3.1, 97.0)		17.5 (2.7, 142.7)		) 17.5 (2.7, 142.7)		
Missing, No. (%)	2941	11.2	1115	16.0	1176	13.6	2291	14.8	

Table 2.1 Patient clinical status at the time of PCI procedure, NCVD-PCI Registry, 2007 – 2014

	2007 - 2012		20	2013		14	2013 - 2014		
	Total proced 264	no. of lures = 483	Total proced 69	no. of lures = 28	Total procec 85	no. of lures = 86	Total proced 15:	no. of lures = 514	
	No.	%	No.	%	No.	%	No.	%	
TRI classification, No. (%)									
Low (< 30)	21779	82.2	5187	74.9	6615	77.1	11802	76.0	
Intermediate (30 – 70)	1742	6.6	614	8.9	777	9.1	1391	9.0	
High (> 70)	21	0.0	12	0.2	18	0.2	30	0.2	
Missing	2941	11.2	1115	16.0	1176	13.6	2291	14.8	
Baseline ECG, No. (%)									
Sinus rhythm	22907	86.4	5621	81.2	7467	87.0	13088	84.4	
Atrial fibrillation	256	1.0	90	1.2	86	1.0	176	1.2	
2 <sup>nd</sup> /3 <sup>rd</sup> AVB	111	0.4	20	0.2	23	0.2	43	0.2	
LBBB	107	0.4	28	0.4	31	0.4	59	0.4	
RBBB	155	0.6	22	0.4	17	0.2	39	0.2	
HbA1c, %									
Ν			52	27	23	49	28	76	
Mean (SD)			7.8 (	(2.9)	7.4	(2.4)	7.4 (	(2.5)	
Median (min, max)			7.0 (4.0	), 32.0)	6.7 (4.0	), 32.0)	6.7 (4.0	), 32.0)	
Missing, No. (%)			6401	92.4	6237	72.6	12638	81.4	
NYHA, No. (%)									
Total no. of procedures among patients with heart failure	969	100	251	100	402	100	653	100	
NYHA I	306	31.6	106	42.1	201	50.1	307	47.1	
NYHA II	463	47.8	81	32.3	131	32.6	212	32.5	
NYHA III	130	13.4	24	9.6	35	8.7	59	9.0	
NYHA IV	35	3.6	13	5.2	21	5.2	34	5.2	
Not available	33	3.4	22	8.8	9	2.2	31	4.7	
Missing	2	0.2	5	2.0	5	1.2	10	1.5	
Functional ischaemia, No. (%)									
Positive	4684	17.7	645	9.4	520	6.1	1165	7.5	
Negative	440	1.6	46	0.6	49	0.7	95	0.5	
Equivocal	276	1.0	105	1.6	38	0.4	143	1.0	
Not applicable	20716	78.3	3590	51.8	2891	33.6	6481	41.8	
Missing	367	1.4	2542	36.6	5088	59.2	7630	49.2	

	2007 - 2012		20	2013		14	2013 - 2014		
	Total proced 264	no. of lures = 183	Total proced 69	no. of lures = 28	Total proced 85	no. of lures = 86	Total proced 15	no. of lures = 514	
	No.	%	No.	%	No.	%	No.	%	
Canadian cardiovascular score (CCS), No. (%)									
CCS 1	7535	28.4	2371	34.2	2758	32.1	5129	33.0	
CCS 2	11240	42.4	1437	20.8	2319	26.9	3756	24.2	
CCS 3	1340	5.0	286	4.2	440	5.1	726	4.6	
CCS 4	800	3.0	528	7.6	473	5.5	1001	6.4	
Asymptomatic	3211	12.2	1076	15.6	1305	15.2	2381	15.4	
Not available	1688	6.4	560	8.0	576	6.8	1136	7.4	
Missing	669	2.6	670	9.6	715	8.4	1385	9.0	
*Intra-aortic balloon pump (IABP), No. (%)	(49		150		142	1.7	201	2.0	
Yes	648	2.4	159	2.2	142	1./	301	2.0	
NO	25452	96.2	6035	87.2	8215	95.7	14250	91.8	
Not Applicable	0	0	217	3.2	1/	0.2	234	1.0	
Missing	383	1.4	517	7.4	212	2.4	729	4.6	
Acute coronary syndrome (ACS), No. (%)									
Yes	10256	38.7	2356	34.0	3062	35.6	5418	35.0	
No	16140	60.9	4572	66.0	5524	64.4	10096	65.0	
Missing	87	0.4	0	0	0	0	0	0	
ACS type, No. (%)									
STEMI	5722	55.8	1374	58.3	1741	56.8	3115	57.5	
NSTEMI	3308	32.2	507	21.5	772	25.2	1279	23.7	
UA	1140	11.2	451	19.2	495	16.2	946	17.4	
Not available	76	0.8	24	1.0	54	1.8	78	1.4	
Missing	10	0.0	0	0	0	0	0	0	
STEMI, No. (%)									
Anterior	3137	54.8	765	55.6	984	56.5	1749	56.2	
Non-anterior	1916	33.5	499	36.4	667	38.3	1166	37.4	
Not available	139	2.5	60	4.4	90	5.2	150	4.8	
Missing	530	9.2	50	3.6	0	0	50	1.6	

	2007 - 2012		20	13	20	14	2013 - 2014		
	Total	no. of	Total	no. of	Total	no. of	Total	no. of	
	proced 264	lures = 483	proced 69	lures = 28	proced 85	lures = 86	proced 155	lures = 514	
	No.	%	No.	%	No.	%	No.	%	
Ejection fraction (EF) status									
Ν	96	30	23	43	31	27	54	70	
Mean (SD)	51.6	(12.7)	51.1	(12.6)	50.5	(12.7)	50.8	(12.6)	
Median (min, max)	53.0 (10	.0, 80.0)	53.0 (10.0, 80.0)		51.0 (10.0, 80.0)		52.0 (10.0, 80.0)		
Not available, No. (%)	15604	59.0	3666	53.0	4522	52.6	8188	52.8	
Missing, No. (%)	1249	4.8	919	13.2	937	11.0	1856	12.0	
Ejection fraction (EF) status, No. (%)									
< 30	423	1.6	119	1.8	160	1.8	279	1.8	
30 - < 45	2258	8.6	532	7.6	788	9.2	1320	8.6	
45 - < 55	2502	9.3	583	8.4	796	9.2	1379	8.8	
≥ 55	4447	16.7	1109	16.0	1383	16.2	2492	16.0	
Not available	15604	59.0	3666	53.0	4522	52.6	8188	52.8	
Missing	1249	4.8	919	13.2	937	11.0	1856	12.0	
Killip class, No. (%)									
Total no. of									
procedures among patients with PCI	5722	100	1231	100	1423	100	2654	100	
STEMI**									
Ι	2046	35.9	673	54.7	906	63.7	1579	59.5	
II	1937	33.9	160	13.0	162	11.4	322	12.1	
III	117	2.0	46	3.7	30	2.1	76	2.9	
IV	358	6.2	166	13.5	229	16.1	395	14.9	
Not applicable/Not available	1217	21.2	127	10.3	80	5.6	207	7.8	
Missing	47	0.8	59	4.8	16	1.1	75	2.8	
STEMI: Time-to- treatment analysis^									
Symptom-to-door time, minutes									
N	68	37	10	00	12	22	22	22	
Mean (SD)	270.3 (	(221.8)	100.6	(44.3)	101.5	(41.4)	101.1	(42.6)	
Median (min, max)	197.0 (10.0, 1350.0)		10 (20.0,	0.5 176.0)	10 (15.0,	4.0 173.0)	102.5 (15.0, 176.0)		
Negative/zero, No. (%)	113 2.0		146	37.1	214	43.7	360	40.7	
Not available, No. (%)	4922	86.0	148	37.6	154	31.4	302	34.2	

	2007 - 2012		20	13	20	14	2013 - 2014		
	Total proced 264	no. of lures = 483	Total procec 69	no. of lures = 28	Total proced 85	no. of lures = 86	Total proced 155	no. of lures = 514	
	No.	%	No.	%	No.	%	No.	%	
Door-to-balloon time, minutes									
Ν	66	56	18	84	25	54	43	38	
Mean (SD)	139.6 (	(149.2)	71.9 (36.5)		78.1	(38.7)	75.5 (37.9)		
Median (min, max)	90.0 (3.0, 963.0)		67.5 (15.	0, 171.0)	70.0 (11.	0, 178.0)	70.0 (11.	0, 178.0)	
Negative/zero, No. (%)	77	1.3	51	12.9	79	16.1	130	14.7	
Not available, No. (%)	4979	87.0	159	40.4	157	32.0	316	35.7	
Door-to-balloon time, minutes, No. (%)									
< 90	327	5.7	127	32.2	164	33.5	291	32.9	
$\geq 90$	339	5.9	57	14.5	90	18.4	147	16.6	
Negative/zero, No. (%)	77	1.3	51	12.9	79	16.1	130	14.8	
Not available	4979	87.1	159	40.4	157	32.0	316	35.7	
*Transfer time									
N	20	00	37		6	51	98		
Mean (SD)	257.0 (	(203.5)	84.2	(39.9)	63.9	(33.4)	71.6 (37.1)		
Median (min, max)	201.5 126	(15.0, 0.0)	80 (14.0,	).0 171.0)	63.0 (12.0, 165.0)		65.5 (12.0, 171.0)		
Negative/zero, No. (%)	121	2.1	85	21.6	177	36.1	262	29.6	
Not available, No. (%)	5401	94.4	272	69.0	252	51.4	524	59.3	
Glomerular filtration rate (GFR), MDRD, No. (%)									
< 15	772	2.9	182	2.7	240	2.7	422	2.8	
15 - < 30	533	2.0	128	1.9	153	1.8	281	1.8	
30 - < 45	1285	4.9	301	4.3	386	4.5	687	4.4	
45 - < 60	3453	13.0	764	11.0	926	10.8	1690	10.9	
$\geq \overline{60}$	18079	68.3	4491	64.8	5647	65.8	10138	65.3	
Missing	2361	8.9	1062	15.3	1234	14.4	2296	14.8	

\*IABP was listed in separate sections in the previous and new CRFs. In the old CRF, it was reported in Section 6 (cath lab visit) and in the new CRF, it was reported in Section 7 (PCI procedure details) \*\*The definition of STEMI is different in the 2007 – 2012 and 2013 – 2014 results. In the 2007 – 2009 results, the patient's

clinical status was presented for patients with ACS STEMI (Section 5, no. 4) In 2013 – 2014, it was presented for PCI STEMI patients (Section 6, no. 2) ^Results were presented differently in 2007 – 2012 and 2013 – 2014

In 2007 – 2012, it was presented for ACS STEMI patients In 2013 – 2014, it was presented for PCI STEMI patients with primary PCI

Voor		With t	ransfer	
I cai	2007 - 2012	2013	2014	2013 - 2014
	Total no. of procedures = 26483	Total no. of procedures = 6928	Total no. of procedures = 8586	Total no. of procedures = 15514
Symptom-to-door time (minutes)				
Ν	256	44	75	119
Mean (SD)	325.3 (242.5)	112.1 (39.4)	101.2 (40.0)	105.2 (39.9)
Median (min, max)	263.5 (13.0, 1350.0)	110.5 (35.0, 176.0)	105 (15.0, 171.0)	107 (15.0, 176.0)
N for negative/zero time	49	76	159	235
Door-to-balloon time (minutes)				
Ν	240	86	166	252
Mean (SD)	137.0 (178.4)	61.8 (36.0)	76.5 (41.5)	71.5 (40.2)
Median (min, max)	74 (5.0, 963.0)	59.0 (15.0, 160.0)	65.5 (11.0, 178.0)	61.5 (11.0, 178.0)
N for negative/zero time	31	28	62	90
Transfer-to-PCI centre time (minutes)				
Ν	200	37	61	98
Mean (SD)	257 (203.5)	84.2 (39.9)	63.9 (33.4)	71.6 (37.1)
Median (min, max)	201.5 (15.0, 1260.0)	80.0 (14.0, 171.0)	63.0 (12.0, 165.0)	65.5 (12.0, 171.0)
N for negative/zero time	121	85	177	262
Symptom-to-balloon time (minutes)				
N	236	16	35	51
Mean (SD)	406.4 (262.2)	117.4 (43.6)	117.3 (39.9)	117.4 (40.7)
Median (min, max)	353.0 (41.0, 1412.0)	120.0 (24.0, 178.0)	127 (20.0, 169.0)	122.0 (20.0, 178.0)
N for negative/zero time	59	100	198	298

Table 2.2.1 Time to treatment for STEMI, with transfer, NCVD-PCI Registry, 2007 – 2014^

<sup>A</sup>Results were presented differently in 2007 – 2012 and 2013 – 2014 In 2007 – 2012, it was presented for ACS STEMI patients In 2013 – 2014, it was presented for PCI STEMI patients with primary PCI

Voor		Without	transfer	
I cai	2007 - 2012	2013	2014	2013 - 2014
	Total no. of procedures = 26483	Total no. of procedures = 6928	Total no. of procedures = 8586	Total no. of procedures = 15514
Symptom-to-door time (minutes)				
Ν	357	41	35	76
Mean (SD)	243.1 (207.6)	91.7 (43.9)	98.1 (45.4)	94.7 (44.4)
Median (min, max)	175.0 (10.0, 1070.0)	80.0 (28.0, 175.0)	95.0 (23.0, 173.0)	87.5 (23.0, 175.0)
N for negative/zero time	52	55	41	96
Door-to-balloon time (minutes)				
Ν	349	79	64	143
Mean (SD)	144.2 (127.0)	81.9 (35.6)	80.1 (31.9)	81.1 (33.9)
Median (min, max)	104.0 (3.0, 870.0)	74 (15.0, 171.0)	72.0 (28.0, 172.0)	73.0 (15.0, 172.0)
N for negative/zero time	39	15	9	24
Symptom-to-balloon time (minutes)				
Ν	319	27	19	46
Mean (SD)	358.2 (218.4)	109.1 (41.9)	121.8 (36.7)	114.3 (40.0)
Median (min, max)	300.0 (2.0, 1175.0)	113 (11.0, 178.0)	130.0 (37.0, 166.0)	118.5 (11.0, 178.0)
N for negative/zero time	63	64	58	122

Table 2.2.2 Time to treatment for STEMI, without transfer, NCVD-PCI Registry, 2007 – 2014^

Aresults were presented differently in 2007 – 2012 and 2013 – 2014 In 2007 – 2012, it was presented for ACS STEMI patients In 2013 – 2014, it was presented for PCI STEMI patients with primary PCI

Voor	Heart rate	Elec	tive	NSTE	MI/UA	STH	EMI	Not available		Missing	
Tear	(beats/min)	No.	%	No.	%	No.	%	No.	%	No.	%
33	< 60	4629	20.0	186	13.4	156	7.8	7	28.0	2	11.8
of 2649	60 - 80	12582	54.6	692	49.6	681	34.0	12	48.0	8	47.0
- 20) no.	> 80 - 100	3216	14.0	297	21.2	543	27.0	5	20.0	1	5.9
07 - otal dure	> 100	646	2.8	82	5.8	369	18.4	0	0	1	5.9
.000 J	Missing	1966	8.6	140	10.0	256	12.8	1	4.0	5	29.4
ıd	Total	23039	100.0	1397	100.0	2005	100.0	25	100.0	17	100.0
×	< 60	841	16.5	84	13.4	76	6.2	0	0	0	0
of 692	60 - 80	2555	50.3	297	47.6	422	34.2	0	0	0	0
no. es =	> 80 - 100	808	16.0	133	21.2	375	30.4	0	0	0	0
20 otal dur	> 100	159	3.2	36	5.8	189	15.4	0	0	0	0
D	Missing	709	14.0	75	12.0	169	13.8	0	0	0	0
d	Total	5072	100.0	625	100.0	1231	100.0	0	0	0	0
9	< 60	981	15.2	66	8.9	122	8.6	0	0	0	0
of 858	60 - 80	3324	51.8	380	50.9	502	35.2	0	0	0	0
14 no. es =	> 80 - 100	1139	17.8	193	25.8	419	29.4	0	0	0	0
20 otal	> 100	225	3.6	53	7.0	238	16.8	0	0	0	0
L DOC	Missing	747	11.6	55	7.4	142	10.0	0	0	0	0
d	Total	6416	100.0	747	100.0	1423	100.0	0	0	0	0
14	< 60	1822	15.8	150	11.0	198	7.4	0	0	0	0
14 of 155	60 - 80	5879	51.2	677	49.4	924	34.8	0	0	0	0
- 20) ss =	> 80 - 100	1947	17.0	326	23.8	794	30.0	0	0	0	0
)13 - otal durc	> 100	384	3.4	89	6.4	427	16.0	0	0	0	0
2(Cef 1)	Missing	1456	12.6	130	9.4	311	11.8	0	0	0	0
Ы	Total	11488	100.0	1372	100.0	2654	100.0	0	0	0	0

Table 2.3 Comparison of heart rate according to PCI status, NCVD-PCI Registry, 2007 – 2014

Veer	Heart rate	STEMI		NST	EMI	U	A	Not available		Missing	
rear	(beats/min)	No.	%	No.	%	No.	%	No.	%	No.	%
Ires	< 60	827	14.4	636	19.2	207	18.1	8	10.6	2	20.0
12 cedu	60 - 80	2793	48.8	1778	53.7	581	51.0	26	34.2	5	50.0
- 20] pro	> 80 - 100	1167	20.4	586	17.7	170	15.0	9	11.8	3	30.0
007 - 0. of = 26	> 100	496	8.7	151	4.6	40	3.6	2	2.6	0	0
20 al nc	Missing	439	7.7	157	4.8	142	12.3	31	40.8	0	0
Tot	Total	5722	100.0	3308	100.0	1140	100.0	76	100.0	10	100.0
8	< 60	97	7.0	66	12.9	66	14.5	5	20.8	0	0
of 692	60 - 80	486	35.4	244	48.1	217	48.1	11	45.8	0	0
13 no.	> 80 - 100	404	29.4	97	19.2	97	21.6	4	16.6	0	0
20 otal dur	> 100	200	14.6	33	6.6	15	3.4	2	8.4	0	0
D Toce	Missing	187	13.6	67	13.2	56	12.4	2	8.4	0	0
d	Total	1374	100.0	507	100.0	451	100.0	24	100.0	0	0
9	< 60	170	9.8	79	10.3	65	13.1	4	7.3	0	0
of 858	60 - 80	669	38.4	403	52.3	254	51.3	22	40.7	0	0
114 no.	> 80 - 100	473	27.2	186	24.0	98	19.8	15	27.8	0	0
20 otal sdur	> 100	244	14.0	44	5.6	16	3.2	2	3.8	0	0
L T	Missing	185	10.6	60	7.8	62	12.6	11	20.4	0	0
d	Total	1741	100.0	772	100.0	495	100.0	54	100.0	0	0
14	< 60	267	8.6	145	11.3	131	13.9	9	11.5	0	0
14 of 155	60 - 80	1155	37.0	647	50.5	471	49.9	33	42.3	0	0
- 20) no.	> 80 - 100	877	28.2	283	22.2	195	20.6	19	24.4	0	0
)13 - otal durc	> 100	444	14.2	77	6.0	31	3.2	4	5.2	0	0
0 CG 1	Missing	372	12.0	127	10.0	118	12.4	13	16.6	0	0
Id	Total	3115	100.0	1279	100.0	946	100.0	78	100.0	0	0

Table 2.4 Comparison of heart rate according to ACS subtypes, NCVD-PCI Registry, 2007 – 2014

Year	Systolic BP	Elec	tive	NST	EMI	STH	EMI	Not av	ailable	Missing	
	(mmHg)	No.	%	No.	%	No.	%	No.	%	No.	%
$\int_{0}^{12} $	< 90	121	0.5	30	2.2	110	5.4	0	0	0	0
- 200 no 183	$\geq$ 90	20737	90.0	1203	86.1	1599	79.8	25	100	12	70.6
07 - otal oced 264	Missing	2181	9.5	164	11.7	296	14.8	0	0	5	29.4
20 Tc prq	Total	23039	100.0	1397	100.0	2005	100.0	25	100.0	17	100.0
of s =	< 90	41	0.8	12	1.9	77	6.3	0	0	0	0
13 10. 28	$\geq$ 90	4245	83.7	535	85.6	963	78.2	0	0	0	0
20 otal oced 69	Missing	786	15.5	78	12.5	191	15.5	0	0	0	0
D I	Total	5072	100.0	625	100.0	1231	100.0	0	0	0	0
of s =	< 90	47	0.7	19	2.6	93	6.5	0	0	0	0
14 10. 86	$\geq$ 90	5530	86.2	665	89.0	1175	82.6	0	0	0	0
20 Dtal SS	Missing	839	13.1	63	8.4	155	10.9	0	0	0	0
Drd	Total	6416	100.0	747	100.0	1423	100.0	0	0	0	0
$\int_{s=1}^{14}$	< 90	88	0.8	31	2.2	170	6.4	0	0	0	0
- 20] no. ( 14	$\geq$ 90	9775	85.1	1200	87.5	2138	80.6	0	0	0	0
13 - otal oced 155	Missing	1625	14.1	141	10.3	346	13.0	0	0	0	0
50 I I	Total	11488	100.0	1372	100.0	2654	100.0	0	0	0	0

Table 2.5 Comparison of systolic blood pressure according to PCI status, NCVD-PCI Registry, 2007 – 2014

Year	Arterial bloodNPPpressure, mmHgPPPN207891230			STEMI	Not available	Missing
	Ν	20789	1230	1695	25	12
2012 0. of res = 3	Mean (SD)	96.8 (14.3)	94.1 (15.4)	91.7 (18.0)	97.6 (15.7)	103.5 (14.2)
07 – 2 otal no ocedu 2648	Median (min, max)	96.3 (44.0, 155.0)	93.3 (48.7, 148.7)	91.7 (39.0, 150.0)	101.0 (71.3, 124.7)	104.3 (77.3, 127.3)
20 Tr	Missing, No. (%)	2250 (9.8)	167 (12.0)	310 (15.5)	0 (0)	5 (29.4)
	Ν	4275	544	1035	0	0
o. of res =	Mean (SD)	96.9 (14.4)	94.3 (14.6)	90.4 (17.4)	N/A	N/A
2013 tal no cedur 6928	Median (min, max)	96.7 (36.0, 146.7)	94.3 (53.7, 142.3)	90.3 (33.3, 150.0)	N/A	N/A
Tc	Missing, No. (%)	797 (15.7)	81 (13.0)	196 (15.9)	0 (0)	0 (0)
. 11	Ν	5554	684	1259	0	0
o. of res =	Mean (SD)	98.5 (14.7)	96.2 (16.1)	93.2 (17.7)	N/A	N/A
2014 otal no ocedui 8586	Median (min, max)	97.7 (44.0, 152.7)	95.5 (35.7, 150.0)	93.0 (34.0, 143.3)	N/A	N/A
ord DT	Missing, No. (%)	862 (13.4)	63 (8.4)	164 (11.5)	0 (0)	0 (0)
	Ν	9829	1228	2294	0	0
2014 5. of res = 4	Mean (SD)	97.8 (14.6)	95.3 (15.5)	91.9 (17.6)	N/A	N/A
13 – 20 otal no. ocedure 15514	Median (min, max)	97.0 (36.0, 152.7)	95.2 (35.7, 150.0)	91.7 (33.3, 150.0)	N/A	N/A
20 Jr	Missing, No. (%)	1659 (14.4)	144 (10.5)	360 (13.6)	0 (0)	0 (0)

Table 2.6 Comparison of arterial blood pressure according to PCI status, NCVD–PCI Registry, 2007 – 2014

•	TIMI Risk	Elec	tive	NST	EMI	STI	EMI	Not av	ailable	Mis	sing
Year	Index	No.	%	No.	%	No.	%	No.	%	No.	%
ures	Low (< 30)	19370	84.1	1063	76.1	1313	65.5	21	84.0	12	70.6
012 rocedi 3	Intermediate (30 – 70)	1229	5.3	150	10.7	360	18.0	3	12.0	0	0
7 – 2 of p = 2648	High (> 70)	2	0.0	7	0.5	12	0.5	0	0	0	0
20( 1 no.	Missing	2438	10.6	177	12.7	320	16.0	1	4.0	5	29.4
Totz	Total	23039	100.0	1397	100.0	2005	100.0	25	100.0	17	100.0
Ires	Low (< 30)	3913	77.2	460	73.6	814	66.2	0	0	0	0
rocedi	Intermediate (30 – 70)	328	6.5	78	12.5	208	16.9	0	0	0	0
2013 of p = 6928	High (> 70)	2	0	2	0.3	8	0.6	0	0	0	0
l no.	Missing	829	16.3	85	13.6	201	16.3	0	0	0	0
Tot	Total	5072	100.0	625	100.0	1231	100.0	0	0	0	0
Ires	Low (< 30)	5035	78.5	567	75.9	1013	71.2	0	0	0	0
rocedi	Intermediate (30 – 70)	455	7.1	100	13.4	222	15.6	0	0	0	0
2014 of p = 8586	High (> 70)	1	0	5	0.7	12	0.8	0	0	0	0
l no.	Missing	925	14.4	75	10.0	176	12.4	0	0	0	0
Totz	Total	6416	100.0	747	100.0	1423	100.0	0	0	0	0
Ires	Low (< 30)	8948	77.9	1027	74.8	1827	68.8	0	0	0	0
2014 rocedi 4	Intermediate (30 – 70)	783	6.8	178	13.0	430	16.2	0	0	0	0
3 – 2   of p  =  1551-	High (> 70)	3	0	7	0.5	20	0.8	0	0	0	0
201 al no.	Missing	1754	15.3	160	11.7	377	14.2	0	0	0	0
Totz	Total	11488	100.0	1372	100.0	2654	100.0	0	0	0	0

Table 2.7 Comparison of TIMI risk index according to PCI status, NCVD-PCI Registry, 2007 – 2014

<b>X</b> 7	Ejection	Elec	tive	NST	EMI	STE	EMI	Not av	ailable	Mis	sing
y ear	fraction (EF)	No.	%	No.	%	No.	%	No.	%	No.	%
 S	< 30	360	1.6	25	1.8	38	1.9	0	0	0	0
lure	30 - < 45	1906	8.3	120	8.6	232	11.6	0	0	0	0
012 0cec 3	45 - < 55	2139	9.3	132	9.4	226	11.3	4	16.0	1	5.9
7 – 2 f pr (648:	$\geq$ 55	4174	18.1	158	11.3	111	5.5	3	12.0	1	5.9
200 0. 0	Not available	13449	58.3	869	62.2	1265	63.1	18	72.0	3	17.6
tal n	Missing	1011	4.4	93	6.7	133	6.6	0	0	12	70.6
Toi	Total	23039	100.0	1397	100.0	2005	100.0	25	100.0	17	100.0
s	< 30	94	1.8	15	2.4	10	0.9	0	0	0	0
lure	30 - < 45	368	7.3	56	9.0	108	8.8	0	0	0	0
Dece a	45 - < 55	437	8.6	52	8.3	94	7.6	0	0	0	0
2013 f pr 6928	$\geq$ 55	963	19.0	94	15.0	52	4.2	0	0	0	0
0.0	Not available	2516	49.6	331	53.0	819	66.5	0	0	0	0
s = Total no. of <sub>F</sub>	Missing	694	13.7	77	12.3	148	12.0	0	0	0	0
To	Total	5072	100.0	625	100.0	1231	100.0	0	0	0	0
 20	< 30	127	2.0	11	1.5	22	1.6	0	0	0	0
lure	30 - < 45	596	9.3	59	7.9	133	9.3	0	0	0	0
	45 - <55	621	9.7	60	8.0	115	8.1	0	0	0	0
2014 f pr 8586	$\geq$ 55	1215	18.9	108	14.5	60	4.2	0	0	0	0
ġ	Not available	3153	49.1	432	57.8	937	65.8	0	0	0	0
tal n	Missing	704	11.0	77	10.3	156	11.0	0	0	0	0
To	Total	6416	100.0	747	100.0	1423	100.0	0	0	0	0
ية اا	< 30	221	1.9	26	1.9	32	1.2	0	0	0	0
Jure	30 - < 45	964	8.4	115	8.4	241	9.1	0	0	0	0
2014 ocec 4	45 - < 55	1058	9.2	112	8.2	209	7.8	0	0	0	0
3 – 3 f pr 551	≥ 55	2178	19.0	202	14.7	112	4.2	0	0	0	0
201. 10. 0 1	Not available	5669	49.3	763	55.6	1756	66.2	0	0	0	0
tal r	Missing	1398	12.2	154	11.2	304	11.5	0	0	0	0
Toi	Total	11488	100.0	1372	100.0	2654	100.0	0	0	0	0

 Table 2.8 Comparison of ejection fraction according to PCI status, NCVD-PCI Registry, 2007 – 2014

\$7	NYHA	Elec	ctive	NST	EMI	STI	EMI	Not av	ailable	Mis	sing
y ear	classification	No.	%	No.	%	No.	%	No.	%	No.	%
 	NYHA I	277	33.3	14	17.5	14	24.6	1	100	0	0
7 – 2012 of procedures 26483	NYHA II	413	49.7	35	43.8	15	26.2	0	0	0	0
2012 0ced 3	NYHA III	100	12.0	18	22.5	12	21.2	0	0	0	0
7 – 2 f pr 648:	NYHA IV	11	1.3	9	11.3	15	26.2	0	0	0	0
200 10. 0 2	Not available	29	3.5	3	3.8	1	1.8	0	0	0	0
tal n	Missing	1	0.2	1	1.1	0	0	0	0	0	0
Tot	Total	831	100.0	80	100.0	57	100.0	1	100.0	0	0
 S	NYHA I	86	45.0	14	35.0	6	30.0	0	0	0	0
lure	NYHA II	64	33.5	15	37.5	2	10.0	0	0	0	0
Dece .	NYHA III	16	8.4	6	15.0	2	10.0	0	0	0	0
2013 f pr 6928	NYHA IV	4	2.1	3	7.5	6	30.0	0	0	0	0
0.0	Not available	17	8.9	1	2.5	4	20.0	0	0	0	0
Total no. e	Missing	4	2.1	1	2.5	0	0	0	0	0	0
To	Total	191	100.0	40	100.0	20	100.0	0	0	0	0
 S	NYHA I	173	54.9	14	32.6	14	31.9	0	0	0	0
lure	NYHA II	109	34.7	16	37.2	6	13.6	0	0	0	0
	NYHA III	22	7.0	8	18.6	5	11.4	0	0	0	0
2014 f pr 8586	NYHA IV	2	0.6	5	11.6	14	31.8	0	0	0	0
0 0 °	Not available	7	2.2	0	0	2	4.5	0	0	0	0
tal n	Missing	2	0.6	0	0	3	6.8	0	0	0	0
To	Total	315	100.0	43	100.0	44	100.0	0	0	0	0
 S	NYHA I	259	51.2	28	33.8	20	31.2	0	0	0	0
lure	NYHA II	173	34.2	31	37.3	8	12.5	0	0	0	0
014 0000	NYHA III	38	7.5	14	16.9	7	10.9	0	0	0	0
3 – 2 f pr 551	NYHA IV	6	1.2	8	9.6	20	31.3	0	0	0	0
2013 – 201 no. of proce 15514	Not available	24	4.7	1	1.2	6	9.4	0	0	0	0
tal n	Missing	6	1.2	1	1.2	3	4.7	0	0	0	0
Tot	Total	506	100.0	83	100.0	64	100.0	0	0	0	0

Table 2.9 Comparison of NYHA according to PCI status among patients with heart failure, NCVD–PCI Registry, 2007 – 2014

N7	D DCI	Elec	tive	NST	EMI	STE	EMI	Not av	ailable	Mis	sing
y ear	Previous PCI	No.	%	No.	%	No.	%	No.	%	No.	%
12 of s =	Yes	5561	24.1	284	20.3	169	8.4	5	20.0	2	11.8
- 20 no lure 183	No	17466	75.8	1112	79.6	1836	91.6	20	80.0	9	52.9
07 - otal oced 264	Missing	12	0.1	1	0.1	0	0	0	0	6	35.3
20 Tc prq	Total	23039	100.0	1397	100.0	2005	100.0	25	100.0	17	100.0
2013 al no. of edures = 5928	Yes	1285	25.3	131	21.0	93	7.6	0	0	0	0
13 no. 28	No	3787	74.7	494	79.0	1138	92.4	0	0	0	0
201 otal r ocedi 692	Missing	0	0	0	0	0	0	0	0	0	0
Drq DT	Total	5072	100.0	625	100.0	1231	100.0	0	0	0	0
of s =	Yes	1720	26.8	154	20.6	104	7.3	0	0	0	0
14 no lure- 86	No	4696	73.2	593	79.4	1319	92.7	0	0	0	0
20 otal oced 85	Missing	0	0	0	0	0	0	0	0	0	0
Tc	Total	6416	100.0	747	100.0	1423	100.0	0	0	0	0
14 of s =	Yes	3005	26.2	285	20.8	197	7.4	0	0	0	0
- 20 no.	No	8483	73.8	1087	79.2	2457	92.6	0	0	0	0
13 – . otal n ocedu 1551	Missing	0	0	0	0	0	0	0	0	0	0
20 Ta	Total	11488	100.0	1372	100.0	2654	100.0	0	0	0	0

Table 2.10 Comparison of previous PCI according to PCI status, NCVD-PCI Registry, 2007 – 2014

Table 2.11 Comparison of HbA1c according to PCI status, NCVD-PCI Registry, 2007 – 2014

Year	HbA1c,	Eleo	ctive	NST	EMI	STI	EMI	Not av	ailable	Mis	sing
rear	mmol/L	No.	%	No.	%	No.	%	No.	%	No.	%
	Ν	34	92	14	42	13	39	(	)	(	)
2012 0. of 1res = 13	Mean (SD)	8.2 (	16.8)	7.6	(2.1)	10.9	(19.4)	N	/A	N	/A
2013     2007 - 3       otal no. of     Total n       ocedures =     procedu       6928     2648	Median (min, max)	7.0 (0.9	, 908.0)	7.2 (4.0	0, 15.8)	7.3 (2.3	, 165.0)	N	/A	N	'A
pr 1 2	Missing, No. (%)	19547	84.8	1255	89.8	1866	93.1	25	100.0	17	100.0
	Ν	4.	34	3	7	5	6	(	)	(	)
3 0.01 8	Mean (SD)	7.7	(2.8)	7.3	(1.9)	9.0	(3.7)	N	/A	N	/A
2013 Total no. ( procedures 6928	Median (min, max)	6.9 (4.0	0, 32.0)	7.1 (4.2	2, 12.9)	8.6 (4.4, 27.9)		N	/A	N/A	
L	Missing, No. (%)	4638	91.4	588	94.1	1175	95.5	0	0	0	0
	Ν	2056		12	20	17	73	(	)	(	)
4 0.01 fres:	Mean (SD)	7.3	(2.3)	7.7	(3.3)	7.4	(3.1)	N	/A	N	/A
201. otal n ocedu 858	Median (min, max)	6.7 (4.0	0, 30.0)	6.8 (4.'	7, 31.0)	6.3 (4.	5, 32.0)	N	/A	N	/A
L	Missing, No. (%)	4360	68.0	627	83.9	1250	87.8	0	0	0	0
	Ν	24	.90	1:	57	22	29	(	)	(	)
2014 0. of 1res	Mean (SD)	7.4	(2.4)	7.6	(3.0)	7.8	(3.3)	N	/A	N	'A
2013 – 2014 Fotal no. of rocedures = 15514	Median (min, max)	6.7 (4.0	0, 32.0)	6.9 (4.2	2, 31.0)	6.5 (4.4	4, 32.0)	N/A		N/A	
Z I I	Missing, No. (%)	8998	78.3	1215	88.6	2425	91.4	0	0	0	0

Year	Baseline meetinine meet/I	Elec	Elective		EMI	STI	EMI	Not available		Missing	
rear	Baseline creatinine, mmol/L	No.	%	No.	%	No.	%	No.	%	No.	%
	N	213	371	12	11	15	03	2	5	12	2
012 0. of res =	Mean (SD)	117.5	(125.5)	116.2	(110.5)	111.6	(89.6)	156.0	(169.1)	102.8 (	(31.1)
7 – 2 al nc edui 648.	Median (min, max)	93.0 (44.0	), 6500.0)	91.0 (45.	0, 1533.0)	92.0 (44.0	), 1222.0)	100.0 (60	.0, 740.0)	100.0 (54.	0, 182.0)
2005 Tot: Proc	Not available, No. (%)	594	2.6	82	5.9	281	14.0	0	0	0	0
-	Missing, No. (%)	1074	4.7	104	7.4	221	11.0	0	0	5	29.4
	N	44	-36	52	28	90	)2	(	)	0	1
o. of res =	Mean (SD)	116.2	(118.8)	133.3	(151.7)	105.9	(78.6)	N	/A	N/.	A
2013 al nc edui 6928	Median (min, max)	92.0 (44.0	0, 1466.0)	94.0 (44.	0, 1510.0)	93.0 (44.0	), 1378.0)	N	/A	N/.	A
Tot	Not available, No. (%)	246	4.9	36	5.8	147	11.9	0	0	0	0
-	Missing, No. (%)	390	7.7	61	9.8	182	14.8	0	0	0	0
	Ν	56	31	6	53	10	68	(	)	0	1
o. of res =	Mean (SD)	116.2	(116.2)	122.9	(137.6)	111.5	(103.1)	N	/A	N/.	A
2014 al nc edu 8586	Median (min, max)	91.0 (44.0	0, 1632.0)	91.0 (45.	0, 1606.0)	92.0 (44.0	), 1615.0)	N	/A	N/.	A
Tot	Not available, No. (%)	420	6.5	52	7	221	15.5	0	0	0	0
	Missing, No. (%)	365	5.7	42	5.6	134	9.4	0	0	0	0
	Ν	100	067	11	81	19	70	(	)	0	1
014 0. of res = 4	Mean (SD)	116.2	(117.3)	127.6	(144.1)	108.9	(92.7)	N	/A	N/.	A
3 – 2 al nc edur 551	Median (min, max)	92.0 (44.0	0, 1632.0)	92.0 (44.	0, 1606.0)	92.0 (44.0	), 1615.0)	N	/A	N/.	А
1 1 1 1 1 1 1 1	Not available, No. (%)	666	5.8	88	6.4	368	13.9	0	0	0	0
	Missing, No. (%)	755	6.6	103	7.5	316	11.9	0	0	0	0

Table 2.12 Comparison of baseline creatinine according to PCI status, NCVD-PCI Registry, 2007 – 2014

Year	CED	Eleo	ctive	NST	EMI	STI	EMI	Not av	ailable	Mis	sing
rear	GFK	No.	%	No.	%	No.	%	No.	%	No.	%
	Ν	213	371	12	11	15	03	2	.5	1	2
012 0. of res =	Mean (SD)	73.8	(24.9)	74.0	(26.5)	76.0	(27.9)	65.7	(26.8)	73.2 (	(19.9)
07 – 2 04 nc 05 nc 05 05 05 05 05 05 05 05 05 05 05 05 05 05 05 05 05 05 05 0	Median (min, max)	74 (0.6, 2	4.8 207.4)	76 (2.8,	5.1 172.1)	76 (4.1, 2	5.9 212.5)	71 (6.9,	.1 96.5)	70.4	(37.9, 1.1)
20 Prc	Missing, No. (%)	1668	7.2	186	13.3	502	25.0	0	0	5	29.4
. 11	N	44	36	52	28	90	02	(	)	(	)
2013 Total no. of procedures = 6928	Mean (SD)	75.0	(25.2)	71.7	(28.5)	78.1	(26.6)	N	/A	N	/A
	Median (min, max)	75 (2.9, 1	5.4 179.2)	73.1 (3.4, 177.5)		76 (3.6, 1	5.6 177.7)	N	/A	N	/A
Tc	Missing, No. (%)	636	12.5	97	15.5	329	26.7	0	0	0	0
of Tota	Ν	56	32	6	53	10	68	(	0		)
b. of	Mean (SD)	75.1	(25.5)	75.5	(29.2)	77.7	(26.8)	N	/A	N	/A
2014 otal no ocedu 858(	Median (min, max)	76 (0.4, 1	5.1 198.6)	76 (3.1,	5.2 177.0)	77 (2.8, 2	7.9 200.5)	N	/A	N	/A
T	Missing, No. (%)	784	12.2	94	12.6	355	24.9	0	0	0	0
	Ν	100	)68	11	81	1970		(	C	(	)
014 0. of res : 4	Mean (SD)	75.0	(25.4)	73.8	(29.0)	77.9	(26.7)	N	/A	N	/A
013 - 2014 0tal no. of ocedures = 15514	Median (min, max)	75 (0.4, 1	5.7 198.6)	74 (3.1, 1	l.8 177.5)	77 (2.8, 2	7.6 200.5)	N	/A	N	/A
20 Tr	Missing, No. (%)	1420	12.4	191	13.9	684	25.8	0	0	0	0

Table 2.13 Comparison of GFR according to PCI status, NCVD-PCI Registry, 2007 – 2014

Year	Total cholesterol	Elec	ctive	NST	EMI	STI	EMI	Not av	ailable	Mis	sing
	mmol/L	No.	%	No.	%	No.	%	No.	%	No.	%
 S	Ν	150	)94	73	33	80	67	1	2		7
lure	Mean (SD)	4.5 (	(1.2)	4.8	(1.5)	5.3	(1.6)	4.8	(1.0)	6.4 (	(5.2)
- 2012 proced 483	Median (min, max)	4.3 (2.0	), 24.2)	4.7 (2.0	0, 22.0)	5.2 (2.0	0, 23.0)	4.9 (3.	1, 6.0)	4.9 (3.3	3, 18.0)
2007 - 1 no. of 1 26⁄	Not available, No. (%)	5887	25.6	484	34.6	823	41.0	6	24.0	5	29.4
Tota	Missing, No. (%)	2058	8.9	180	12.9	315	15.7	7	28.0	5	29.4
<b>S</b> 11	Ν	29	00	32	22	50	02	(	)	(	)
lure	Mean (SD)	4.4 (	(1.2)	4.7	(1.7)	5.2	(1.6)	N	/A	N	/A
2013 2013 6928	Median (min, max)	4.2 (2.0	), 10.6)	4.5 (2.2	1, 25.0)	5.1(2.0	), 14.5)	N	/A	N	/A
20 20 J no. of 1 69	Not available, No. (%)	1403	27.7	189	30.2	446	36.2	0	0	0	0
dures = $\begin{bmatrix} 2013 \\ Total no. of pr \\ 1 & 1 \\ 2 & 23 \\ 6923 \end{bmatrix}$	Missing, No. (%)	769	15.2	114	18.2	283	23.0	0	0	0	0
<b>S</b> 11	Ν	33	87	32	28	58	85	(	)	(	)
lure	Mean (SD)	4.4 (	(1.4)	4.6	(1.3)	5.2	(1.4)	N	/A	N	/A
14 proced 86	Median (min, max)	4.1 (2.0	), 25.0)	4.4 (2.0	0, 10.3)	5.1(2.0	), 15.0)	N	/A	N	/A
20 1 no. of 1 85	Not available, No. (%)	2121	33.1	300	40.2	569	40.0	0	0	0	0
Tota	Missing, No. (%)	908	14.2	119	15.9	269	18.9	0	0	0	0
 \$	Ν	62	87	65	50	10	87	(	)	(	)
lure	Mean (SD)	4.4 (	(1.3)	4.7	(1.5)	5.2	(1.5)	N	/A	N	/A
- 2014 procedu 514	Median (min, max)	4.1 (2.0	), 25.0)	4.4 (2.0	0, 25.0)	5.1 (2.0	0, 15.0)	N	/A	N	/A
2013 - 1 no. of 1 155	Not available, No. (%)	3524	30.7	489	35.6	1015	38.2	0	0	0	0
Tota	Missing, No. (%)	1677	14.6	233	17.0	552	20.8	0	0	0	0

Table 2.14 Comparison of TC according to PCI status, NCVD-PCI Registry, 2007 – 2014

Year	I.D.I. shelestand surrel/I	Elec	ctive	NST	EMI	STH	EMI	Not available		Missing	
теаг	LDL cholesterol, mmol/L	No.	%	No.	%	No.	%	No.	%	No.	%
	N	14	906	73	34	82	26	1	5	6	i
012 0. of res = 3	Mean (SD)	2.6	(1.1)	3.0	3.0 (1.3)		(1.4)	3.9	(4.0)	2.6 (	1.0)
7 – 2 al no edui 648	Median (min, max)	2.4 (0.	7, 20.0)	2.8 (0.8	8, 20.0)	3.3 (0.8	8, 16.0)	3.1 (1.2	2, 18.0)	2.8 (0.9	), 3.6)
200 Tota Proc	Not available, No. (%)	6061	26.3	501	35.9	845	42.1	9	36.0	5	29.4
1	Missing, No. (%)	2072	9.0	162	11.6	334	16.7	1	4.0	6	35.3
	Ν	28	801	30	06	47	73	(	)	0	)
). of res =	Mean (SD)	2.5	(1.1)	2.9	(1.5)	3.4 (	(1.4)	N	/A	N/	А
2013 al no 6928	Median (min, max)	2.3 (0.	8, 20.0)	2.6 (0.8	8, 18.0)	3.3 (0.9	9, 12.3)	N	/A	N/	А
Tot	Not available, No. (%)	1454	28.7	206	33.0	468	38.0	0	0	0	0
1	Missing, No. (%)	817	16.1	113	18.1	290	23.6	0	0	0	0
	Ν	33	808	31	13	55	56	(	)	0	)
t D. of res =	Mean (SD)	2.5	(1.1)	2.8	(1.2)	3.4 (	(1.3)	N	/A	N/	А
2014 al no edu 8586	Median (min, max)	2.2 (0.	8, 16.0)	2.6 (0.	.8, 8.3)	3.2 (0.8	8, 13.8)	N	/A	N/	А
Tot	Not available, No. (%)	2207	34.4	316	42.3	593	41.7	0	0	0	0
1	Missing, No. (%)	901	14.0	118	15.8	274	19.3	0	0	0	0
	Ν	61	09	6	19	10	29	(	)	0	)
2014 2. of res : 4	Mean (SD)	2.5	(1.1)	2.8	(1.4)	3.4 (	(1.3)	N	/A	N/	А
3 – 2 al no edu 551	Median (min, max)	2.3 (0.	8, 20.0)	2.6 (0.8	8, 18.0)	3.2 (0.8	8, 13.8)	N	/A	N/	А
10t Tot proc	Not available, No. (%)	3661	31.9	522	38.0	1061	40.0	0	0	0	0
	Missing, No. (%)	1718	15.0	231	16.8	564	21.3	0	0	0	0

Table 2.15 Comparison of LDL according to PCI status, NCVD-PCI Registry, 2007 – 2014

Voor	Eurotional izabaamia	Elec	tive	NST	EMI	STI	EMI	Not av	ailable	Mis	sing
rear	r unctional ischaenna	No.	%	No.	%	No.	%	No.	%	No.	%
33	Positive	4402	19.1	140	10.0	135	6.7	6	24.0	1	5.9
12 of 2648	Negative	398	1.8	13	0.9	28	1.4	1	4.0	0	0
- 20) no ss =	Equivocal	251	1.1	11	0.8	13	0.6	0	0	1	5.9
07 - otal dure	Not applicable	17705	76.8	1208	86.5	1780	88.9	18	72.0	5	29.4
.0C6 J	Missing	283	1.2	25	1.8	49	2.4	0	0	10	58.8
ıd	Total	23039	100.0	1397	100.0	2005	100.0	25	100.0	17	100.0
80	Positive	566	11.2	38	6.1	41	3.3	0	0	0	0
of 692	Negative	32	0.6	8	1.3	6	0.5	0	0	0	0
13 no.	Equivocal	77	1.5	15	2.4	13	1.1	0	0	0	0
20 otal dur	Not applicable	2592	51.1	317	50.7	681	55.3	0	0	0	0
Tot proced	Missing	1805	35.6	247	39.5	490	39.8	0	0	0	0
d	Total	5072	100.0	625	100.0	1231	100.0	0	0	0	0
9	Positive	484	7.5	25	3.3	11	0.8	0	0	0	0
of 858	Negative	43	0.7	2	0.3	4	0.3	0	0	0	0
14 no. es =	Equivocal	32	0.5	4	0.5	2	0.1	0	0	0	0
20 otal dur	Not applicable	2118	33.0	247	33.1	526	37.0	0	0	0	0
L Toce	Missing	3739	58.3	469	62.8	880	61.8	0	0	0	0
d	Total	6416	100.0	747	100.0	1423	100.0	0	0	0	0
14	Positive	1050	9.1	63	4.6	52	1.9	0	0	0	0
14 of 155	Negative	75	0.7	10	0.7	10	0.4	0	0	0	0
2013 – 2014 Total no. of rrocedures = 15	Equivocal	109	0.9	19	1.4	15	0.6	0	0	0	0
	Not applicable	4710	41.0	564	41.1	1207	45.5	0	0	0	0
	Missing	5544	48.3	716	52.2	1370	51.6	0	0	0	0
pr	Total	11488	100.0	1372	100.0	2654	100.0	0	0	0	0

Table 2.16 Comparison of functional ischaemia according to PCI status, NCVD-PCI Registry, 2007 – 2014

Year	ECC	STH	EMI	NST	EMI	Ŭ	J <b>A</b>	Not av	ailable	Mis	sing
rear	ECG	No.	%	No.	%	No.	%	No.	%	No.	%
256	Sinus rhythm	4469	43.6	2802	27.3	953	9.3	46	0.4	10	0.1
012 • of = 10	Atrial fibrillation	49	0.5	36	0.4	13	0.1	1	0	0	0
7 – 2 al no ires :	2 <sup>nd</sup> /3 <sup>rd</sup> AVB	65	0.6	7	0.1	5	0.0	0	0	0	0
200 Tot	LBBB	20	0.2	13	0.1	5	0.0	0	0	0	0
pro	RBBB	25	0.2	34	0.3	10	0.1	0	0	0	0
28	Sinus rhythm	1036	44.0	393	16.7	378	16.0	19	0.8	0	0
. of = 69	Atrial fibrillation	16	0.7	5	0.2	3	0.1	0	0	0	0
2013 al no ures	2 <sup>nd</sup> /3 <sup>rd</sup> AVB	11	0.5	6	0.3	1	0	0	0	0	0
Tot	LBBB	9	0.4	3	0.1	1	0	0	0	0	0
14 2013 no. of Total no. o es = 8586 procedures = 6	RBBB	7	0.3	3	0.1	2	0.1	0	0	0	0
86	Sinus rhythm	1483	48.4	650	21.2	409	13.4	46	1.5	0	0
• of = 85	Atrial fibrillation	21	0.7	12	0.4	4	0.1	0	0	0	0
2014 al nc ures	2 <sup>nd</sup> /3 <sup>rd</sup> AVB	20	0.7	0	0	1	0	0	0	0	0
Tot	LBBB	14	0.5	3	0.1	3	0.1	0	0	0	0
pre	RBBB	3	0.1	2	0.1	2	0.1	0	0	0	0
514	Sinus rhythm	2519	46.5	1043	19.3	787	14.5	65	1.2	0	0
014 • of = 15	Atrial fibrillation	37	0.7	17	0.3	7	0.1	0	0	0	0
2013 – 201 Total no cedures =	2 <sup>nd</sup> /3 <sup>rd</sup> AVB	31	0.6	6	0.1	2	0	0	0	0	0
	LBBB	23	0.4	6	0.1	4	0.1	0	0	0	0
pro	RBBB	10	0.2	5	0.1	4	0.1	0	0	0	0

Table 2.17 Comparison of ECG according to ACS subtypes, NCVD-PCI Registry, 2007 – 2014

Xear - 2012 - 20	*1400	STI	EMI	NST	EMI	U	A	Not av	ailable	Mis	sing
	*IABP	No.	%	No.	%	No.	%	No.	%	No.	%
– 2012 l no. of res = 10256	Yes	398	6.9	91	2.8	29	2.5	7	9.2	0	0
012 • of = 10	No	5251	91.8	3179	96.1	1089	95.5	63	82.9	9	90.0
7 – 2 al no tres :	Not applicable										
2007 Tots cedu	Missing	73	1.3	38	1.1	22	2.0	6	7.9	1	10.0
pro	Total	5722	100.0	3308	100.0	1140	100.0	76	100.0	10	100.0
028	Yes	88	6.5	17	3.4	6	1.3	0	0	0	0
. of = 60	No	1083	78.8	430	84.7	375	83.1	23	95.8	0	0
2013 al nc ures	Not applicable	54	3.9	17	3.4	17	3.8	0	0	0	0
2 Totaj ocedu	Missing	149	10.8	43	8.5	53	11.8	1	4.2	0	0
pro	Total	1374	100.0	507	100.0	451	100.0	24	100.0	0	0
586	Yes	88	5.1	17	2.2	2	0.4	1	1.9	0	0
• • • • •	No	1580	90.7	719	93.2	469	94.8	35	64.8	0	0
2014 al nc ures	Not applicable	5	0.3	1	0.1	1	0.2	0	0	0	0
Tota	Missing	68	3.9	35	4.5	23	4.6	18	33.3	0	0
pro	Total	1741	100.0	772	100.0	495	100.0	54	100.0	0	0
514	Yes	176	5.7	34	2.7	8	0.8	1	1.3	0	0
014 0. of = 15	No	2663	85.5	1149	89.8	844	89.2	58	74.3	0	0
3 – 201 al no. c ires = ]	Not applicable	59	1.9	18	1.4	18	1.9	0	0	0	0
201: Toti cedu	Missing	217	6.9	78	6.1	76	8.1	19	24.4	0	0
proc	Total	3115	100.0	1279	100.0	946	100.0	78	100.0	0	0

Table 2.18 Comparison of IABP use according to ACS subtypes, NCVD-PCI Registry, 2007 – 2014

\*IABP was listed in separate sections in the previous and new CRFs. In the old CRF, it was reported in Section 6 (cath lab visit), and in the new CRF, it was reported in Section 7 (PCI procedure details)

# **PROCEDURAL SETTINGS**

Aslannif Roslan, Tan Kin Leong, Al Fazir Omar, Rosli Mohd Ali, and Robaayah Zambahari Institut Jantung Negara, Kuala Lumpur

### Summary

- 1. Majority of PCIs performed in Malaysia from 2013 2014 were performed as elective cases (n = 11,488, 74.1%). The number of PCI procedures had increased over the years; and there had been an increasing trend of PCI performed in the setting of acute coronary syndrome (STEMI/NSTEMI/UA).
- Radial access (57%) had become the preferred percutaneous entry in the year 2013 2014.
- 3. The use of closure device had increased in 2013 2014 (13%) compared to only 3.9% in the year 2007–2012.
- 4. Aspirin and clopidogrel remained the two most common antiplatelet therapies for patients undergoing coronary angioplasty.
- 5. The overall use of clopidogrel had decreased in 2013 2014, with the introduction of newer antiplatelet agents such as ticagrelor.

This chapter discusses the procedural details and treatment received by patients who underwent PCI from 2013 to 2014.

A total of 15,514 PCI procedures were performed during this two year period in 15 centres across Malaysia. The total number of procedures reported steadily increased over the years; with an average of 4,413/year during 2007 – 2012 to 6,928 and 8,586 in 2013 and 2014, respectively. [Table 3.1]

Most of the PCIs were performed as elective cases (n = 11,488, 74.1%). About 17.1% (n = 2,654) of the total procedures were performed for acute ST-elevation myocardial infarction (STEMI) and 8.8% (n = 1,372) were for non-ST-elevation myocardial infarction/unstable angina (NSTEMI/UA). [Table 3.1]

There were decreases in the percentage of elective cases from 90.1% in 2007 – 2009 to 84.6% in 2010 – 2012 and 74.1% in 2013 – 2014. There was an increase in the number of PCIs performed during index admission with acute coronary syndrome (STEMI/NSTEMI/UA) for the year 2013 – 2014 (n = 3,397, 12.8%) compared to 2007 – 2012 registry (n = 4,026, 25.9%). [Table 3.1]

In the cohort of STEMI PCI (n = 2,654), nearly one-third was performed as primary PCI (n = 884, 33.3%), while another third was treated in the rescue PCI setting (n = 844, 31.8%). [Table 3.1]

### Procedural access, guiding size and closure

Based on the previous registry (2007–2012), the preferred percutaneous entry of PCI was femoral artery access (52.3%). However, during 2013 – 2014, femoral access had decreased to 45.9% while radial percutaneous entry became the preferred choice (54.3% in 2013 and 59.2% in 2014). The most common size of guiding catheter was 6Fr (91.8%) followed by 7Fr (7.4%). [Table 3.1]

Majority of post procedural access closure was by manual compression (80.8% in 2013 - 2014). However, there was an increased in the use of closure devices from 3.9% (2007 to 2012) to 13.0% (2013 - 2014). [Table 3.1]

### Extent of coronary diseases

About two-thirds of patients who went for PCI in this cohort had single vessel disease (64.4% in 2013 -2014 vs. 46.1% in 2007 -2012). [Table 3.1]

Only 2.9% (n = 470) of patients had left main stem involvement, however this was higher in 2013 - 2014 than in 2007 - 2012 (n = 171). [Table 3.1]

Coronary angioplasty was done in 1.3% (n = 198) of patients who have had bypass grafts . [Table 3.1]

#### PCI procedure

The mean fluoroscopy time was 19.3 minutes (SD 16.7), the median was 14.5 minutes. The values were similar to values in 2007 - 2012. [Table 3.1]

In terms of contrast volume, the mean for 2013 - 2014 was 162.8 ml (SD 68.9 ml) and the median was 150 ml. The mean and median contrast volume were comparable to the previous registry in 2007 - 2012 which had a mean of 177.2 ml (SD 68.9) and median of 150.0 ml. [Table 3.1]

### Treatment of patients undergoing PCI

#### GP IIb/IIIa blocker.

Overall, the use of GP IIb/IIIa blocker remained low; even lower compared to the previous cohort (3.8% in 2013 - 2014 and 4.8% in 2007 - 2012).

*Intravenous unfractionated heparin infusion and low molecular weight heparin (LMWH)* Intravenous unfractionated heparin remained the choice of anticoagulant used during PCI, which was 95.2% between 2007 – 2012 and 95.6% between 2013 – 2014. [Table 3.1]

#### Anti-platelets

Aspirin and clopidogrel were the two most common antiplatelet agents used in PCI in 2013 - 2014. The majority of patients received aspirin during PCI (98.9% in 2013 - 2014 and 98.6% in 2007 - 2012). [Table 3.1]

There was a decrease in clopidogrel use from 97.9% in 2007 - 2012 to 90.8% in 2013 - 2014. This was reflected in the increased use of other newer antiplatelet agents such as ticagrelor (10.5% of the patients in 2013 - 2014 and 0% in 2007-2012). [Table 3.1]

There was an increasing trend of clopidogrel use for 12 months, 55.2% in 2007 - 2012 to 76.3% in 2013 - 2014. [Table 3.1] The increase in the duration of antiplatelet therapies could possibly reflect the higher use of drug-eluting stents in 2013 - 2014. [Table 3.2]

	2007 -	- 2012	20	13	20	14	2013 -	- 2014
	Total procedure	no. of es = 26483	Total procedur	no. of es = 6928	Total procedur	no. of es = 8586	Total procedure	no. of es = 15514
	No.	%	No.	%	No.	%	No.	%
PCI status, No. (%)								
Elective	23039	87.0	5072	73.2	6416	74.7	11488	74.1
NSTEMI/UA	1397	5.3	625	9.0	747	8.7	1372	8.8
STEMI	2005	7.5	1231	17.8	1423	16.6	2654	17.1
Not available	25	0.1	0	0	0	0	0	0
Missing	17	0.1	0	0	0	0	0	0
Elective, No. (%)	23039	87.0	5072	73.2	6416	74.7	11488	74.1
Staged PCI	5111	24.2	1442	20.8	2009	23.4	3451	22.2
Ad hoc	16046	75.8	3594	51.9	4362	50.8	7956	51.3
NSTEMI/UA, No. (%)	1397	5.3	625	9.0	747	8.7	1372	8.8
Urgent	824.0	60.1	218	34.9	228	30.5	446	32.5
Non-urgent	548.0	39.9	401	64.2	511	68.4	912	66.5
STEMI, No. (%)	2005	7.5	1231	17.8	1423	16.6	2654	17.1
Rescue	737	37.1	410	33.3	434	30.5	844	31.8
Primary	762	38.3	394	32.0	490	34.4	884	33.3
Facilitated	26	1.3	25	2.0	43	3.0	68	2.6
Delayed PCI	464	23.3	67	5.4	0	0	67	2.5
Delayed routine PCI			162	13.2	218	15.3	380	14.3
Delayed selective PCI			110	8.9	136	9.6	246	9.3
Pharmacoinvasive			38	3.1	93	6.5	131	4.9
<sup>#</sup> Percutaneous entry,								
Brachial	183	0.7	67	1.0	47	0.5	114	0.7
Radial	11301	42.7	3763	54.3	5083	59.2	8846	57.0
Femoral	13857	52.3	3221	46.5	3899	45.4	7120	45.9
<sup>\$^</sup> French size type, No. (%)								
Guiding catheter			8229	96.7	10518	97.3	18747	97.0
Guiding sheath			149	1.7	273	2.5	422	2.2
Not available			42	0.5	20	0.2	62	0.3
Missing			97	1.1	1	0.0	98	0.5

Table 3.1 PCI status of patients who underwent procedures, NCVD-PCI Registry, 2007 – 2014

	2007 - 2012		2013		20	14	2013 - 2014	
	Total procedure	no. of es = 26483	Total procedur	Total no. of procedures = 6928		no. of es = 8586	Total procedure	no. of es = 15514
	No.	%	No.	%	No.	%	No.	%
<sup>^</sup> French size (guiding catheter), No. (%)								
4			27	0.4	8	0.1	35	0.2
5	249	0.9	20	0.2	15	0.1	35	0.2
6	21667	81.8	7405	90.0	9822	93.5	17227	91.8
7	3441	13.0	728	8.8	654	6.2	1382	7.4
8	155	0.6	16	0.2	5	0.0	21	0.1
*9	2	0.0	0	0	1	0.0	1	0.0
Others	9	0.0	0	0	11	0.1	11	0.1
Not available	330	1.3	33	0.4	2	0.0	35	0.2
Missing	630	2.4	0	0	0	0	0	0
<sup>^</sup> French size (guiding sheath), No. (%)								
4			0	0	0	0	0	0
5			0	0	0	0	0	0
6			129	86.5	245	89.8	374	88.6
7			0	0	0	0	0	0
8			19	12.8	26	9.5	45	10.7
*9			1	0.7	2	0.7	3	0.7
Others			0	0	0	0	0	0
Not available			0	0	0	0	0	0
Missing			0	0	0	0	0	0
Closure device, No. (%)								
No	23702	89.5	5984	86.3	6547	76.3	12531	80.8
Seal	512	1.9	157	2.3	226	2.6	383	2.5
Suture	494	1.9	245	3.5	715	8.3	960	6.2
Exoseal			52	0.8	93	1.1	145	0.9
Others	39	0.1	80	1.2	454	5.3	534	3.4
Not available	380	1.4	89	1.3	61	0.7	150	1.0
Missing	1356	5.2	321	4.6	490	5.7	811	5.2
<sup>#^</sup> Extent of coronary disease, No. (%)								
Single vessel disease	12198	46.1	4109	59.3	5875	68.4	9984	64.4
Multiple vessel disease	12322	46.5	2382	34.4	2329	27.1	4711	30.4
Left main/LMS	171	0.6	200	2.9	270	3.1	470	2.9
Graft	292	1.1	90	1.3	108	1.3	198	1.3
Not available			147	2.1	4	0.1	151	1.0

	2007 - 2012		2013		20	14	2013 - 2014	
	Total no. of procedures = 26483		Total no. of procedures = 6928		Total no. of procedures = 8586		Total no. of procedures = 15514	
	No.	%	No.	%	No.	%	No.	%
Fluoroscopy time, min								
Ν	227	773	59	30	75	58	134	188
Mean (SD)	20.4 (	(18.3)	19.2	(17.1)	19.3	(16.3)	19.3 (16.7)	
Median (min, max)	15.3 (2.0	), 180.0)	14.4 (2.0	0, 171.0)	14.5 (2.0	0, 175.0)	14.5 (2.0	), 175.0)
Not available, No. (%)	2222	8.4	595	8.6	670	7.8	1265	8.2
Missing, No. (%)	1488	5.6	403	5.8	358	4.2	761	4.9
Fluoroscopy total dose, mGy								
N	115	527	31	13	46	16	77	29
Mean (SD)	3316.3 (2	26882.6)	71682.5 (1	635133.5)	55394.0 (	408095.8)	61954.5 (1	084518.4)
Median (min, max)	18 (0.5, 119	7.0 99417.0)	165 (0.0, 900	56.0 93904.0)	1900.1 (1.4, 26434900.0)		1792.0 (0.0, 90093904.0)	
Not available, No. (%)	10473	39.5	2737	39.5	2622	30.5	5359	34.5
Missing, No. (%)	4483	16.9	1078	15.6	1348	15.7	2426	15.6
Contrast type, No. (%)								
Ionic	229	0.9						
Non-ionic	24225	91.5						
Not available	1542	5.8						
Missing	487	1.8						
Contrast volume, ml								
N	236	650	5937		7494		13431	
Mean (SD)	177.2	(68.9)	162.5	(69.4)	163.0	(68.5)	162.8	(68.9)
Median (min, max)	150.0 (15	.0, 500.0)	150.0 (16	.0, 500.0)	150.0 (18	.0, 500.0)	150.0 (16	.0, 500.0)
Not available, No. (%)	1891	7.1	529	7.6	549	6.4	1078	6.9
Missing, No. (%)	942	3.6	462	6.7	543	6.3	1005	6.5
Thrombolytics prior to PCI procedure in ACS STEMI, No. (%)								
Total no. of procedures among ACS STEMI patients	5722	100	1374	100	1741	100	3115	100
Yes	1258	22.0	607	44.2	706	40.6	1313	42.2
No	4458	77.9	767	55.8	1035	59.4	1802	57.8
Missing	6	0.1	0	0	0	0	0	0

	2007 - 2012		2013		20	14	2013 - 2014	
	Total no. of procedures = 26483		Total no. of procedures = 6928		Total no. of procedures = 8586		Total no. of procedures = 15514	
	No.	%	No.	%	No.	%	No.	%
Duration of thrombolytics given prior to PCI procedure in ACS STEMI, No. (%)								
< 3 hrs	77	6.8	51	10.8	84	14.7	135	12.9
3 – 6 hrs	132	11.6	88	18.7	114	19.9	202	19.4
6 – 12 hrs	109	9.6	82	17.4	90	15.7	172	16.5
12 – 24 hrs	146	12.8	221	46.9	284	49.7	505	48.4
> 24 hrs			29	6.2	0	0	29	2.8
1 – 7 days	450	39.5						
>7 days	225	19.7						
Not available	26		69		56		125	
Missing	93		67		78		145	

*#Patients were allowed to be in more than one type of category* 

\$French size type was not available in the old CRF. In the old CRF, information on French size was only collected for guiding catheter ^French size is reported by number of lesions instead of number of procedures. In the old CRF, French size was reported under Section 6 cath lab visit, no 6b, whereas in the new CRF, it was reported under Section 7 PCI proc details, no 11

\* In the new CRF, French size 9 was not listed. However, there was one patient with guiding catheter and French size 9 and three patients with guiding sheath and French size 9

^Results were presented differently in 2007 – 2012 and 2013 – 2014. In 2007 – 2012, patients were allowed to be presented in different categories. In 2013 – 2014, patients were included in a unique category

Single vessel disease is for patients with single vessel disease information (old CRF)/ patients with only one information of LAD, LCx, or RCA

Multiple vessel disease is for patients with multiple vessel disease information (old CRF)/patients with more than one information of LAD, LCx or RCA

Left main stem (LMS) is for patients with information on LMS (LMS alone or combination with LAD, LCx, RCA or single vessel disease) Graft is for patients with information on graft (graft alone or combination with LAD, LCx, RCA, single vessel disease, multiple vessel disease or LMS)

	2007 - 2012		2013		20	14	2013 - 2014	
	Total no. of procedures = 26483		Total procedur	Total no. of procedures = 6928		no. of es = 8586	Total procedure	no. of es = 15514
	No.	%	No.	%	No.	%	No.	%
IIb/IIIa Blockade, No. (%)								
Yes	1275	4.8	238	3.4	347	4.0	585	3.8
No	25163	95.0	6690	96.6	8239	96.0	14929	96.2
Missing	45	0.2	0	0	0	0	0	0
IIb/IIIa Blockade given status, No. (%)								
Prior	447	37.9	64	29.2	150	50.5	214	41.5
During	629	53.3	25	11.4	20	6.7	45	8.7
After	104	8.8	130	59.4	127	42.8	257	49.8
Not available	23		0		1		1	
Missing	72		19		49		68	
Heparin, No. (%)								
Yes	25205	95.2	6576	94.9	8253	96.1	14829	95.6
No	1250	4.7	352	5.1	333	3.9	685	4.4
Missing	28	0.1	0	0	0	0	0	0
Heparin given status, No. (%)								
Prior	4863	19.7	2978	46.5	3588	44.5	6566	45.4
During	19789	80.2	5	0.1	2	0	7	0
After	35	0.1	3416	53.4	4470	55.5	7886	54.6
Not available	40		16		1		17	
Missing	478		161		192		353	
LMWH, No. (%)								
Yes	895	3.4	223	3.2	301	3.5	524	3.4
No	25520	96.4	6705	96.8	8285	96.5	14990	96.6
Missing	68	0.2	0	0	0	0	0	0
LMWH given status, No. (%)								
Prior	728	86.5	184	86.4	265	96.0	449	91.8
During	61	7.2	15	7.0	5	1.8	20	4.1
After	53	6.3	14	6.6	6	2.2	20	4.1
Not available	3		1		0		1	
Missing	50		9		25		34	

	2007 – 2012 Total no. of procedures = 26483		2013		20	14	2013 - 2014	
			Total procedur	Total no. of procedures = 6928		no. of es = 8586	Total procedure	no. of es = 15514
	No.	%	No.	%	No.	%	No.	%
Ticlopidine, No. (%)								
Yes	542	2.0	93	1.3	65	0.8	158	1.0
No	25891	97.8	6835	98.7	8521	99.2	15356	99.0
Missing	50	0.2	0	0	0	0	0	0
Ticlopidine given status, No. (%)								
Prior	492	96.9	86	96.6	60	98.4	146	97.3
During	10	1.9	0	0	1	1.6	1	0.7
After	6	1.2	3	3.4	0	0	3	2.0
Not available	7		0		0		0	
Missing	27		4		4		8	
Aspirin, No. (%)								
Yes	25788	97.4	6751	97.4	8242	96.0	14993	96.6
No	668	2.5	177	2.6	344	4.0	521	3.4
Missing	27	0.1	0	0	0	0	0	0
Aspirin given status, No. (%)								
Prior	24679	98.6	6488	98.7	7950	99.2	14438	98.9
During	237	0.9	52	0.8	11	0.1	63	0.4
After	119	0.5	34	0.5	60	0.7	94	0.7
Not available	191		3		6		9	
Missing	562		174		215		389	
Clopidogrel, No. (%)								
Yes	25933	97.9	6355	91.7	7724	90.0	14079	90.8
No	531	2.0	573	8.3	862	10.0	1435	9.2
Missing	19	0.1	0	0	0	0	0	0
Clopidogrel given status, No. (%)								
Prior	24807	97.0	5862	93.3	7331	95.9	13193	94.7
During	351	1.4	28	0.4	19	0.2	47	0.3
After	404	1.6	398	6.3	301	3.9	699	5.0
Not available	178		8		6		14	
Missing	193		59		67		126	

	2007 - 2012		2013		20	14	2013 - 2014	
	Total procedure	no. of es = 26483	Total no. of procedures = 6928		Total procedur	no. of es = 8586	Total no. of procedures = 15514	
	No.	%	No.	%	No.	%	No.	%
Duration of clopidogrel given prior to PCI procedure, hrs, No. (%)								
< 6	5872	25.3	1593	29.5	2058	30.1	3651	29.9
6 – 24	7485	32.2	1246	23.1	1893	27.6	3139	25.6
> 24 - 72	4127	17.7	533	9.9	719	10.5	1252	10.2
> 72	5771	24.8	2021	37.5	2181	31.8	4202	34.3
Not available	677		192		92		284	
Missing	875		277		388		665	
First starting dose, mg,								
75	11567	50.8	2725	50.4	3719	55.3	6444	53.1
300	8977	39.4	2174	40.2	2299	34.2	4473	36.9
600	2237	9.8	509	9.4	706	10.5	1215	10.0
≥ 1200	6	0.0	1	0.0	0	0	1	0.0
Not available	1187		289		199		488	
Missing	1959		657		801		1458	
*Clopidogrel dose of ACS STEMI patient, mg, No. (%)								
Total no. of PCI procedures among ACS STEMI patients who were taking clopidogrel.	5629	100	1183	100	1499	100	2682	100
75	2441	47.8	187	19.9	372	30.2	559	25.8
300	2165	42.5	607	64.7	705	57.4	1312	60.5
600	497	9.7	145	15.4	152	12.4	297	13.7
≥ 1200	2	0.0	0	0	0	0	0	0
Not available	211		50		25		75	
Missing	313		194		245		439	
Fondaparinox, No. (%)								
Yes	582	2.2	751	10.8	645	7.5	1396	9.0
No	14135	53.4	6128	88.5	7941	92.5	14069	90.7
Missing	11766	44.4	49	0.7	0	0	49	0.3
Fondaparinox given status, No. (%)								
Prior	482	93.6	635	86.9	576	95.2	1211	90.6
During	5	1.0	91	12.4	21	3.5	112	8.4
After	28	5.4	5	0.7	8	1.3	13	1.0
Not available	6		1		1		2	
Missing	61		19		39		58	

	2007 - 2012		2013		20	14	2013 - 2014	
	Total procedure	no. of es = 26483	Total no. of procedures = 6928		Total no. of procedures = 8586		Total no. of procedures = 15514	
	No.	%	No.	%	No.	%	No.	%
Prasugrel, No. (%)								
Yes			23	0.3	44	0.5	67	0.4
No			5517	79.6	8539	99.5	14056	90.6
Missing			1388	20.1	3	0.0	1391	9.0
Prasugrel given status, No. (%)								
Prior			19	90.5	29	74.4	48	80.0
During			2	9.5	2	5.1	4	6.7
After			0	0	8	20.5	8	13.3
Not available			0		0		0	
Missing			2		5		7	
Ticagrelor, No. (%)								
Yes			561	8.1	1071	12.5	1632	10.5
No			4979	71.9	7512	87.5	12491	80.5
Missing			1388	20.0	3	0.0	1391	9.0
Ticagrelor given status, No. (%)								
Prior			414	81.0	830	82.7	1244	82.1
During			21	4.1	24	2.4	45	3.0
After			76	14.9	150	14.9	226	14.9
Not available			1		0		1	
Missing			49		67		116	
Planned duration of clopidogrel/ticlopidine, month, No. (%)								
1	4846	18.3	714	10.3	579	6.6	1293	8.3
3	1417	5.4	287	4.1	245	2.9	532	3.4
6	1882	7.1	335	4.8	413	4.8	748	4.8
12	14619	55.2	5034	72.7	6807	79.3	11841	76.3
> 12	1774	6.7	88	1.3	65	0.8	153	1.1
Not available	1317	4.9	311	4.5	349	4.1	660	4.3
Missing	628	2.4	159	2.3	128	1.5	287	1.8

\*Only applicable to STEMI patients who were taking clopidogrel

	Dianned duration of	<sup>#</sup> Intracoronary devices used								
Year	clopidogrel/ticlopidine	Balloon or	nly/POBA	Drug-elu	ting stent	Bare metal stent				
	(months)	No.	%	No.	%	No.	%			
ŝ	1	588	23.6	299	1.5	4409	45.4			
3487	3	142	5.7	433	2.1	867	8.9			
<b>8 1</b>	6	210	8.4	1317	6.5	843	8.7			
201 sions	12	1100	44.2	15485	76.0	2472	25.4			
07 - of le	> 12	156	6.3	1790	8.8	534	5.5			
20 no.	Not available	253	10.2	553	2.7	415	4.3			
otal	Missing	41	1.6	493	2.4	176	1.8			
E	Total	2490	100.0	20370	100.0	9716	100.0			
	1	165	18.7	51	0.9	563	39.6			
8517	3	65	7.4	47	0.8	133	9.4			
= SI	6	38	4.3	120	2.1	103	7.3			
13 esior	12	527	59.6	5149	90.8	525	37.0			
20 of le	> 12	16	1.8	76	1.3	9	0.6			
no.	Not available	55	6.2	118	2.1	53	3.7			
lotal	Missing	18	2.0	116	2.0	34	2.4			
	Total	884	100.0	5677	100.0	1420	100.0			
5	1	174	10.9	129	1.7	323	31.1			
1081	3	57	3.5	49	0.7	92	8.9			
ן וו ג	6	94	5.8	209	2.9	66	6.4			
14 sion	12	1158	72.0	6667	91.1	501	48.5			
20 of le	> 12	22	1.4	53	0.7	4	0.4			
no.	Not available	80	5.0	128	1.7	34	3.3			
otal	Missing	23	1.4	86	1.2	14	1.4			
L	Total	1608	100.0	7321	100.0	1034	100.0			
6	1	339	13.7	180	1.4	886	36.1			
1932	3	122	4.9	96	0.7	225	9.2			
14 Is = [	6	132	5.3	329	2.5	169	6.9			
- 20) sion	12	1685	67.6	11816	90.9	1026	41.8			
013 - of le	> 12	38	1.5	129	1.0	13	0.5			
2( no.	Not available	135	5.4	246	1.9	87	3.5			
otal	Missing	41	1.6	202	1.6	48	2.0			
L	Total	2492	100.0	12998	100.0	2454	100.0			

Table 3.2 Duration of thienopyridine in patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014

<sup>#</sup>Patients were allowed to be in more than one type of category
							PCI s	status					
Year	<sup>#</sup> Percutaneous entry	Elec	tive	NSTE	MI/UA	AI	MI	Not av	ailable	Mis	sing	То	tal
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
012 of es =	Brachial	167	91.3	7	3.8	8	4.4	1	0.5	0	0	183	100
17 – 2( tal no. cedur	Radial	10378	91.8	444	3.9	467	4.2	10	0.1	2	0.0	11301	100
200 Toi proo	Femoral	11475	82.8	903	6.5	1463	10.6	13	0.1	3	0.0	13857	100
. of es =	Brachial	51	1.0	4	0.6	12	1.0	0	0	0	0	67	1.0
2013 tal no. cedur 6928	Radial	2947	57.0	333	52.3	483	38.9	0	0	0	0	3763	53.4
Toi	Femoral	2173	42.0	300	47.1	748	60.2	0	0	0	0	3221	45.6
of = ss	Brachial	27	0.4	9	1.2	11	0.8	0	0	0	0	47	0.5
2014 tal no. cedure 8586	Radial	3969	58.5	449	57.4	665	45.4	0	0	0	0	5083	56.3
Tot	Femoral	2786	41.1	324	41.4	789	53.9	0	0	0	0	3899	43.2
014 • of es =	Brachial	78	0.7	13	0.9	23	0.8	0	0	0	0	114	0.7
(3 – 201 tal no. ( cedures 15514	Radial	6916	57.9	782	55.1	1148	42.4	0	0	0	0	8846	55.0
201 Tol pro	Femoral	4959	41.5	624	44.0	1537	56.8	0	0	0	0	7120	44.3

## Table 3.3 Access site of patients who underwent procedures, by PCI status, NCVD-PCI Registry, 2007 – 2014

<sup>#</sup>Patients were allowed to be in more than one type of category

## LESION CHARACTERISTICS

Sridhar Ganiga Srinivasaiah, Ahmad Syadi Mahmood, Chee Kok Han and Wan Azman Wan Ahmad University Malaya Medical Centre, Kuala Lumpur

### Summary

- 1. LAD remains the most commonly treated lesion, as reported in previous years.
- 2. Complex lesions (B2 and C) made up 59% of all PCIs with an increase in the rate of type C lesions compared to the previous years.
- 3. DES is the most commonly used stent (69.7%); its use increased compared to the previous years.
- 4. Most of ISR lesions were treated with drug-eluting balloon (DEB).
- 5. The rate of procedural complications remained low.
- 6. A significant increase in the number of LMS intervention (541 lesions) was reported in the 2013 2014 cohort compared to 2007–2012. Majority of the lesions were treated with DES (84.3%), and were interestingly followed by DEB (3.8%) and BMS (3.4%). The success rate was 98.5%.
- Most of the graft PCIs was performed on SVG. When compared to the previous registry, the incidence of in-stent restenosis was slightly higher (10.8% vs. 9.0%), and the use of DEB in PCI to grafts had significantly increased in this cohort compared to the 2007 – 2012 cohort (15.7% vs. 9.8%).
- 8. Majority of CTO lesions were de novo lesions. Approximately half of the CTO PCI was performed via radial approach, however in the past radial approach was only 34.2%.

### Anatomical location of lesions

A total of 19,392 lesions were treated from the years 2013 to 2014. LAD remained the most common location (48.1%) followed by RCA (31.2%) and left circumflex (16.9%). The proximal segment of each vessel (LAD/RCA/LCx) was the most frequently treated. [Table 4.1]

There was a slight increase in LMS lesion (2.8%), but a reduction in graft PCI (0.9%) compared to the previous years. The saphenous vein graft was the most commonly treated graft (0.8%). The comparison in lesion location between 2013 to 2014 and 2007 to 2012 did not show any significant difference. [Table 4.1.1]

 Table 4.1 Summary of location of lesions treated with percutaneous coronary intervention, NCVD-PCI

 Registry, 2007 – 2014

Location of lesion	2007 - Total lesions :	- 2012 no. of = 34873	20 Total lesions	13 no. of = 8517	20 Total lesions :	14 no. of = 10812	2013 - Total lesions :	- 2014 no. of = 19329
	No.	%	No.	%	No.	%	No.	%
None	3	0.0	0	0	5	0	5	0
Left main stem	749	2.2	223	2.6	318	2.9	541	2.8
Left anterior descending artery (LAD)	16631	47.7	4120	48.4	5184	47.9	9304	48.1
LAD proximal	11604	33.3	2910	34.3	3567	33.0	6477	33.5
LAD mid	3626	10.4	895	10.5	1203	11.1	2098	10.9
LAD distal	520	1.5	148	1.7	202	1.9	350	1.8
D1	798	2.3	144	1.7	181	1.7	325	1.7
D2	72	0.2	20	0.2	26	0.2	46	0.2
D3	11	0.0	3	0	5	0	8	0
Right coronary artery (RCA)	10472	30.0	2722	31.9	3289	30.6	6011	31.2
RCA proximal	4655	13.3	1194	14.0	1513	14.1	2707	14.0
RCA mid	3351	9.6	845	9.9	984	9.1	1829	9.5
RCA distal	1848	5.3	512	6.0	568	5.3	1080	5.6
PDA	297	0.9	83	1.0	125	1.2	208	1.1
PLV	321	0.9	88	1.0	99	0.9	187	1.0
Left circumflex artery (LCx)	6370	18.3	1372	16.1	1915	17.7	3287	16.9
LCX proximal	2882	8.3	681	8.0	967	8.9	1648	8.5
LCX distal	2135	6.1	408	4.8	577	5.4	985	5.1
OM1	1060	3.0	229	2.7	299	2.8	528	2.7
OM2	229	0.7	42	0.5	58	0.5	100	0.5
OM3	64	0.2	12	0.1	14	0.1	26	0.1
Graft	481	1.3	75	0.9	91	0.8	166	0.9
Saphenous vein graft	423	1.2	68	0.8	81	0.7	149	0.8
Left internal mammary artery graft	51	0.1	5	0.1	10	0.1	15	0.1
Right internal mammary artery graft	3	0.0	0	0	0	0	0	0
Radial artery graft	4	0.0	2	0	0	0	2	0
Missing	167	0.5	5	0.1	10	0.1	15	0.1

# Table 4.1.1 Comparison between 2007 – 2012 and 2013 – 2014 results

Location of lesion	2007 - Total no. ( 348	- 2012 of lesions = 873	2013 - Total no. ( 193	p-value	
	No.	%	No.	%	
Left main stem	749	2.2	541	2.8	0.492
Left anterior descending artery (LAD)	16631	47.7	9304	48.1	0.536
Right coronary artery (RCA)	10472	30.0	6011	31.2	0.107
Left circumflex artery (LCx)	6370	18.3	3287	16.9	0.089
Graft	481	1.3	166	0.9	0.683

### Lesion characteristics

Of all lesions treated with PCI, 87.5% achieved TIMI III flow. [Table 4.5] A large majority of lesions treated were the de novo type (94.9%). The rate of PCI due to stent thrombosis remained low at 0.4% from 2007 - 2014. [Table 4.2] There was a reducing trend for in-stent restenosis intervention (4.2% in 2013 - 2014 vs. 4.7% in 2007 - 2012).

Complex lesions (Type B2 and C) made up 59.0% of all PCIs. There is an increase in the rate of Type C lesions compared to years 2007 to 2012. [Table 4.3]

Among the high-risk lesions, there appeared to be an increase in ostial and thrombotic PCIs and decrease in bifurcation and CTO PCIs. [Table 4.4] Calcified lesion PCI made up 6.0% of high risk PCI. [Table 4.4] There was an increase in LMS PCI. (2.8% vs. 2.2%). [Table 4.1]

### Types of stents and devices used

Drug-eluting stent remained as the most used stent (69.7%), and its use increased compared to the previous years, 2007 to 2012 (58.8%). The use of bare-metal stents showed a gradual decrease in trend, however, they were still the second most used device (11.9%). There was also an increased use of bio-absorbable stents, combo stents, and drug-eluting balloons in 2013 – 2014. The use of bifurcated and covered stents were rare and combined constituted < 0.5% of stents. [Table 4.6]

POBA was only done in 12.9% of lesions treated and this was interestingly higher than years 2007 to 2012 (7.1%). Cutting balloon/scoring balloon and rotablator use were low at 1.4% and 0.9%, respectively. [Table 4.8]

The use of intravascular guided imaging PCI and physiological assessment (FFR) were was low. The IVUS study was 2.7%, OCT was 0.8%, and FFR was 1.2%. [Table 4.8].

### Lesion complication during PCI

The rate of complication was low with dissection occurring in 1.7% (non-flow limiting in 85.6%), no reflow in 0.6% (69.6% transient), and perforation in 0.3% of all treated lesions. The rate of dissection and no reflow, both showed decreasing trends compared to years 2007 to 2012, but perforation rate remained constant. [Table 4.9]

Types of lesions	2007 – 2012 Total no. of lesions = 34873		20 Total no. = 8	13 of lesions 517	20 Total no. = 10	14 of lesions )812	2013 - Total no. = 19	- 2014 of lesions 0329
	No.	%	No.	%	No.	%	No.	%
De novo	32543	93.3	8066	94.7	10281	95.0	18347	94.9
Restenosis (no prior stent)	65	0.2	8	0.1	11	0.1	19	0.1
Stent thrombosis	147	0.4	45	0.5	40	0.4	85	0.4
In-stent restenosis	1618	4.7	366	4.3	438	4.1	804	4.2
Not available	284	0.8	32	0.4	42	0.4	74	0.4
Missing	216	0.6	0	0	0	0	0	0
Total	34873	100.0	8517	100.0	10812	100.0	19329	100.0

Table 4.2 Characteristics of lesions treated by PCI, NCVD-PCI Registry, 2007 – 2014

Table 4.3 Prevalence of lesions according to the An	erican College of Cardiology (ACC) classifications,
NCVD-PCI Registry, 2007 – 2014	

Types of lesions	2007 – 2012 Total no. of lesions = 34873		20 Total no. = 8	13 of lesions 517	20 Total no. = 10	14 of lesions 0812	2013 - Total no. = 19	- 2014 of lesions 9329
	No.	%	No.	%	No.	%	No.	%
А	3926	11.2	991	11.6	1188	11.0	2179	11.2
B1	9102	26.1	2276	26.7	3215	29.7	5491	28.4
B2	8199	23.5	1299	15.3	1464	13.5	2763	14.3
С	12855	36.9	3846	45.2	4788	44.3	8634	44.7
Not available	591	1.7	105	1.2	157	1.5	262	1.4
Missing	200	0.6	0	0	0	0	0	0
Total	34873	100.0	8517	100.0	10812	100.0	19329	100.0

Table 4.4 Prevalence of high risk lesion type, NCVD-PCI Registry, 2007 – 2014

<sup>#</sup> Types of lesions	2007 – 2012 Total no. of lesions = 34873		20 Total no. = 8	13 of lesions 517	20 Total no. = 10	14 of lesions )812	2013 - Total no. = 19	- 2014 of lesions 9329
	No.	%	No.	%	No.	%	No.	%
Ostial	2361	6.8	604	7.1	831	7.7	1435	7.4
Bifurcation	3285	9.4	560	6.6	699	6.5	1259	6.5
Total occlusion	1617	4.6	523	6.1	617	5.7	1140	5.9
CTO > 3 mo	2626	7.5	550	6.5	735	6.8	1285	6.6
Thrombus	1080	3.1	467	5.5	618	5.7	1085	5.6
Calcified lesion			293	3.4	867	8.0	1160	6.0
LMS			162	1.9	263	2.4	425	2.2

<sup>#</sup>Patients were allowed to be in more than one type of category

TIMI Flow	Tot	2007 – 2012 Total no. of lesions = 34873			То	20 tal no. of l	13 esions = 8	517	Tot	20 al no. of le	14 sions = 10	812	Tot	2013 – 2014 Total no. of lesions = 19329			
Grade	Pre-procedure Post-proce		ocedure	Pre-pro	ocedure	Post-pr	ost-procedure Pre-procedure Post-procedure		Pre-pro	Pre-procedure Post-proc		ocedure					
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
TIMI-0	4296	12.3	656	1.9	1177	13.8	154	1.9	1418	13.2	190	1.8	2595	13.4	344	1.8	
TIMI-1	2493	7.2	129	0.4	928	10.9	45	0.5	625	5.8	40	0.4	1553	8.0	85	0.4	
TIMI-2	6657	19.1	351	1.0	2386	28.0	149	1.7	2360	21.8	177	1.6	4746	24.6	326	1.7	
TIMI-3	18770	53.8	31050	89.0	3260	38.3	7546	88.6	5147	47.6	9361	86.6	8407	43.5	16907	87.5	
Not available	383	1.1	354	1.0	317	3.7	199	2.3	273	2.5	189	1.7	590	3.1	388	2.0	
Missing	2274	6.5	2333	6.7	449	5.3	424	5.0	989	9.1	855	7.9	1438	7.4	1279	6.6	
Total	34873	100.0	34873	100.0	8517	100.0	8517	100.0	10812	100.0	10812	100.0	19329	100.0	19329	100.0	

Table 4.5 Comparison of TIMI flow grade by pre- and post-procedure, NCVD-PCI Registry, 2007 – 2014

## Table 4.6 Types of stents used, NCVD-PCI Registry, 2007 – 2014

	2007 -	- 2012	20	13	20	14	2013 -	- 2014
Types of stents	Total no. of ster	nts used = 43839	Total no. of ster	nts used = 10415	Total no. of ster	nts used = 13123	Total no. of ster	nts used = 23538
	No.	%	No.	%	No.	%	No.	%
Drug-eluting stent	25786	58.8	7229	69.4	9183	69.9	16412	69.7
Bare metal stent	10354	23.6	1613	15.5	1189	9.1	2802	11.9
Bio-absorbable stent	37	0.1	90	0.9	204	1.6	294	1.2
Antibody-coated stent	629	1.5	28	0.3	20	0.2	48	0.2
Others	2812	6.4	160	1.5	130	0.9	290	1.2
Drug-eluting balloon	0	0	518	4.9	1054	8	1572	6.7
Bifurcated stent	0	0	42	0.4	28	0.2	70	0.3
Covered stent	13	0.0	0	0	23	0.2	23	0.1
Combo stent	0	0	226	2.2	665	5.1	891	3.9
Missing	4208	9.6	509	4.9	627	4.8	1136	4.8
Total	43839	100.0	10415	100.0	13123	100.0	23538	100.0

	2007 - Total no. = 34	- 2012 of lesions 1873	20 Total no. = 8	013 of lesions 517	20 Total no. = 10	014 of lesions 0812	2013 - Total no. = 19	- 2014 of lesions 0329
	No.	%	No.	%	No.	%	No.	%
Pre-procedure stenosis, %								
N	329	953	80	39	10	386	184	425
Mean (SD)	84.8 (	(12.2)	86.7	(12.0)	86.5	(11.4)	86.6	(11.7)
Median (min, max)	90.0 (0.0	), 100.0)	90.0 (0.0	0, 100.0)	90.0 (0.	0, 100.0)	90.0 (0.0	0, 100.0)
Missing, No. (%)	1920	5.5	478	5.6	426	3.9	904	4.7
Post-procedure stenosis, %								
Ν	315	566	80	070	104	459	185	529
Mean (SD)	4.3 (	18.4)	4.2 (	18.0)	4.2 (	17.8)	4.2 (	17.9)
Median (min, max)	0.0 (0.0	, 100.0)	0.0 (0.0	, 100.0)	0.0 (0.0	), 100.0)	0.0 (0.0	, 100.0)
Missing, No. (%)	3307	9.5	447	5.2	353	3.3	800	4.1
Estimated laster law oth								
mm								
Ν	317	733	78	45	10	029	175	874
Mean (SD)	23.6 (	(14.2)	24.7	(15.7)	25.9	(15.8)	25.4	(15.7)
Median (min, max)	20.0 (1.0	), 142.0)	20.0 (1.0	0, 129.0)	21.0 (2.	0, 131.0)	20.0 (1.0	0, 131.0)
Missing, No. (%)	3140	9.0	672	7.9	783	7.2	1455	7.5
Lesion result, No. (%)								
Successful	33515	96.1	8245	96.8	10424	96.4	18669	96.6
Unsuccessful	1094	3.1	256	3.0	344	3.2	600	3.1
Not available	37	0.1	16	0.2	44	0.4	60	0.3
Missing	227	0.7	0	0	0	0	0	0
*Stent length, mm								
N	304	145	76	99	98	379	17:	578
Mean (SD)	29.4 (	(16.7)	29.8	(17.0)	30.5	(16.9)	30.2	(16.9)
Median (min, max)	24.0 (8.0	), 166.0)	24.0 (8.0	0, 140.0)	26.0 (8.	0, 167.0)	25.0 (8.0	0, 167.0)
Not available, No. (%)	4428	12.7	818	9.6	933	8.6	1751	9.1
**Stent diameter, mm								
N	303	329	76	95	98	867	17:	562
Mean (SD)	3.0 (	(0.4)	2.9	(0.4)	2.9	(0.4)	2.9	(0.4)
Median (min, max)	3.0 (2.	0, 7.0)	3.0 (2.	0, 5.8)	3.0 (2.	.0, 5.0)	3.0 (2.	0, 5.8)
Not available, No. (%)	4544	13.0	822	9.7	945	8.7	1767	9.1

Table 4.7 Lesion characteristics for patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014

	2007 - Total no. = 34	- 2012 of lesions  873	20 Total no. = 8	13 of lesions 517	20 Total no. = 10	14 of lesions )812	2013 - Total no. = 19	- 2014 of lesions 9329
	No.	%	No.	%	No.	%	No.	%
Maximum balloon size used, mm								
Ν	316	563	77	29	100	)29	177	758
Mean (SD)	3.1 (	(0.6)	3.0 (	(0.6)	3.1 (	(0.6)	3.0 (	(0.6)
Median (min, max)	3.0 (1.	0, 6.0)	3.0 (1.	0, 6.0)	3.0 (1.	0, 5.2)	3.0 (1.	0, 6.0)
Missing, No. (%)	3210	9.2	788	9.3	783	7.2	1571	8.1
Maximum stent/balloon deploy pressure, atm								
N	315	552	76	62	99	09	175	571
Mean (SD)	15.7	(4.0)	15.8	(4.2)	15.7	(4.5)	15.7	(4.4)
Median (min, max)	16.0 (1.	0, 30.0)	16.0 (1.	0, 40.0)	16.0 (1.	0, 40.0)	16.0 (1.	0, 40.0)
Missing, No. (%)	3321	9.5	855	10.0	903	8.4	1758	9.1
Direct stenting, No. (%)								
Yes	4147	11.9	650	7.6	752	7.0	1402	7.3
No	29149	83.6	7453	87.5	9932	91.9	17385	89.9
Not applicable	1375	3.9	414	4.9	128	1.2	542	2.8
Missing	202	0.6	0	0	0	0	0	0
Other adjunctive procedure, No. (%)								
Yes			171	2.0	233	2.2	404	2.1
IABP								
Ventilator			42	24.6	90	38.6	132	32.7
Temporary cardiac pacing wire			36	21.1	43	18.5	79	19.6
No			6135	72.0	10367	95.8	16502	85.3
Not applicable			272	3.2	30	0.3	302	1.6
Missing			1939	22.8	182	1.7	2121	11.0

\*Summation of stent length was used for lesions which were treated with more than one stent \*\*Average of stent diameter was used for lesions which were treated with more than one stent

<sup>#</sup> Intracoronary devices	– 2007 Total no. of lea	- 2012 sions = 34873	20 Total no. of le	13 esions = 8517	20 Total no. of le	14 sions = 10812	2013 - Total no. of le	- 2014 esions = 19329
	No.	%	No.	%	No.	%	No.	%
Aspiration/aspiration catheter	523	1.5	478	5.6	628	5.8	1106	5.7
Balloon only/POBA	2490	7.1	884	10.4	1608	14.9	2492	12.9
Drug-eluting balloon	1674	4.8	528	6.2	929	8.6	1457	7.5
Drug-eluting stent	20370	58.4	5677	66.7	7321	67.7	12998	67.2
Cutting balloon/scoring balloon	645	1.8	120	1.4	159	1.5	279	1.4
Coil			15	0.2	4	0	19	0.1
OCT			51	0.6	110	1.0	161	0.8
Mother and child			8	0.1	15	0.1	23	0.1
Micro catheter			348	4.1	536	5.0	884	4.6
Angiojet			7	0.1	19	0.2	26	0.1
IVUS	1248	3.6	258	3.0	258	2.4	516	2.7
Flowire/FFR	78	0.2	100	1.2	132	1.2	232	1.2
Rotablator	309	0.9	81	1.0	101	0.9	182	0.9
Bare metal stent	9716	27.9	1420	16.7	1034	9.6	2454	12.7
Embolic protection	140	0.4	22	0.3	9	0.1	31	0.2
Filter			5	83.3	5	100	10	90.9
Balloon/distal			0	0	0	0	0	0
Proximal			1	16.7	0	0	1	9.1
Missing			16		4		20	
Others	1795	5.1	1260	14.8	482	4.5	1742	9.0

Table 4.8 Types of devices used during percutaneous coronary intervention, NCVD-PCI Registry, 2007 – 2014

#Patients were allowed to be in more than one type of category

*Types of post-procedure complications	2007 – 2012 Total no. of lesions = 34873		2013 Total no. of lesions = 8517		2014 Total no. of lesions = 10812		2013 – 2014 Total no. of lesions = 19329	
	No.	%	No.	%	No.	%	No.	%
Dissection	1102	3.2	155	1.8	169	1.6	324	1.7
Flow limiting			22	16.3	20	12.8	42	14.4
Non-flow limiting			113	83.7	136	87.2	249	85.6
Not available			9		13		22	
Missing			11		0		11	
No reflow	368	1.1	64	0.8	56	0.5	120	0.6
Transient	265	78.2	43	69.4	35	70.0	78	69.6
Persistent	74	21.8	19	30.6	15	30.0	34	30.4
Not available	20		2		6		8	
Missing	9		0		0		0	
Acute closure	95	0.3						
Perforation	94	0.3	23	0.3	26	0.2	49	0.3

Table 4.9 Types of post-procedure complications, NCVD-PCI Registry, 2007 – 2014

\*Results are only showed for patients who were reported to have the complications

### In-stent restenosis (ISR)

A total of 804 ISR lesions were treated in 2013 to 2014. [Table 4.2] Of these, 24.1% were presented with acute coronary syndrome (ACS). [Table 4.10]

Drug-eluting balloon was the most frequently used treatment (57.6%), followed by drug-eluting stents (31%), POBA (23.6%), and cutting/scoring balloon (12.6%). [Table 4.11 and Table 4.12] The IVUS was used in 10.4% when treating ISR. The use of other types of treatment modalities were infrequent. There was a gradual decrease in DES used in ISR. [Table 4.11]

The complication rate during the treatment of ISR was very low. Dissection occured in 1.4% and no-reflow in 0.1%. [Table 4.13]

able 4.10 Acute coronary syndrome status of in-stent restenosis percutaneous coronary intervention	ι,
CVD-PCI Registry, 2007 – 2014	

Types of prior stents used in ISR	2007 – 2012 Total no. of lesions = 1618		2013 Total no. of lesions = 366		2014 Total no. of lesions = 438		2013 - 2014 Total no. of lesions = 804	
	No.	%	No.	%	No.	%	No.	%
Acute coronary syndrome, No. (%)								
Yes	541	33.5	85	23.2	109	24.9	194	24.1
No	1070	66.1	281	76.8	329	75.1	610	75.9
Missing	7	0.4	0	0	0	0	0	0
ACS type, No. (%)								
STEMI	203	37.6	23	27.7	36	33.4	59	30.9
NSTEMI	236	43.7	22	26.5	36	33.3	58	30.4
UA	101	18.7	38	45.8	36	33.3	74	38.7
Not available	1		2		1		3	
Missing	0		0		0		0	
STEMI, No. (%)								
Anterior			16	76.2	23	67.6	39	70.9
Non-anterior			5	23.8	11	32.4	16	29.1
Not available			2		2		4	
Missing			0		0		0	
Total	1618	100.0	366	100.0	438	100.0	804	100.0

<b>Table 4.11</b>	Types of s	stents used in	the in-stent	restenosis.	NCVD-PC	I Registry.	2007 -	- 2014

Types of stents used in the ISR	2007 – 2012 Total no. of stents used = 1859		2013 Total no. of stents used = 360		2014 Total no. of stents used = 507		2013 – 2014 Total no. of stents used = 867	
	No.	%	No.	%	No.	%	No.	%
Drug-eluting stent	804	43.2	142	39.4	159	31.4	301	34.7
Bare metal stent	128	6.9	12	3.4	10	2	22	2.5
Bio-absorbable stent	1	0.1	0	0	1	0.2	1	0.1
Antibody-coated stent	5	0.3	0	0	0	0	0	0
Others	84	4.5	1	0.3	3	0.6	4	0.5
Drug-eluting balloon	0	0	197	54.7	314	61.9	511	59.0
Bifurcated stent	0	0	0	0	1	0.2	1	0.1
Covered stent	2	0.1	0	0	0	0	0	0
Combo stent	0	0	3	0.8	8	1.5	11	1.3
Missing	835	44.9	5	1.4	11	2.2	16	1.8
Total	1859	100.0	360	100.0	507	100.0	867	100.0

<sup>#</sup> Intracoronary devices used in ISR	2007 – 2012 Total no. of lesions = 1618		2013 Total no. of lesions = 366		20 Total lesions	14 no. of : = 438	2013 – 2014 Total no. of lesions = 804	
	No.	%	No.	%	No.	%	No.	%
Aspiration/aspiration catheter	17	1.1	10	2.7	14	3.2	24	3.0
Balloon only/POBA	382	23.6	92	25.1	98	22.4	190	23.6
Drug-eluting balloon	483	29.9	195	53.3	268	61.2	463	57.6
Drug-eluting stent	613	37.9	120	32.8	129	29.5	249	31.0
Cutting balloon/scoring balloon	290	17.9	46	12.6	55	12.6	101	12.6
Coil			1	0.3	0	0	1	0.1
OCT			10	2.7	10	2.3	20	2.5
Mother and child			0	0	0	0	0	0
Micro catheter			21	5.7	33	7.5	54	6.7
Angiojet			0	0	0	0	0	0
IVUS	315	19.5	45	12.3	39	8.9	84	10.4
Flowire/FFR	4	0.2	3	0.8	9	2.1	12	1.5
Rotablator	10	0.6	3	0.8	0	0	3	0.4
Bare metal stent	107	6.6	10	2.7	10	2.3	20	2.5
Embolic protection	7	0.4	0	0	1	0.2	1	0.1
Filter			0	0	0	0	0	0
Balloon/distal			0	0	0	0	0	0
Proximal			0	0	0	0	0	0
Missing			0		1		1	
Others	68	4.2	39	10.7	17	3.9	56	7.0

Table 4.12 Types of devices used in the in-stent restenosis, NCVD-PCI Registry, 2007 – 2014

<sup>#</sup>Patients were allowed to be in more than one type of category

# Table 4.13 Types of complications in post in-stent restenosis, NCVD-PCI Registry, 2007 – 2014

*Types of complications in ISR	2007 – 2012 Total no. of lesions = 1618		2013 Total no. of lesions = 366		20 Total no. = 4	14 of lesions I38	2013 – 2014 Total no. of lesions = 804	
	No.	%	No.	%	No.	%	No.	%
Dissection	36	2.2	1	0.3	10	2.3	11	1.4
Flow limiting			0	0	1	10.0	1	9.1
Non-flow limiting			1	100	9	90.0	10	90.9
Not available			0		0		0	
Missing			0		0		0	
No reflow	11	0.7	0	0	1	0.2	1	0.1
Transient	10	90.9	0	0	0	0	0	0
Persistent	1	9.1	0	0	0	0	0	0
Not available	0		0		1		1	
Missing	0		0		0		0	
Acute closure	2	0.1						
Perforation	9	0.6	0	0	0	0	0	0

\*Results are only showed for patients with the complications

### PCI of left main stem (LMS)

From 2013 to 2014, a total of 541 LMS interventions were performed. [Table 4.1] Most were de novo lesions and 5.2% were in-stent restenosis. [Table 4.14] From 2007 - 2012, the number of LMS PCI performed were 749, however in this 2013 - 2014 cohort, there was a significant increase in the number of LMS PCIs. [Table 4.1.1]

Majority of LMS interventions were performed on unprotected LMS, and this was almost similar to the 2007 – 2012 cohort; only 12.8% had history of previous coronary artery bypass (CABG) surgery. [Table 4.15]

For LMS PCI, the use of femoral artery route was more common (70.4%) than non LMS intervention. [Table 4.15]

Majority of LMS interventions were elective cases (77.3%), followed by NSTEMI/UA (11.8%) and STEMI (10.9%). [Table 4.15] Among the STEMI group, 46% had primary PCI, followed by 41.1% rescue PCI and the rest were delayed PCI. There was an increasing trend of LMS PCI in the ACS setting compared to the 2007 – 2012 cohort. [Table 4.15]

In 2007 – 2012, the mean pre-procedure stenosis was 80.9% with TIMI III flow in 57.8%; the mean lesion length was 27.1 mm. The present cohort (2013 – 2014) shows that we were treating more complex lesions (severe stenosis and longer lesions) with mean pre-procedure stenosis of 83% (SD 13.2) with TIMI III flow in only 39.9% cases; the mean lesion length was 28.7 mm. Post procedure results were excellent showing 91.6% achieving TIMI III flow and less than 1% withTIMI 0 to TIMI I flow. [Table 4.15 and Table 4.16]

Majority of the lesions were treated with DES (84.3%), and interestingly were followed by DEB (3.8%) and BMS (3.4%); the rest were treated with various other stents (Combo, Bio-absorbable etc). [Table 4.17] The mean stent length and diameter were 34.0 mm (SD 20.5 mm) and 3.3 mm (SD 0.4 mm), respectively. Conventional pre-dilatation followed by stenting was the preferred choice, however, direct stenting was also observed in 6.7%. [Table 4.15]

Despite dealing with more complex lesions compared to the past, the use of IVUS had become increasingly uncommon (27.1%, 2007 - 2012 vs. 20%, 2013 - 2014). [Table 4.18] However, the success rate was 98.5%, with very few complications like dissection (3%). Most of the dissections were non-flow limiting, and no reflow was observed in 0.9%. [Table 4.15 and Table 4.19]

About 84.5% of patients received DAPT for 12 months. The use of DAPT for more than 12 months was observed in only 4.8% vs. 25.2% (2007 - 2012); this significant reduction could be due to newer generation stents with more promising evidence. [Table 4.20]

Types of lesion in left main stem procedure	2007 – 2012 Total no. of lesions = 749		2013 Total no. of lesions = 223		2014 Total no. of lesions = 318		2013 – 2014 Total no. of lesions = 541	
-	No.	%	No.	%	No.	%	No.	%
De novo	693	92.5	208	93.4	298	93.7	506	93.5
Restenosis (no prior stent)	3	0.4	1	0.4	0	0	1	0.2
Stent thrombosis	2	0.3	1	0.4	4	1.3	5	0.9
In-stent restenosis	48	6.4	13	5.8	15	4.7	28	5.2
Previous DES	31	75.6	6	85.7	7	87.5	13	86.7
Previous BMS	10	24.4	1	14.3	1	12.5	2	13.3
Previous others	0	0	0	0	0	0	0	0
Not available	6		6		7		13	
Missing	1		0		0		0	
Not available	1	0.1	0	0	1	0.3	1	0.2
Missing	2	0.3	0	0	0	0	0	0
Total	749	100.0	223	100.0	318	100.0	541	100.0

Table 4.14 Types of lesions in left main stem procedure, NCVD-PCI Registry, 2007 – 2014

# Table 4.15 Clinical presentation of left main stem, NCVD-PCI Registry, 2007 – 2014

Clinical presentation in left main stem procedure	2007 – 2012 Total no. of lesions = 749		2013 Total no. of lesions = 223		2014 Total no. of lesions = 318		2013 - 2014 Total no. of lesions = 541	
_	No.	%	No.	%	No.	%	No.	%
Acute coronary syndrome, No. (%)								
Total	241	100	59	100	98	100	157	100
STEMI	116	48.1	24	40.7	48	49.0	72	45.9
NSTEMI	95	39.4	19	32.2	27	27.6	46	29.3
UA	28	11.6	16	27.1	22	22.4	38	24.2
Not available	2	0.9	0	0	1	1.0	1	0.6
Previous PCI, No. (%)								
Yes	210	28.0	74	33.2	111	34.9	185	34.2
No	539	72.0	149	66.8	207	65.1	356	65.8
Missing	0	0	0	0	0	0	0	0
Previous CABG, No. (%)								
Yes	94	12.6	36	16.1	33	10.4	69	12.8
No	655	87.4	187	83.9	285	89.6	472	87.2
Missing	0	0	0	0	0	0	0	0

Clinical presentation in left main stem procedure	2007 - 2012 Total no. of lesions = 749		2013 Total no. of lesions = 223		201 Total no. ( = 3	14 of lesions 18	2013 – 2014 Total no. of lesions = 541	
	No.	%	No.	%	No.	%	No.	%
PCI status, No. (%)								
Elective	666	88.9	179	80.2	239	75.1	418	77.3
NSTEMI/UA	40	5.4	24	10.8	40	12.6	64	11.8
AMI/STEMI	42	5.6	20	9.0	39	12.3	59	10.9
Not available	1	0.1	0	0	0	0	0	0
Missing	0	0	0	0	0	0	0	0
Elective, No. (%)								
Staged PCI			77	43.3	121	50.8	198	47.6
Ad hoc			101	56.7	117	49.2	218	52.4
Not available			1		1		2	
Missing			0		0		0	
NSTEMI/UA, No. (%)								
Urgent			4	16.7	14	35.9	18	28.6
Non-urgent			20	83.3	25	64.1	45	71.4
Not available			0		1		1	
Missing			0		0		0	
STEMI, No. (%)								
Rescue			7	41.2	16	41.0	23	41.1
Primary			7	41.2	19	48.7	26	46.3
Facilitated			0	0	0	0	0	0
Delayed PCI			0	0	0	0	0	0
Delayed routine PCI			1	5.9	2	5.1	3	5.4
Delayed selective PCI			2	11.7	1	2.6	3	5.4
Pharmacoinvasive			0	0	1	2.6	1	1.8
Not available			3		0		3	
<sup>#</sup> Percutaneous entry, No. (%)								
Brachial	3	0.4	1	0.4	0	0	1	0.2
Radial	184	24.6	79	35.4	107	33.6	186	34.4
Femoral	539	72.0	149	66.8	232	73.0	381	70.4
Pre-procedure % of stenosis								
N	6	93	202	2	30	2	5	04
Mean (SD)	80.9	(14.6)	81.9 (1	(4.4)	83.7 (	12.3)	83.0	(13.2)
Median (min, max)	80.0 (0.	0, 100.0)	80.0 (0.0,	100.0)	85.0 (30.0	), 100.0)	85.0 (0.	0, 100.0)
Missing, No. (%)	56	7.5	21	9.4	16	5.0	37	6.8

Clinical presentation in left main stem procedure	2007 Total no. =	– 2012 . of lesions 749	201 Total r lesions	3 10. of = 223	20) Total no. = 3	2014 Total no. of lesions = 318		2013 – 2014 Total no. of lesions = 541	
	No.	%	No.	%	No.	%	No.	%	
Pre-procedure TIMI flow, No. (%)									
TIMI-0	67	8.9	15	6.7	24	7.5	39	7.2	
TIMI-1	44	5.9	25	11.2	16	5.0	41	7.6	
TIMI-2	149	19.9	87	39.1	99	31.1	186	34.4	
TIMI-3	433	57.8	73	32.7	143	45.1	216	39.9	
Not available	4	0.5	10	4.5	5	1.6	15	2.8	
Missing	52	7.0	13	5.8	31	9.7	44	8.1	
Post-procedure % of stenosis									
N	6	60	205	5	31	1	5	16	
Mean (SD)	2.0 (	(10.6)	3.2 (1-	4.8)	2.2 (1	2.4)	2.6 (	(13.4)	
Median (min, max)	0.0 (0.0	), 100.0)	0.0 (0.0,	100.0)	0.0 (0.0,	100.0)	0.0 (0.0	), 100.0)	
Missing, No. (%)	89	11.9	18	8.1	7	2.2	25	4.6	
Post-procedure TIMI flow, No. (%)									
TIMI-0	7	0.9	1	0.4	1	0.3	2	0.4	
TIMI-1	4	0.5	1	0.4	1	0.3	2	0.4	
TIMI-2	7	0.9	4	1.8	5	1.6	9	1.7	
TIMI-3	672	89.7	206	92.5	290	91.2	496	91.6	
Not available	5	0.7	4	1.8	0	0	4	0.7	
Missing	54	7.3	7	3.1	21	6.6	28	5.2	
Estimated lesion length, mm									
N	6	73	210	)	30	2	5	12	
Mean (SD)	27.1	(17.5)	26.9 (2	20.1)	29.9 (	19.6)	28.7	(19.8)	
Median (min, max)	20.0 (4	.0, 90.0)	20.0 (3.0	, 98.0)	24.0 (4.0	, 100.0)	21.0 (3.	0, 100.0)	
Missing, No. (%)	76	10.1	13	5.8	16	5.0	29	5.4	
Lesion result, No. (%)									
Successful	737	98.4	220	98.7	313	98.4	533	98.5	
Unsuccessful	11	1.5	3	1.3	5	1.6	8	1.5	
Not available	0	0	0	0	0	0	0	0	
Missing	1	0.1	0	0	0	0	0	0	
*Stent length, mm									
N	6	92	209	Ð	30	7	5	16	
Mean (SD)	33.6	(20.1)	32.6 (2	21.0)	35.0 (	20.2)	34.0	(20.5)	
Median (min, max)	28.0 (8.	0, 108.0)	24.0 (8.0,	107.0)	29.0 (8.0	, 102.0)	28.0 (8.	0, 107.0)	
Not available, No. (%)	76	10.1	13	5.8	16	5.0	29	5.4	

Clinical presentation in left main stem procedure	2007 – 2012 Total no. of lesions = 749		2013 Total no. of lesions = 223		2014 Total no. of lesions = 318		2013 – 2014 Total no. of lesions = 541	
	No.	%	No.	%	No.	%	No.	%
**Stent diameter, mm								
Ν	6	93	210	)	30	17	5	17
Mean (SD)	3.3	(0.5)	3.3 (0	).4)	3.3 (	0.4)	3.3	(0.4)
Median (min, max)	3.4 (2	3.4 (2.3 ,4.5)		3.3 (2.4, 4.5)		3, 4.5)	3.3 (2	.3, 4.5)
Not available, No. (%)	56	7.5	13	5.8	11	3.5	24	4.4
Direct stenting, No. (%)								
Yes	60	8.0	17	7.6	19	6.0	36	6.7
No	674	90.0	195	87.5	297	93.4	492	90.9
Not applicable	15	2.0	11	4.9	2	0.6	13	2.4
Missing	0	0	0	0	0	0	0	0

\*Average of stent diameter was used for lesions which were treated with more than one stent

Table 4.16 TIMI flow prior to intervention in left main stem procedure, NCVD-PCI Registry, 2007 – 201	4
---	---

TIMI flow prior to intervention in left	2007 – 2012 Total no. of lesions = 749		2013 Total no. of lesions = 223		2014 Total no. of lesions = 318		2013 – 2014 Total no. of lesions = 541	
main stem procedure	No.	%	No.	%	No.	%	No.	%
TIMI-0	67	8.9	15	6.7	24	7.5	39	7.2
TIMI-1	44	5.9	25	11.2	16	5.0	41	7.6
TIMI-2	149	19.9	87	39.1	99	31.1	186	34.4
TIMI-3	433	57.8	73	32.7	143	45.1	216	39.9
Not available	4	0.5	10	4.5	5	1.6	15	2.8
Missing	52	7.0	13	5.8	31	9.7	44	8.1
Total	749	100.0	223	100.0	318	100.0	541	100.0

Types of stent used in left main stem procedure	2007 – 2012 Total no. of stents used = 1095		2013 Total no. of stents used = 300		2014 Total no. of stents used = 459		2013 – 2014 Total no. of stents used = 759	
procedure	No.	%	No.	%	No.	%	No.	%
Drug-eluting stent	882	80.5	259	86.3	380	82.9	639	84.3
Bare metal stent	93	8.5	8	2.7	18	3.9	26	3.4
Bio-absorbable stent	0	0	0	0	1	0.2	1	0.1
Antibody-coated	15	1.4	0	0	1	0.2	1	0.1
Others	46	4.2	2	0.7	2	0.4	4	0.5
Drug-eluting balloon	0	0	10	3.3	19	4.1	29	3.8
Bifurcated stent	0	0	2	0.6	0	0	2	0.3
Covered stent	4	0.4	0	0	1	0.2	1	0.1
Combo stent	0	0	14	4.7	31	6.8	45	6.0
Missing	55	5.0	5	1.7	6	1.3	11	1.4
Total	1095	100.0	300	100.0	459	100.0	759	100.0

Table 4.17 Types of stents used in left main stem procedure, NCVD-PCI Registry, 2007 – 2014

\*Stents which were not listed in the NCVD-PCI Stent List

### Table 4.18 Types of devices used in left main stem procedure, NCVD-PCI Registry, 2007 – 2014

<sup>#</sup> Intracoronary devices used in left main stem procedure	2007 – 2012 Total no. of lesions = 749		2013 Total no. of lesions = 223		20 Total no. = 3	14 of lesions 318	2013 - 2014 Total no. of lesions = 541	
procedure	No.	%	No.	%	No.	%	No.	%
Aspiration/aspiration catheter	5	0.7	4	1.8	17	5.3	21	3.9
Balloon only/POBA	29	3.9	17	7.6	27	8.5	44	8.1
Drug-eluting balloon	49	6.5	13	5.8	16	5.0	29	5.4
Drug-eluting stent	613	81.8	187	83.9	257	80.8	444	82.1
Cutting balloon/scoring balloon	23	3.1	5	2.2	5	1.6	10	1.8
Coil			0	0	1	0.3	1	0.2
OCT			9	4.0	14	4.4	23	4.3
Mother and child			2	0.9	0	0	2	0.4
Micro catheter			15	6.7	21	6.6	36	6.7
Angiojet			0	0	0	0	0	0
IVUS	203	27.1	53	23.8	55	17.3	108	20.0
Flowire/FFR	1	0.1	5	2.2	2	0.6	7	1.3
Rotablator	36	4.8	14	6.3	16	5.0	30	5.5
Bare metal stent	78	10.4	8	3.6	14	4.4	22	4.1
Embolic protection	3	0.4	1	0.4	0	0	1	0.2
Others	30	4.0	16	7.2	16	5.0	32	5.9

#Patients were allowed to be in more than one type of category

Types of complications	2007 - 2012 Total no. of lesions = 749		2013 Total no. of lesions = 223		2014 Total no. of lesions = 318		2013 – 2014 Total no. of lesions = 541	
	No.	%	No.	%	No.	%	No.	%
<sup>#</sup> Types of complications								
Dissection	56	7.5	9	4.0	7	2.2	16	3.0
Flow limiting			2	28.6	2	28.6	4	28.6
Non-flow limiting			5	71.4	5	71.4	10	71.4
Not available			1		0		1	
Missing			1		0		1	
No reflow	11	1.5	2	0.9	3	0.9	5	0.9
Transient	8	72.7	1	50.0	0	0	1	20.0
Persistent	3	27.3	1	50.0	3	100	4	80.0
Not available	0		0		0		0	
Missing	0		0		0		0	
Acute closure	2	0.3						
Perforation	6	0.8	1	0.4	0	0	1	0.2

Table 4.19 Types of complications in post left main stem, NCVD-PCI Registry, 2007 - 2014

#Patients were allowed to be in more than one type of category

Table 4.20 Planned duration of dual antiplatelet therapy in left main stem procedure, N	NCVD-PCI
Registry, 2007 – 2014	

Planned duration of dual antiplatelet therapy in left main stem procedure	2007 – 2012 Total no. of lesions = 749		2013 Total no. of lesions = 223		2014 Total no. of lesions = 318		2013 – 2014 Total no. of lesions = 541	
(months)	No.	%	No.	%	No.	%	No.	%
1	29	3.9	4	1.9	13	4.2	17	3.1
3	23	3.1	3	1.3	3	0.9	6	1.1
6	23	3.1	3	1.3	9	2.8	12	2.2
12	442	59.0	179	80.3	278	87.4	457	84.5
> 12	189	25.2	25	11.2	1	0.3	26	4.8
Not available	31	4.1	8	3.6	13	4.1	21	3.9
Missing	12	1.6	1	0.4	1	0.3	2	0.4
Total	749	100.0	223	100.0	318	100.0	541	100.0

### PCI to the grafts

From 2013 to 2014, a total of 166 bypass graft PCIs were performed; 89.7% were on SVG, 9.1% on LIMA and the rest were on radial grafts. [Table 4.22] Most graft PCIs were de novo lesions (89.2%), but there was a slightly higher incidence of in-stent restenosis (10.8% in 2013 – 2014 vs. 9.0% in 2007 – 2012). [Table 4.21]

The mean lesion length was 20.1 mm with a TIMI III flow in only 25.9% of lesions. [Table 4.22] Most of the lesions were stented with a DES (63.9%), followed by DEB (15.7%), BMS (12.0%), and POBA only (6%); embolic protection device was used in only 8.4%. [Table 4.22 and Table 4.23]

When compared to the 2007 - 2012 cohort, the use of DEB in graft PCI had significantly increased in 2013 - 2014 (9.8% vs. 15.7%); however, the use of embolic protection device reduced (20.0% vs. 8.4%). [Table 4.22 and Table 4.23] Successful PCI with TIMI III flow was achieved in 92.2%, with a mean stent length and diameter of 24.5 mm (SD 13.3 mm) and 3.0 mm (SD 0.6 mm), respectively. [Table 4.22] No major complications were reported. [Table 4.24]

Long term DAPT was still the preferred choice, with 83.1% receiving DAPT for 12 months. [Table 4.25]

Lesion type in graft PCI	2007 – 2012 Total no. of lesions = 481		2013 Total no. of lesions = 75		2014 Total no. of lesions = 91		2013 – 2014 Total no. of lesions = 166	
	No.	%	No.	%	No.	%	No.	%
De novo	428	89.0	66	88.0	82	90.1	148	89.2
Restenosis (no prior stent)	4	0.8	0	0	0	0	0	0
Stent thrombosis	0	0	0	0	0	0	0	0
In-stent restenosis	43	9.0	9	12.0	9	9.9	18	10.8
Not available	3	0.6	0	0	0	0	0	0
Missing	3	0.6	0	0	0	0	0	0
Total	481	100.0	75	100.0	91	100.0	166	100.0

Table 4.21 Lesion types in graft PCI, NCVD-PCI Registry, 2007 – 2014

	2007 - Total no. = 4	- 2012 of lesions I81	20 Total no. = '	13 of lesions 75	20 Total no. =	14 of lesions 91	2013 - Total no. = 1	- 2014 of lesions 66
	No.	%	No.	%	No.	%	No.	%
Graft, No. (%)								
18 LIMA	51	10.6	5	6.7	10	11.0	15	9.1
19 RIMA	3	0.6	0	0	0	0	0	0
20 SVG1	343	71.3	63	84.1	72	79.1	135	81.3
21 SVG2	61	12.7	4	5.3	7	7.7	11	6.6
22 SVG3	19	4.0	1	1.3	2	2.2	3	1.8
23 RAD1	3	0.6	1	1.3	0	0	1	0.6
24 RAD2	0	0	0	0	0	0	0	0
25 RAD3	1	0.2	1	1.3	0	0	1	0.6
Pre-procedure stenosis %								
N	44	45	6	7	8	3	1.	50
Mean (SD)	84.0 (	(12.4)	87.4 (	(11.3)	85.2	(11.0)	86.2	(11.1)
Median (min, max)	90.0 (20.	0, 100.0)	90.0 (50.	0, 100.0)	85.0 (60.	0, 100.0)	90.0 (50.	0, 100.0)
Missing, No. (%)	36	7.5	8	10.7	8	8.8	16	9.6
Post-procedure stenosis %								
Ν	41	18	6	8	8	6	1:	54
Mean (SD)	2.7 (	13.0)	2.1 (	12.3)	5.3 (20.5)		3.9 (	17.4)
Median (min, max)	0.0 (0.0	, 100.0)	0.0 (0.0	), 99.0)	0.0 (0.0	, 100.0)	0.0 (0.0	, 100.0)
Missing, No. (%)	63	13.1	7	9.3	5	5.5	12	7.2
Estimated lesion length, mm								
N	43	36	7	1	8	3	1:	54
Mean (SD)	19.8 (	(12.0)	19.6 (	(14.7)	20.5	(10.9)	20.1	(12.7)
Median (min, max)	16.0 (5.	0, 90.0)	14.0 (5.	0, 90.0)	17.0 (5.	0, 72.0)	16.0 (5.	0, 90.0)
Missing, No. (%)	45	9.4	4	5.3	8	8.8	12	7.2
Lesion result, No. (%)								
Successful	469	97.5	74	98.7	87	95.6	161	97.0
Unsuccessful	10	2.1	1	1.3	4	4.4	5	3.0
Not available	0	0	0	0	0	0	0	0
Missing	2	0.4	0	0	0	0	0	0

# Table 4.22 Clinical presentation of graft PCI, NCVD-PCI Registry, 2007 – 2014

	- 2007 Total no. = 4	- 2012 of lesions  81	20 Total no. =	13 of lesions 75	20 Total no. =	14 of lesions 91	2013 - Total no. = 1	- 2014 of lesions 66
	No.	%	No.	%	No.	%	No.	%
*Stent length, mm								
Ν	40	)8	7	0	8	5	15	55
Mean (SD)	25.5 (	(15.3)	23.8	(14.9)	25.2	(11.9)	24.5 (	(13.3)
Median (min, max)	18.0 (8.0	), 127.0)	18.0 (9.	0, 98.0)	22.0 (10	.0, 80.0)	20.0 (9.	0, 98.0)
Not available, No. (%)	73	15.2	5	6.7	6	6.6	11	6.6
**Stent diameter, mm								
Ν	40	)6	7	0	8	5	15	55
Mean (SD)	3.1 (	(0.6)	3.0	(0.6)	3.1	(0.6)	3.0 (	(0.6)
Median (min, max)	3.0 (2.	3, 7.0)	3.0 (2.	3, 4.5)	3.0 (2.	0, 4.5)	3.0 (2.	0, 4.5)
Not available, No. (%)	75	15.6	5	6.7	6	6.6	11	6.6
*Other intracoronary								
Aspiration/aspiration	17	3.5	6	8.0	3	3.3	9	5.4
Balloon only/POBA	32	67	6	8.0	4	44	10	6.0
Drug-eluting balloon	47	9.8	8	10.7	18	19.8	26	15.7
Drug-eluting stent	278	57.8	48	64.0	58	63.7	106	63.9
Cutting balloon/scoring balloon	6	1.2	1	1.3	1	1.1	2	1.2
Coil			0	0	0	0	0	0
OCT			1	1.3	0	0	1	0.6
Mother and child			0	0	1	1.1	1	0.6
Micro catheter			2	2.7	2	2.2	4	2.4
Angiojet			0	0	0	0	0	0
IVUS	9	1.9	2	2.7	0	0	2	1.2
Flowire/FFR	2	0.4	0	0	0	0	0	0
Rotablator	0	0	1	1.3	0	0	1	0.6
Bare metal stent	119	24.7	15	20.0	5	5.5	20	12.0
Embolic protection	96	20.0	8	10.7	6	6.6	14	8.4
Others	25	5.2	4	5.3	0	0	4	2.4
Embolic protection status, No. (%)								
Filter	91	97.8	1	100	5	100	6	100
Balloon/distal	2	2.2	0	0	0	0	0	0
Proximal	0	0	0	0	0	0	0	0
Not available	0		7		1		8	
Missing	3		0		0		0	

	2007 – 2012 Total no. of lesions = 481		2013 Total no. of lesions = 75		2014 Total no. of lesions = 91		2013 – 2014 Total no. of lesions = 166	
	No.	%	No.	%	No.	%	No.	%
Direct stenting, No. (%)								
Yes	78	16.2	10	13.3	9	9.9	19	11.4
No	392	81.5	64	85.4	82	90.1	146	88.0
Not applicable	10	2.1	1	1.3	0	0	1	0.6
Missing	1	0.2	0	0	0	0	0	0

<sup>#</sup>Patients were allowed to be in more than one type of category \*Summation of stent length was used for lesions which were treated with more than one stent \*\*Average of stent diameter was used for lesions which were treated with more than one stent

Types of stent used in graft PCI	2007 – 2012 Total no. of stents used = 579		2013 Total no. of stents used = 450		2014 Total no. of stents used = 546		2013 – 2014 Total no. of stents used = 996	
	No.	%	No.	%	No.	%	No.	%
Drug-eluting stent (DES)	348	60.1	57	12.7	69	12.6	126	12.7
Bare metal stent (BMS)	143	24.7	18	4.0	6	1.1	24	2.4
Bio-absorbable stent	0	0	1	0.2	0	0	1	0.1
Antibody-coated stent	10	1.7	0	0	0	0	0	0
Others	6	1.0	0	0	0	0	0	0
Drug-eluting balloon	0	0	8	1.8	18	3.3	26	2.6
Bifurcated stent	0	0	0	0	0	0	0	0
Covered stent	0	0	0	0	2	0.4	2	0.2
Combo stent	0	0	4	0.9	7	1.3	11	1.1
Missing	72	12.5	362	80.4	444	81.3	806	80.9
Total	579	100.0	450	100.0	546	100.0	996	100.0

Table 4.23 Types of stents used in graft PCI, NCVD-PCI Registry, 2007 – 2014

\*Stents which were not listed in the NCVD-PCI Stent List

Types of complications	2007 – 2012 Total no. of lesions = 481		2013 Total no. of lesions = 75		2014 Total no. of lesions = 91		2013 – 2014 Total no. of lesions = 166	
	No.	%	No.	%	No.	%	No.	%
Dissection	8	1.7	1	1.3	0	0	1	0.6
Flow limiting			0	0	0	0	0	0
Non-flow limiting			1	100	0	0	1	100
Not available			0		0		0	
Missing			0		0		0	
No reflow	4	0.8	0		0		0	
Transient	3	75.0						
Persistent	1	25.0						
Not available	0							
Missing	0							
Acute closure	1	0.2						
Perforation	1	0.2	0		0		0	

Table 4.24 Types of complications in graft PCI, NCVD-PCI Registry, 2007 – 2014

#Patients were allowed to be in more than one type of category

Table 4.25 Planned duration of dual a	ntiplatelet therapy in gra	aft PCI. NCVD-PCI Registry.	2007 - 2014

Planned duration of dual antiplatelet therapy in graft PCI	2007 – 2012 Total no. of lesions = 481		2013 Total no. of lesions = 75		2014 Total no. of lesions = 91		2013 – 2014 Total no. of lesions = 166	
(months)	No.	%	No.	%	No.	%	No.	%
1	52	10.8	6	8.1	1	1.1	7	4.2
3	24	5.0	4	5.3	4	4.4	8	4.8
6	36	7.5	2	2.7	3	3.3	5	3.1
12	301	62.6	58	77.3	80	87.9	138	83.1
> 12	30	6.2	4	5.3	0	0	4	2.4
Not available	20	4.2	0	0	3	3.3	3	1.8
Missing	18	3.7	1	1.3	0	0	1	0.6
Total	481	100	75	100	91	100	166	100

### PCI of chronic total occlusion (> 3 months)

From 2013 – 2014, a total of 1285 chronic total occlusions > 3 months were noted; out of which 90.5% were elective and 9.5% presented with ACS (STEMI-3.0%, NSTEMI/UA-6.5%). [Table 4.27]

Majority of the CTO lesions involved left anterior descending artery (42.6%), followed by right coronary artery (40.6%), and left circumflex artery (14.9%); 95.3% were de novo lesions and 4.0%. were in-stent restenosis CTO. [Table 4.26]

### Entry site, guide catheter size and closure device

Approximately half of the CTO PCI was performed via radial approach. However, in the past, only 34.2% used the radial approach. [Table 4.27] A 6 French guide catheter was used in 83% of cases, 7 French in 15.7% and 8 French in 1%. Around 25% of access was closed using closure devices. [Table 4.27]

### Types of stents and devices used

Drug-eluting stents were used more frequently in CTO lesions (65.8%), followed by POBA in only 13.8%, DEB in 9.2% and BMS in 4.6%. [Table 4.28 and Table 4.29] The use of adjunctive devices such as IVUS (5.1%), Rotablator (1.5%), cutting balloon (1.2%), and OCT (0.9%) were uncommon. [Table 4.29]

### Results and complications

Out of 1285 lesions, the mean length of the CTO was 42 mm (SD 23.6), and 78.1% of lesions were successfully treated with PCI. The mean stent length and diameter were 49 mm (SD 25.6) and 2.8 mm (SD 0.4%), respectively. [Table 4.28] No major complications were observed; dissection was noted in 4.3% and perforation in 0.9%. [Table 4.30] Majority of them received standard DAPT for 12 months. There was no significant difference observed when compared to the 2007 - 2012 data. [Table 4.31]

Table 4.26 Summary of location of lesions treated with percutaneous coronary intervention and for lesion with description of CTO > 3 months only, NCVD-PCI Registry, 2007 – 2014

Location of lesion with CTO > 3 mo	2007 – 2012 Total no. of lesions = 2626		2013 Total no. of lesions = 550		2014 Total no. of lesions = 735		2013 – 2014 Total no. of lesions = 1285	
	No.	%	No.	%	No.	%	No.	%
None	0	0	0	0	0	0	0	0
Left main stem	32	1.2	12	2.2	9	1.2	21	1.7
Left anterior descending artery (LAD)	1207	46.0	242	44.0	305	41.5	547	42.6
LAD proximal	940	35.8	177	32.2	236	32.1	413	32.2
LAD mid	239	9.1	61	11.1	64	8.7	125	9.7
LAD distal	13	0.5	3	0.5	3	0.4	6	0.5
D1	15	0.6	1	0.2	2	0.3	3	0.2
D2	0	0	0	0	0	0	0	0
D3	0	0	0	0	0	0	0	0
Right coronary artery (RCA)	1024	39.0	219	39.7	303	41.2	522	40.6
RCA proximal	591	22.5	112	20.4	168	22.9	280	21.9
RCA mid	288	11.0	75	13.6	87	11.8	162	12.6
RCA distal	113	4.3	25	4.5	41	5.6	66	5.1
PDA	15	0.6	4	0.7	3	0.4	7	0.5
PLV	17	0.6	3	0.5	4	0.5	7	0.5
Left circumflex artery (LCx)	340	12.9	76	13.9	116	15.8	192	14.9
LCX proximal	183	7.0	40	7.3	69	9.4	109	8.5
LCX distal	102	3.9	24	4.4	29	3.9	53	4.1
OM1	43	1.6	11	2.0	16	2.2	27	2.1
OM2	9	0.3	1	0.2	2	0.3	3	0.2
OM3	3	0.1	0	0	0	0	0	0
Graft	23	0.9	1	0.2	2	0.3	3	0.2
LIMA	3	0.1	0	0	0	0	0	0
RIMA	0	0	0	0	0	0	0	0
SVG1	15	0.6	1	0.2	2	0.3	3	0.2
SVG2	3	0.1	0	0	0	0	0	0
SVG3	2	0.1	0	0	0	0	0	0
RAD1	0	0	0	0	0	0	0	0
RAD2	0	0	0	0	0	0	0	0
RAD3	0	0	0	0	0	0	0	0
Missing			0	0	0	0	0	0

	2007 – 2012 Total no. of lesions = 2626		20 Total no. = 5	13 of lesions 550	20 Total no. = 7	14 of lesions /35	2013 – 2014 Total no. of lesions = 1285	
	No.	%	No.	%	No.	%	No.	%
PCI status, No. (%)								
Elective	2461	93.7	510	92.7	653	88.9	1163	90.5
NSTEMI/UA	95	3.6	29	5.3	54	7.3	83	6.5
AMI/STEMI	68	2.6	11	2.0	28	3.8	39	3.0
Not available	0	0	0	0	0	0	0	0
Missing	2	0.1	0	0	0	0	0	0
Elective, No. (%)								
Staged PCI			217	42.8	329	50.5	546	47.2
Ad hoc			290	57.2	322	49.5	612	52.8
Not available			3		2		5	
Missing			0		0		0	
NSTEMI/UA, No. (%)								
Urgent			6	20.7	11	20.4	17	20.5
Non-urgent			23	79.3	43	79.6	66	79.5
Not available			0		0		0	
Missing			0		0		0	
STEMI, No. (%)								
Rescue			4	36.3	8	28.5	12	30.7
Primary			5	45.5	14	50.0	19	48.7
Facilitated			0	0	0	0	0	0
Delayed PCI			0	0	0	0	0	0
Delayed routine PCI			0	0	4	14.3	4	10.3
Delayed selective			2	18.2	1	3.6	3	7.7
Pharmacoinvasive			0	0	1	3.6	1	2.6
Not available			0		0		0	
Missing			0		0		0	
<sup>#</sup> Percutaneous entry, No. (%)								
Brachial	29	1.1	6	1.1	5	0.7	11	0.9
Radial	899	34.2	270	49.1	367	49.9	637	49.6
Femoral	1606	61.2	324	58.9	474	64.5	798	62.1
<sup>\$</sup> <sup>F</sup> rench size type								
Guiding catheter			521	94.8	702	95.5	1223	95.2
Guiding sheath			16	2.9	30	4.1	46	3.5
Not available			3	0.5	3	0.4	6	0.5
Missing			10	1.8	0	0	10	0.8

Table 4.27 Characteristics of PCI procedures performed for lesion with description of CTO >3 months only, NCVD-PCI Registry, 2007 – 2014

	2007 – 2012 Total no. of lesions = 2626		2013 Total no. of lesions = 550		2014 Total no. of lesions = 735		2013 - 2014 Total no. of lesions = 1285	
	No.	%	No.	%	No.	%	No.	%
<sup>^</sup> French size (guiding catheter), No. (%)								
4			0	0	0	0	0	0
5	32	1.2	1	0.2	0	0	1	0.1
6	1863	80.0	420	80.6	595	84.8	1015	83.0
7	616	23.5	90	17.3	102	14.5	192	15.7
8	30	1.1	8	1.5	4	0.6	12	1.0
9	0	0	0	0	0	0	0	0
Others	1	0.0	0	0	0	0	0	0
Not available	30	1.1	2	0.4	1	0.1	3	0.2
Missing	54	2.1	0	0	0	0	0	0
Closure device, No. (%)								
No	2383	90.7	459	83.4	515	70.1	974	75.7
Seal	74	2.8	18	3.3	44	5.9	62	4.8
Suture	31	1.2	22	4.0	61	8.3	83	6.5
Exoseal			12	2.2	21	2.9	33	2.6
Others	4	0.2	8	1.5	39	5.3	47	3.7
Not available	27	1.0	4	0.7	5	0.7	9	0.7
Missing	107	4.1	27	4.9	50	6.8	77	6.0
<sup>#</sup> Extent of coronary disease. No. (%)								
Single vessel disease	1094	41.7	310	56.4	501	68.2	811	63.1
Multiple vessel disease	1329	50.6	209	38.0	204	27.8	413	32.1
Graft	24	0.9	13	2.4	21	2.8	34	2.7
Left main	12	0.5	3	0.5	8	1.1	11	0.9
Not available			15	2.7	1	0.1	16	1.2
Fluoroscopy time, min								
Ν	23	04	40	59	63	35	11	04
Mean (SD)	31.8 (	21.7)	38.2	(24.6)	34.2 (	(22.6)	35.9	(23.6)
Median (min, max)	26.8 (2.0	), 178.0)	32.2 (2.5	5, 158.0)	29.4 (2.8	3, 148.5)	30.4 (2.5	5, 158.0)
Not available, No. (%)	214	8.1	52	9.5	68	9.3	120	9.3
Missing, No. (%)	108	4.1	29	5.3	32	4.4	61	4.7
Fluoroscopy total dose, mGy								
N		1334		243		410		653
Mean (SD)	4639.4	(44865.7)	32789.6 (	(104878.4)	68879.4 (	148477.4)	55449.3 (	134968.9)
Median (min, max)	280 (0.9, 119	).0 99417.0)	245 (1.6, 71	56.0 0958.0)	345 (5.4, 108	57.5 32615.0)	298 (1.6, 108	8.0 32615.0)
Not available, No. (%)	982	37.4	205	37.3	206	28.0	411	32.0
Missing, No. (%)	310	11.8	102	18.5	119	16.2	221	17.2

	2007 – 2012 Total no. of lesions = 2626		2013 Total no. of lesions = 550		2014 Total no. of lesions = 735		2013 – 2014 Total no. of lesions = 1285	
	No.	%	No.	%	No.	%	No.	%
Contrast type, No. (%)								
Ionic	19	0.7	0	0	0	0	0	0
Non-ionic	2391	91.1	113	20.6	0	0	113	8.8
Not available	173	6.6	5	0.9	1	0.1	6	0.5
Missing	43	1.6	432	78.5	734	99.9	1166	90.7
Contrast volume, ml								
N	2374		40	464		24	10	88
Mean (SD)	217.9	(85.8)	223.8	(90.1)	209.7	(90.5)	215.7	(90.6)
Median (min, max)	200.0 (18	.0, 500.0)	200.0 (27	.0, 500.0)	200.0 (26	.0, 500.0)	200.0 (26	.0, 500.0)
Not available, No. (%)	194	7.4	56	10.2	65	8.8	121	9.4
Missing, No. (%)	58	2.2	30	5.5	46	6.3	76	5.9
Thrombolytics prior to PCI procedure in STEMI, No. (%)								
Total no. of procedures among STEMI patients	479	100	18	100	61	100	79	100
Yes	35	7.3	4	22.2	16	26.2	20	25.3
No	444	92.7	14	77.8	45	73.8	59	74.7
Missing	0	0	0	0	0	0	0	0

<sup>#</sup>Patients are allowed to be in more than one type of category

<sup>8</sup>French size type was not available in the old CRF. In the old CRF, information on French size was only collected for guiding catheter. <sup>^</sup>French size is reported by number of lesions instead of number of procedures. In the old CRF, French size was reported under Section 6 cath lab visit, no 6b, whereas in the new CRF, it was reported under Section 7 PCI proc details, no 11.

\* In the new CRF, French size 9 is not listed. However, there is one patient with guiding catheter and French size 9 and three patients with gyuiding sheath and French size 9.

<sup>7</sup>*Results as presented differently in 2007 – 2012 and 2013 – 2014. In 2007 – 2012, patients are allowed to be presented in different categories. In 2013 – 2014, patients are included in a unique category.* 

• Single vessel disease is for patients with single vessel disease information (old CRF)/ patients with only one information of either LAD, LCx or RCA.

Multiple vessel disease is for patients with multiple vessel disease information (old CRF)/patients with more than one
information of LAD, LCx or RCA.

• Left main stem (LMS) is for patients with information of LMS (LMS alone or combination with LAD, LCx, RCA or single vessel disease)

Graft is for patients with information of graft (graft alone or combination with LAD, LCx, RCA, single vessel disease, multiple vessel disease or LMS)

No.No.%No.%No.%No.%No.%Pre-procedure stenois %277797.577.5198.597.998.5<		2007 - 2012 Total no. of lesions = 2626		20 Total no. = 5	13 of lesions 550	20 Total no. = 7	14 of lesions /35	2013 - 2014 Total no. of lesions = 1285	
$\begin{array}{                                    $		No.	%	No.	%	No.	%	No.	%
N $25 - V$ $52 - V$ $72 - V$ $124 + V$ Median (min, max) $100.0 (0.0 + 0.0.0)$ $100.0 (0.0 + 0.0.0)$ $100.0 (0.0 + 0.0.0)$ $100.0 (0.0 + 0.0.0)$ Missing, No. (%)       S4 $2.1$ $24$ $4$ $13$ $1.8$ $37$ $2.9$ Post-procedure stenosis % $24$ $2.1$ $22$ $4 - 13$ $1.8$ $37$ $2.9$ N $24 + 32 + 0$ $2.9 (1 - 2)$ $2.2 (1 - 2)$ $2.2 (1 - 2)$ $2.2 (1 - 2)$ $2.1 - 2)$ Mean (SD) $20 \cdot 0 \cdot 0.00$ $0.0 (0.0 - 0.00)$ $0.0 (0.0 - 0.00)$ $0.0 (0.0 - 0.00)$ $0.0 (0.0 - 0.00)$ Missing, No. (%) $167$ $6.4$ $37$ $6.7$ $31$ $4.2$ $68$ $5.3$ Estimated lesion length, mm $30.(5 \cup 1.0.0)$ $38.0 (8.0 + 28.0)$ $37.5 (4 \cup 13.00)$ $38.0 (4.0 + 20.0)$ $38.0 (8.0 + 28.0)$ $37.5 (4 \cup 13.00)$ $38.0 (4.0 + 20.0)$ Mean (SD) $30.5 (5 - 14.00)$ $38.0 (8.0 + 28.0)$ $37.5 (4 \cup 13.00)$ $38.0 (4.0 + 10.0)$ $38.0 (8.0 + 28.0)$ $37.5 (4 \cup 13.00)$ $38.0 (4.0 + 10.0)$ $38.0 (8.0 + 28.0)$ $37.5 (4$	Pre-procedure stenosis %								
Mean (SD)         97.8 (9.5)         99.3 (5.3)         97.9 (9.8)         98.5 (8.2)           Median (min, max)         100.0 (0.10.0)         100.0 (9.10.0)         100.0 (0.10.0)         100.0 (0.10.0)         100.0 (0.10.0)           Missing, No. (%)         54         2.1         24         4.4         13         1.8         37         2.9           Post-procedure stenosis %         Image: Constraint of the standard stand	Ν	25	72	526		722		1248	
Median (min, max)         100.0 (0) <td>Mean (SD)</td> <td>97.8</td> <td>(9.5)</td> <td>99.3</td> <td>(5.3)</td> <td>97.9</td> <td>(9.8)</td> <td>98.5</td> <td>(8.2)</td>	Mean (SD)	97.8	(9.5)	99.3	(5.3)	97.9	(9.8)	98.5	(8.2)
Missing, No. (%)         54         2.1         24         4.4         13         1.8         37         2.9           Post-procedure stenosis <td< td=""><td>Median (min, max)</td><td>100.0 (0.</td><td>0, 100.0)</td><td>100.0 (9.</td><td>0, 100.0)</td><td>100.0 (0.</td><td>0, 100.0)</td><td>100.0 (0.</td><td>0, 100.0)</td></td<>	Median (min, max)	100.0 (0.	0, 100.0)	100.0 (9.	0, 100.0)	100.0 (0.	0, 100.0)	100.0 (0.	0, 100.0)
	Missing, No. (%)	54	2.1	24	4.4	13	1.8	37	2.9
Post-procedure stenosis %         Image: Constraint of the step is t									
N       2459       513 $704$ 1217         Mean (SD)       20.2 (3).1)       22.9 (41.2)       22.6 (41.2)       22.7 (41.2)       22.7 (41.2)         Mean (SD)       0.0 (0.0 ∪ 100.0)       0.0 (0.0 ∪ 100.0)       0.0 (0.0 ∪ 100.0)       0.0 (0.0 ∪ 100.0)       0.0 (0.0 ∪ 100.0)       0.0 (0.0 ∪ 100.0)         Missing, No. (%)       167       6.4       37       6.7       31       4.2       68       5.3         Estimated lesion length, mm       107       4.3       108       108       108       108       108       108       108         N       2221       4.35       600       10.3       42.0 (2.36)         Mean (SD)       35.1 (2.1)       43.0 (2.4)       41.3 (2.80)       38.0 (4.0, 130.0)         Missing, No. (%)       405       15.4       115       20.9       135       18.4       250       19.5         Meain (SD)       4005       15.4       115       20.9       135       18.4       250       19.5         Lesion result, No. (%)       40.2       43.0       78.2       57.3       78.0       1003       78.1         Unsuccessful       512       19.5       100       0       0       0       0<	Post-procedure stenosis %								
Mean (SD)         20.2 (3·.1)         22.9 (41.2)         22.6 (41.2)         22.7 (41.2)           Median (min, max)         0.0 (0.0, 100.0)         0.0 (0.0, 100.0)         0.0 (0.0, 100.0)         0.0 (0.0, 100.0)         0.0 (0.0, 100.0)           Missing, No. (%)         167         6.4         37         6.7         31         4.2         6.8         5.3           Estimated lesion length, mm         1         1         1         1         1         1         1         1           N         2221         43.5         600         10.3         42.0 (2.3, 13.0)           Median (min, max)         30.0 (5.0 140.0)         38.0 (8.0 128.0)         37.5 (4.13.0)         38.0 (4.0, 13.0)           Missing, No. (%)         405         15.4         115         20.9         13.5         18.4         25.0         19.5           Lesion result, No. (%)         400         10.1         10.4         10.4         10.4         10.4         10.4           Successful         2107         80.2         43.0         78.2         57.3         78.0         100.3         78.1           Unsuccessful         512         19.5         12.0         21.8         160         21.7         28.0         21.7	Ν	24	59	51	13	70	)4	12	17
Median (min, max)         0.0 (0.0, 100.0)         0.0 (0.0, 100.0)         0.0 (0.0, 100.0)         0.0 (0.0, 100.0)           Missing, No. (%)         167         6.4         37         6.7         31         4.2         68         5.3           Estimated lesion length, mm         Image: Constraint of the state of	Mean (SD)	20.2 (	39.1)	22.9 (	(41.2)	22.6 (	(41.2)	22.7 (	(41.2)
Missing, No. (%)         167         6.4         37         6.7         31         4.2         68         5.3           Estimated lesion length, mm         Image: Constraint of the const	Median (min, max)	0.0 (0.0	, 100.0)	0.0 (0.0	, 100.0)	0.0 (0.0	, 100.0)	0.0 (0.0	, 100.0)
$ \begin{array}{ c c c c c } \mbox{Hermit} &  c c c c c c c c c c } \mbox{Hermit} &  c c c c c c c c c c c c c c c c c c $	Missing, No. (%)	167	6.4	37	6.7	31	4.2	68	5.3
Estimated lesion length, mm         1         43         60         10           N         221         435         60         1035           Mean (SD)         35.1         43.0 (24.4)         41.3 (23.0)         38.0 (4.130.0)           Median (min, max)         30.0 (5.140.0)         38.0 (24.4)         31.5 (4.0)         38.0 (4.130.0)           Missing, No. (%)         405         15.4         115         20.9         135         18.4         250         19.5           Lesion result, No. (%)         405         15.4         115         20.9         135         18.4         250         19.5           Successful         2107         80.2         430         78.2         573         78.0         1003         78.1           Unsuccessful         512         19.5         120         21.8         160         21.7         28.0         21.7           Na available         3         0.1         0         <									
N         2221         435         600         1035           Mean (SD)         35.1 (21.1)         43.0 (24.4)         41.3 (23.0)         38.0 (4.0 (23.6)           Median (min, max)         30.0 (5.0 (10.0)         38.0 (8.0 (128.0)         37.5 (4.0 (13.00)         38.0 (4.0 (13.00)           Missing, No. (%)         405         15.4         115         20.9         135         18.4         250         19.5           Lesion result, No. (%)         405         15.4         115         20.9         135         18.4         250         19.5           Lesion result, No. (%)         10         10         10         11.5         20.9         13.5         18.4         250         19.5           Successful         2107         80.2         43.0         78.2         57.3         78.0         1003         78.1           Unsuccessful         512         19.5         120         21.8         160         21.7         28.0         21.7           Not available         3         0.1         0         0         0         0         0         0         0           Mean (SD)         45.1 (24.2)         51.2 (25.3)         47.3 (25.7)         49.0 (25.6)           M	Estimated lesion length, mm								
Mean (SD)       35.1 (21.1)       43.0 (24.4)       41.3 (23.0)       42.0 (23.6)         Median (min, max)       30.0 (5.0, 140.0)       38.0 (8., 128.0)       37.5 (4.0, 130.0)       38.0 (4., 130.0)         Missing, No. (%)       405       15.4       115       20.9       135       18.4       250       19.5         Lesion result, No. (%)       405       15.4       115       20.9       135       18.4       250       19.5         Lesion result, No. (%)       2107       80.2       430       78.2       573       78.0       1003       78.1         Unsuccessful       512       19.5       120       21.8       160       21.7       280       21.7         Not available       3       0.1       0       0       2       0.3       2       0.2         Missing       4       0.2       0       <	N	22	21	43	35	60	00	10	35
Median (min, max)       30.0 (5.0, 140.0)       38.0 (8.0, 128.0)       37.5 (4.0, 130.0)       38.0 (4.0, 130.0)         Missing, No. (%)       405       15.4       115       20.9       135       18.4       250       19.5         Lesion result, No. (%)       405       15.4       115       20.9       135       18.4       250       19.5         Successful       2107       80.2       430       78.2       57.3       78.0       1003       78.1         Unsuccessful       512       19.5       120       21.8       160       21.7       280       21.7         Not available       3       0.1       0       0       2       0.3       2       0.2         Missing       4       0.2       0 <td>Mean (SD)</td> <td>35.1 (</td> <td>21.1)</td> <td>43.0 (</td> <td>(24.4)</td> <td>41.3 (</td> <td>(23.0)</td> <td>42.0 (</td> <td>(23.6)</td>	Mean (SD)	35.1 (	21.1)	43.0 (	(24.4)	41.3 (	(23.0)	42.0 (	(23.6)
Missing, No. (%)         405         154         115         20.9         135         18.4         250         19.5           Lesion result, No. (%)         Image: Construct of the	Median (min, max)	30.0 (5.0	), 140.0)	38.0 (8.0	), 128.0)	37.5 (4.0	), 130.0)	38.0 (4.0	), 130.0)
Lesion result, No. (%)         Image: Constraint of the second sec	Missing, No. (%)	405	15.4	115	20.9	135	18.4	250	19.5
Lesion result, No. (%)       Image: design of the second s									
Successful       2107       80.2       430       78.2       573       78.0       1003       78.1         Unsuccessful       512       19.5       120       21.8       160       21.7       280       21.7         Not available       3       0.1       0       0       2       0.3       2       0.2         Missing       4       0.2       0       0       0       0       0       0       0         *Stent length, mm       1       <	Lesion result, No. (%)								
Unsuccessful       512       19.5       120       21.8       160       21.7       280       21.7         Not available       3       0.1       0       0       2       0.3       2       0.2         Missing       4       0.2       0       0       0       0       0       0       0         Missing       4       0.2       0       0       0       0       0       0       0       0         Missing       4       0.2       0 <th0< th="">       0       0       <th0< th=""></th0<></th0<>	Successful	2107	80.2	430	78.2	573	78.0	1003	78.1
Not available       3       0.1       0       0       2       0.3       2       0.2         Missing       4       0.2       0       0       0       0       0       0       0         Missing       4       0.2       0       0       0       0       0       0       0       0         **Stent length, mm       1949       407       561       968         Mean (SD)       45.1 (24.2)       51.2 (25.3)       47.3 (25.7)       49.0 (25.6)         Median (min, max)       38.0 (8.0, 152.0)       48.0 (12.0, 132.0)       40.0 (8.0, 167.0)       44.0 (8.0, 167.0)         Not available, No. (%)       677       25.8       143       26.0       174       23.7       317       24.7         **Stent diameter, mm       1947       407       558       965       965         Mean (SD)       2.8 (0.4)       2.8 (0.4)       2.8 (0.4)       2.8 (0.4)       2.8 (0.4)       2.8 (0.4)       2.8 (0.4)         Not available, No. (%)       679       25.9       143       26.0       177       24.1       320       24.9         Median (min, max)       2.8 (2.0, 4.7)       2.8 (2.0, 4.0)       2.8 (2.0, 4.0)       2.8 (2.0, 4.0)       <	Unsuccessful	512	19.5	120	21.8	160	21.7	280	21.7
Missing       4       0.2       0       0       0       0       0       0       0         *Stent length, mm       I       I       I       I       I       I       I       I         N $194$ $407$ $561$ 968         Mean (SD) $45.1$ (24.2) $51.2$ (25.3) $47.3$ (25.7) $49.0$ (25.6)         Median (min, max) $38.0$ (8.0, 152.0) $48.0$ (12.0, 132.0) $40.0$ (8.0, 167.0) $44.0$ (8.0, 167.0)         Not available, No. (%) $677$ $25.8$ $143$ $26.0$ $174$ $23.7$ $317$ $24.7$ **Stent diameter, mm       I       I       I       I       I       I       I       I         N $1947$ $407$ $558$ $965$ $965$ Mean (SD) $2.8$ (0.4, 7) $2.8$ (0.4) $2.8$ (0.4) $2.8$ (0.4) $2.8$ (0.4) $2.8$ (0.4) $2.8$ (0.4)         N defan (min, max) $2.8$ (2.0, 4.7) $2.8$ (2.0, 4.0) $2.8$ (2.0, 4.0) $2.8$ (2.0, 4.0) $2.8$ (2.0, 4.0) $2.8$ (2.0, 4.0) $2.8$ (2.0, 4.0) $2.8$ (2.0, 4.0) $2.8$ (2.0, 4.0) $2.8$ (2.0, 4.0) $2.8$	Not available	3	0.1	0	0	2	0.3	2	0.2
*Stent length, mm       Image: line with the symbol in the	Missing	4	0.2	0	0	0	0	0	0
*Stent length, mm       I <thi< th=""></thi<>									
N       1949       407       561       968         Mean (SD)       45.1 (24.2)       51.2 (25.3)       47.3 (25.7)       49.0 (25.6)         Median (min, max)       38.0 (8.0, 152.0)       48.0 (12.0, 132.0)       40.0 (8.0, 167.0)       44.0 (8.0, 167.0)         Not available, No. (%)       677       25.8       143       26.0       174       23.7       317       24.7         **Stent diameter, mm       Image: Second	*Stent length, mm								
Mean (SD) $45.1 (24.2)$ $51.2 (25.3)$ $47.3 (25.7)$ $49.0 (25.6)$ Median (min, max) $38.0 (8.0, 152.0)$ $48.0 (12.0, 132.0)$ $40.0 (8.0, 167.0)$ $44.0 (8.0, 167.0)$ Not available, No. (%) $677$ $25.8$ $143$ $26.0$ $174$ $23.7$ $317$ $24.7$ **Stent diameter, mm       Image: Comparison of the term of the term of	N	19-	49	40	)7	56	51	96	58
Median (min, max)       38.0 (8.0, 152.0)       48.0 (12.0, 132.0)       40.0 (8.0, 167.0)       44.0 (8.0, 167.0)         Not available, No. (%)       677       25.8       143       26.0       174       23.7       317       24.7         **Stent diameter, mm                 N       1947       407       558       965	Mean (SD)	45.1 (	24.2)	51.2 (	(25.3)	47.3 (	(25.7)	49.0 (	(25.6)
Not available, No. (%)       677       25.8       143       26.0       174       23.7       317       24.7         **Stent diameter, mm       Image: constraint of the state of the	Median (min, max)	38.0 (8.0	), 152.0)	48.0 (12.	0, 132.0)	40.0 (8.0	), 167.0)	44.0 (8.0	), 167.0)
Image: system diameter, mm       Image: system diameter, mm <t< td=""><td>Not available, No. (%)</td><td>677</td><td>25.8</td><td>143</td><td>26.0</td><td>174</td><td>23.7</td><td>317</td><td>24.7</td></t<>	Not available, No. (%)	677	25.8	143	26.0	174	23.7	317	24.7
**Stent diameter, mm       1947       407       558       965         Mean (SD)       2.8 (0.4)       2.8 (0.4)       2.8 (0.4)       2.8 (0.4)       2.8 (0.4)         Median (min, max)       2.8 (2.0, 4.7)       2.8 (2.0, 4.0)       2.8 (2.0, 4.0)       2.8 (2.0, 4.0)       2.8 (2.0, 4.0)         Not available, No. (%)       679       25.9       143       26.0       177       24.1       320       24.9         Maximum balloon size used, mm       1       1       1       1       1       1       1         N       2132       422       583       1005       20 (0.6)									
N       1947       407       558       965         Mean (SD) $2.8 (0.4)$ $2.8 (0.4)$ $2.8 (0.4)$ $2.8 (0.4)$ $2.8 (0.4)$ Median (min, max) $2.8 (2.0, 4.7)$ $2.8 (2.0, 4.0)$ $2.8 (2.0, 4.0)$ $2.8 (2.0, 4.0)$ Not available, No. (%)       679       25.9       143       26.0       177       24.1       320       24.9         Maximum balloon size used, mm       1	**Stent diameter, mm								
Mean (SD)       2.8 (0.4)       2.8 (0.4)       2.8 (0.4)       2.8 (0.4)         Median (min, max)       2.8 (2.0, 4.7)       2.8 (2.0, 4.0)       2.8 (2.0, 4.0)       2.8 (2.0, 4.0)         Not available, No. (%)       679       25.9       143       26.0       177       24.1       320       24.9         Maximum balloon size used, mm       1       1       1       1       1       1         N       2132       422       583       1005	N	19	47	40	)7	55	58	96	55
Median (min, max)       2.8 (2.0, 4.7)       2.8 (2.0, 4.0)       2.8 (2.0, 4.0)       2.8 (2.0, 4.0)         Not available, No. (%)       679       25.9       143       26.0       177       24.1       320       24.9         Maximum balloon size used, mm       1       1       1       1       1       1         N       2132       422       583       1005	Mean (SD)	2.8 (	0.4)	2.8 (	(0.4)	2.8 (	(0.4)	2.8 (	0.4)
Not available, No. (%)         679         25.9         143         26.0         177         24.1         320         24.9           Maximum balloon size used, mm <td< td=""><td>Median (min, max)</td><td>2.8 (2.</td><td>0, 4.7)</td><td>2.8 (2.</td><td>0, 4.0)</td><td>2.8 (2.</td><td>0, 4.0)</td><td>2.8 (2.</td><td>0, 4.0)</td></td<>	Median (min, max)	2.8 (2.	0, 4.7)	2.8 (2.	0, 4.0)	2.8 (2.	0, 4.0)	2.8 (2.	0, 4.0)
Maximum balloon size         Image: Constraint of the second	Not available, No. (%)	679	25.9	143	26.0	177	24.1	320	24.9
used, mm         I         I         I           N         2132         422         583         1005           Magn (SD)         20 (0.6)         20 (0.6)         20 (0.6)         20 (0.6)	Maximum balloon size								
Mage (SD)         20 (0.6)         20 (0.6)         20 (0.6)         20 (0.6)	N	21	32		2.2	55	33	10	05
$V(e_{A1}(D_{1})) = V_{A}(D_{1}) = V_{A}(D_{1}) = V_{A}(D_{1}) = V_{A}(D_{1}) = V_{A}(D_{1})$	Mean (SD)	2.90	0.6)	2.97	(0.6)	2.97	(0.6)	2.97	0.6)
Median (min, max) $3.0 (1.0, 5.0)$ $3.0 (1.2, 4.5)$ $3.0 (1.0, 5.0)$ $3.0 (1.0, 5.0)$	Median (min. max)	3.0 (1)	0. 5.0)	3.0 (1	2.4.5)	3.0 (1	0. 5.0)	3.0 (1	0. 5.0)
Missing, No. (%)         494         18.8         128         23.3         152         20.7         280         21.8	Missing, No. (%)	494	18.8	128	23.3	152	20.7	280	21.8

	2007 – 2012 Total no. of lesions = 2626		2013 Total no. of lesions = 550		2014 Total no. of lesions = 735		2013 – 2014 Total no. of lesions = 1285	
	No.	%	No.	%	No.	%	No.	%
Maximum stent/balloon deploy pressure, atm								
Ν	20	51	4	14	57	72	9	86
Mean (SD)	16.3	(4.1)	16.8	(4.3)	16.5	(4.8)	16.6	(4.6)
Median (min, max)	16.0 (4.	0, 30.0)	16.0 (4.	.0, 30.0)	16.0 (2.	.0, 34.0)	16.0 (2.	0, 34.0)
Missing, No. (%)	575	21.9	136	24.7	163	22.2	299	23.3

#Patients were allowed to be in more than one type of category \*Summation of stent length was used for lesions which were treated with more than one stent \*\*Average of stent diameter was used for lesions which were treated with more than one stent

Table 4.28 Types of stents used for lesion with description of CTO > 3 months only, NCVD-PCI Registry, 2007 – 2014

Types of stents for lesion with CTO > 3 mo	2007 – 2012 Total no. of stents used = 4016		2013 Total no. of stents used = 757		2014 Total no. of stents used = 952		2013 - 2014 Total no. of stents = 1709	
	No.	%	No.	%	No.	%	No.	%
Drug-eluting stent	2767	68.9	638	84.3	786	82.6	1424	83.3
Bare metal stent	472	11.8	34	4.5	33	3.5	67	3.9
Bio-absorbable stent	1	0	4	0.5	9	0.9	13	0.8
Antibody-coated	35	0.9	1	0.1	0	0	1	0.1
Others	77	1.9	8	1.1	13	1.4	21	1.2
Drug-eluting balloon	0	0	60	7.9	87	9.1	147	8.6
Bifurcated stent	0	0	0	0	2	0.2	2	0.1
Covered stent	1	0	0	0	1	0.1	1	0.1
Combo stent	0	0	8	1.1	21	2.2	29	1.7
Missing	663	16.5	4	0.5	0	0	4	0.2
Total	4016	100.0	757	100.0	952	100.0	1709	100.0

\*Stents which were not listed in the NCVD-PCI Stent List

<sup>#</sup> Intracoronary devices used for lesion with CTO > 3 mo	2007 – 2012 Total no. of lesions = 2626		2013 Total no. of lesions = 550		2014 Total no. of lesions = 735		2013 – 2014 Total no. of lesions = 1285	
	No.	%	No.	%	No.	%	No.	%
Aspiration/aspiration catheter	50	1.9	10	1.8	10	1.4	20	1.6
Balloon only/POBA	214	8.1	69	12.5	108	14.7	177	13.8
Drug-eluting balloon	138	5.3	49	8.9	69	9.4	118	9.2
Drug-eluting stent	1626	61.9	365	66.4	480	65.3	845	65.8
Cutting balloon/scoring balloon	26	1.0	8	1.5	8	1.1	16	1.2
Coil			5	0.9	0	0	5	0.4
OCT			6	1.1	5	0.7	11	0.9
Mother and child			3	0.5	3	0.4	6	0.5
Micro catheter			188	34.2	279	38.0	467	36.3
Angiojet			0	0	0	0	0	0
IVUS	113	4.3	38	6.9	28	3.8	66	5.1
Flowire/FFR	27	1.0	4	0.7	3	0.4	7	0.5
Rotablator	24	0.9	10	1.8	9	1.2	19	1.5
Bare metal stent	338	12.9	31	5.6	28	3.8	59	4.6
Embolic protection	8	0.3	1	0.2	0	0	1	0.1
Filter			0	0	0	0	0	0
Balloon/distal			0	0	0	0	0	0
Proximal			0	0	0	0	0	0
Missing			1		0		1	
Others	504	19.2	103	18.7	42	5.7	145	11.3

Table 4.29 Types of devices used during percutaneous coronary intervention for lesion with description of CTO > 3 months only, NCVD-PCI Registry, 2007 – 2014

#Patients were allowed to be in more than one type of category

Table 4.30 Types of post procedure	complications for lesion	n with description of	CTO > 3 months only,
NCVD-PCI Registry, 2007 – 2014			

*Types of complication for lesion with CTO > 3	2007 - Total no. = 20	2007 – 2012 Total no. of lesions = 2626		2013 Total no. of lesions = 550		2014 Total no. of lesions = 735		2013 – 2014 Total no. of lesions = 1285	
1110	No.	%	No.	%	No.	%	No.	%	
Dissection	159	6.1	27	4.9	28	3.8	55	4.3	
Flow limiting			2	8.0	2	7.4	4	7.7	
Non-flow limiting			23	92.0	25	92.6	48	92.3	
Not available			1		1		2		
Missing			1		0		1		
No reflow	55	2.1	10	1.8	6	0.8	16	1.2	
Transient	26	56.5	4	40.0	1	20.0	5	33.3	
Persistent	20	43.5	6	60.0	4	80.0	10	66.7	
Not available	6		0		1		1		
Missing	3		0		0		0		
Acute closure	8	0.3							
Perforation	22	0.8	7	1.3	5	0.7	12	0.9	

\*Results are only showed for patients who were reported to have the complications

	Duration of clopidogrel/	<sup>#</sup> Intracoronary devices used							
Year		Balloon or	nly/POBA	Drug-elu	ting stent	Bare metal stent			
$\begin{array}{c cccc} 2014 & & 2013 & & & \\ Total no. of lesions = 735 & Total no. of lesions = 550 & Total no. of lesions = 2626 & & \\ \end{array}$	ticlopidine (months)	No.	%	No.	%	No.	%		
و	1	42	19.6	16	1.0	111	32.8		
262	3	19	8.9	12	0.7	24	7.1		
12 12	6	15	7.0	91	5.6	41	12.1		
- 201 esion	12	73	34.1	1273	78.3	126	37.3		
07 - 0f ld	> 12	12	5.6	165	10.1	13	3.8		
20 no.	Not available	50	23.4	37	2.3	10	3.1		
otal	Missing	3	1.4	32	2.0	13	3.8		
H	Total	214	100.0	1626	100.0	338	100.0		
	1	9	13.1	2	0.5	11	35.5		
: 55(	3	5	7.2	1	0.3	1	3.2		
= SU	6	1	1.4	6	1.6	1	3.2		
13 lesio	12	42	60.9	338	92.7	14	45.2		
20 . of 1	> 12	0	0	8	2.2	1	3.2		
no.	Not available	10	14.5	7	1.9	2	6.5		
lota	Missing	2	2.9	3	0.8	1	3.2		
	Total	69	100.0	365	100.0	31	100.0		
	1	15	13.8	3	0.6	4	14.3		
: 73	3	2	1.9	5	1.0	0	0		
= su	6	4	3.7	7	1.5	2	7.1		
14 lesio	12	66	61.1	446	92.9	19	67.9		
20 . of 1	> 12	5	4.6	9	1.9	1	3.6		
l no	Not available	14	13.0	4	0.8	2	7.1		
Fota	Missing	2	1.9	6	1.3	0	0		
	Total	108	100.0	480	100.0	28	100.0		
ŝ	1	24	13.5	5	0.6	15	25.4		
128	3	7	4.0	6	0.7	1	1.7		
14 ns =	6	5	2.8	13	1.5	3	5.1		
- 20 esio	12	108	61.0	784	92.8	33	55.9		
0f l	> 12	5	2.8	17	2.0	2	3.4		
20 .no.	Not available	24	13.6	11	1.3	4	6.8		
otal	Missing	4	2.3	9	1.1	1	1.7		
L	Total	177	100.0	845	100.0	59	100.0		

Table 4.31 Duration of thienopyridine in patients who underwent PCI and lesion with description of CTO > 3 months only, NCVD-PCI Registry, 2007 – 2014

#Patients were allowed to be in more than one type of category

## OUTCOME

Omar Ismail<sup>1</sup>, Abdul Kahar Abdul Ghapar<sup>2</sup>, Muhamad Ali SK Abdul Kader<sup>1</sup>, Abdul Muizz Abd Malek<sup>2</sup> <sup>1</sup>Hospital Pulau Pinang, Pulau Pinang, <sup>2</sup>Hospital Serdang

### Summary

- Overall in-hospital mortality in the period of 2007 2014 was low at 2.0%; at 30 days, mortality was 2.3% and at 1 year ,mortality was 3.75%. Mortality increased for the years 2013 2014 (2.3%) compared to 2007 2012 (1.5%) due to the increase in ACS patients.
- 2. Incidences of periprocedural complications were low (0 0.8%).
- 3. Mortality prognosticators were being elderly, clinical presentation (Killip Class III/IV and low EF), status of PCI (urgent > elective) and renal impairment. Being female and having diabetes appeared to cause higher but not statistically significant mortality. Patients with high cholesterol and higher blood pressure at presentation appeared to have lower (but statistically not significant) mortality.

There is an increasing trend of mortality in the present cohort for in-hospital mortality and at 30 days. In-hospital mortality for 2007 - 2012 was 1.5% vs. 2.3% in 2013 - 2014; mortality at 30 days for 2007 - 2012 was 2.0% vs. 2.7% in 2013 - 2014. At one year, no difference in mortality between the two cohorts (3.9% vs. 3.5%) was seen [Table 5.2]

In the 2013 - 2014 cohort, mortality within one year was mainly in-hospital (66%) vs. 38% in 2007 - 2012. Therefore, post discharge mortality had reduced in the last two years.

Most of the in-hospital deaths were cardiac related (78.2%); the rate decreased at follow-up (54% at one year) . [Table 5.11]

In the ACS group, mortality was higher in STEMI > NSTEMI > UA. In the present cohort, mortality at discharge for STEMI was 8.1% vs. 4.6% in 2007 – 2012. For NSTEMI, mortality at discharge was 3.4% vs. 1.6% in 2007 – 2012. For UA, the mortality was similar between the two cohorts (1.2% vs. 1.1%). [Table 5.9]

The overall in-hospital complications were less than 2.0%: periprocedural MI (0.7%), cardiogenic shock (0.6%), stroke (0.1%) arrhythmia (0.8%), bleeding (0.2%, only two patients with major bleeding), and new renal impairment (0.5%). Emergency reintervention increased from 0.3% to 0.8%. Bail out CABG was extremely low, affecting only three patients in this cohort. [Table 5.1]

For elective PCI, in-hospital mortality (0.5% in 2007 - 2012 vs. 0.5% in 2013 - 2014) and 30-days mortality (0.9% in 2007 - 2012 vs. 0.8% in 2013 - 2014) were similar in both cohorts. For one year mortality, the present cohort seemed to have lower mortality (1.6%) compared to the previous cohort (2.8%). Non-elective PCI had higher in-hospital, 30-day and one year mortality. [Table 5.8]

In 2013 – 2014 cohort, mortality within one year was mainly in-hospital among non-elective (80%) vs. elective (31.3%). Similar trend was noted in 2007 – 2012, 78% vs. 18% among non-elective and elective respectively.

Higher mortality in elderly > middle age > young (2.5%, 1.3%, and 0.7% in 2010 - 2012 cohort), diabetes (1.8 vs. 1.3 % non-DM), and female (2.1 vs. 1.7% in male). [Table 5.3, Table 5.4 and Table 5.5]

Comparison with other registries:

Table A Com	paring in-hosp	ital morality with	other registeries

	Malaysia	Singapore	Thailand	China	Kerala	Jordan	UK
In-hospital mortality	1.5 – 2.3 %	0.3 - 0.4%	2.4% (< 75 yrs); 5.3% (≥ 75 yrs)	0.32%	0.4-0.5%	0.6%	1.6%

Table 5.1 Summary of in-hospital outcomes for patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014

	2007 – 2012 Total no. of procedures = 26483		2013 Total no. of procedures = 6928		2014 Total no. of procedures = 8586		2013 – 2014 Total no. of procedures = 15514	
	No.	%	No.	%	No.	%	No.	%
Periprocedural MI, No. (%) (based on clinical diagnosis)/ significant periprocedural MI, No. (%)								
Yes	109	0.4	34	0.5	71	0.8	105	0.7
No	26183	98.9	6818	98.4	8412	98	15230	98.2
Not available	90	0.3	26	0.4	42	0.5	68	0.4
Missing	101	0.4	50	0.7	61	0.7	111	0.7
Emergency reintervention/PCI, No. (%)								
Yes	68	0.3	44	0.6	72	0.8	116	0.8
No	26306	99.3	6834	98.7	8453	98.5	15287	98.5
Missing	109	0.4	50	0.7	61	0.7	111	0.7
Bail-out CABG, No. (%)								
Yes	8	0.0	1	0.0	2	0.0	3	0.0
No	26373	99.6	6877	99.3	8509	99.1	15386	99.2
Missing	102	0.4	50	0.7	75	0.9	125	0.8
Other complications								
Cardiogenic shock (after procedure), No. (%)								
Yes	112	0.4	44	0.6	49	0.6	93	0.6
No	26269	99.2	6835	98.7	8474	98.7	15309	98.7
Missing	102	0.4	49	0.7	63	0.7	112	0.7
Arrhythmia (VT/VF/Brady), No. (%)								
Yes	146	0.6	68	1.0	51	0.6	119	0.8
No	26235	99.1	6810	98.3	8473	98.7	15283	98.5
Missing	102	0.3	50	0.7	62	0.7	112	0.7
TIA/Stroke, No. (%)								
Yes	10	0.0	6	0.1	2	0.0	8	0.1
No	26372	99.6	6875	99.2	8524	99.3	1,5399	99.2
Missing	101	0.4	47	0.7	60	0.7	107	0.7

	2007 – 2012 Total no. of procedures = 26483		2013 Total no. of procedures = 6928		2014 Total no. of procedures = 8586		2013 – 2014 Total no. of procedures = 15514	
	No.	%	No.	%	No.	%	No.	%
Tamponade, No. (%)								
Yes	17	0.0	0	0	2	0.0	2	0.0
No	26364	99.6	6877	99.3	8520	99.3	15397	99.3
Missing	102	0.4	51	0.7	64	0.7	115	0.7
Contrast reaction, No. (%)								
Yes	15	0.1	7	0.1	4	0.0	11	0.1
No	26363	99.5	6870	99.2	8520	99.3	15390	99.2
Missing	105	0.4	51	0.7	62	0.7	113	0.7
New onset/worsened heart failure, No. (%)								
Yes	21	0.1	14	0.2	11	0.1	25	0.2
No	26355	99.5	6864	99.1	8512	99.2	15376	99.1
Missing	107	0.4	50	0.7	63	0.7	113	0.7
New renal impairment, No. (%)								
Yes	49	0.2	48	0.7	33	0.4	81	0.5
No	26007	98.2	6821	98.5	8490	98.9	15311	98.7
Not available	321	1.2	10	0.1	2	0.0	12	0.1
Missing	106	0.4	49	0.7	61	0.7	110	0.7
Max post procedural rise in creatinine, No. (%)								
Yes	92	0.3						
No	25566	96.5						
Not available	625	2.4						
Missing	200	0.8						
Max post procedural rise in creatinine results, micromol/L								
N	9	2						
Mean (SD)	427.8(471.6)							
Median (min, max)	355.0(85.	0, 4190.0)						
Vascular complications								
Bleeding, No. (%)								
Yes	137	0.5	18	0.3	10	0.1	28	0.2
No	26212	99.0	6858	98.9	8515	99.2	15373	99.1
Missing	134	0.5	52	0.8	61	0.7	113	0.7
	2007 - Total proced 264	- 2012 no. of lures = 483	20 Total proced 69	13 no. of lures = 28	20 Total proced 85	14 no. of lures = 86	2013 - Total proced 155	- 2014 no. of lures = 514
--	----------------------------------	------------------------------------	-----------------------------	-------------------------------	-----------------------------	-------------------------------	----------------------------------	------------------------------------
	No.	%	No.	%	No.	%	No.	%
Type of bleeding, No. (%)								
Major	13	10.5	2	12.5	0	0	2	8.0
Minor	31	25.0	3	18.8	1	11.1	4	16.0
Minimal	80	64.5	11	68.7	8	88.9	19	76.0
Not available	9		2		0		2	
Missing	4		0		1		1	
Bleeding site, No. (%)								
Retroperitoneal	3	2.5	2	15.4	0	0	2	10.0
Percutaneous entry site	89	74.2	8	61.5	7	100	15	75.0
Others	28	23.3	3	23.1	0	0	3	15.0
Not available	9		5		2		7	
Missing	8		0		1		1	
Access site occlusion, No. (%)								
Yes	12	0.0	0	0	1	0.0	1	0.0
No	26327	99.5	6873	99.2	8521	99.3	15394	99.2
Missing	144	0.5	55	0.8	64	0.7	119	0.8
Loss of distal/radial pulse, No. (%)*								
Yes	2	0.0	0	0	1	0.0	1	0.0
No	26329	99.4	6875	99.2	8524	99.3	15399	99.3
Missing	152	0.6	53	0.8	61	0.7	114	0.7
Dissection, No. (%)								
Yes	37	0.1	4	0.1	3	0.0	7	0.0
No	26287	99.3	6870	99.1	8521	99.3	15391	99.3
Missing	159	0.6	54	0.8	62	0.7	116	0.7
Pseudoaneurysm, No. (%)								
Yes	17	0.1	4	0.1	8	0.1	12	0.1
No	26256	99.1	6863	99.1	8516	99.2	15379	99.1
Missing	210	0.8	61	0.8	62	0.7	123	0.8

	- 2007 Total proced 264	- 2012 no. of lures = 183	20 Total proced 69	13 no. of lures = 28	20 Total proced 85	14 no. of lures = '86	2013 - Total proced 155	- 2014 no. of lures = 514
	No.	%	No.	%	No.	%	No.	%
Management of pseudoaneurysm, No. (%)								
Ultrasound compression	5	41.7	2	66.7	2	40.0	4	50.0
Surgery	1	8.3	1	33.3	0	0	1	12.5
Others	6	50.0	0	0	3	60.0	3	37.5
Not available	4		1		2		3	
Missing	1		0		1		1	
Perforation, No. (%)								
Yes			1	0.0	0	0	1	0.0
No			5401	78.0	8412	98.0	13813	89.0
Missing			1526	22.0	174	2.0	1700	11.0

\*In 2007 – 2012, information was collected for "loss of distal pulse" whereas in 2013 – 2014, information was collected for "loss of radial pulse"

				Overall outcome           **30-day         ***6-month         ****1-ye           No.         %         No.         %           499         2.0         715         2.9         948           23960         98.0         23744         97.1         23511           24459         100.0         24459         100.0         24459           172         2.7         211         3.3         250           6181         97.3         6142         96.7         6103           6353         100.0         6353         100.0         6353           210         2.7         238         3.1         250           7573         97.3         7545         96.9         7533           7783         100         7783         100         7783           7783         97.3         13687         96.8         13636           7783         97.3         13687         96.8         13636					
Year	*Outcome	Outco disch	me at arge	**30	-day	***6-1	nonth	****1	-year
		No.	%	No.	%	No.	%	No.	%
2007 - 2012	Death	371	1.5	499	2.0	715	2.9	948	3.9
Total no. of patients =	Alive	24088	98.5	23960	98.0	23744	97.1	23511	96.1
24459 2013	Total	24459	100.0	24459	100.0	24459	100.0	24459	100.0
2013 Total no. of patients =	Death	136	2.1	172	2.7	211	3.3	250	3.9
	Alive	6217	97.9	6181	97.3	6142	96.7	6103	96.1
6353	Total	6353	100.0	2.1         172         2.7         211         3.3           97.9         6181         97.3         6142         96.7           00.0         6353         100.0         6353         100.0           2.4         210         2.7         238         3.1	100.0	6353	100.0		
2014	Death	184	2.4	210	2.7	238	3.1	250	3.2
Total no. of patients =	Alive	7599	97.6	7573	97.3	7545	96.9	7533	96.8
7783	Total	7783	100	7783	100	7783	100	7783	100
2013 - 2014	Death	320	2.3	7783	2.7	449	3.2	500	3.5
Total no. of patients =	Alive	13816	97.7	7783	97.3	13687	96.8	13636	96.5
14136	Total	14136	100.0	7783	100.0	14136	100.0	14136	100.0

\*The outcome data was derived based on National Death Register data

\*\*Including patients who died in-hospital and at 30 days \*\*\*Including patients who died in-hospital and at 30 days \*\*\*\*Including patients who died in-hospital, at 30 days, and six months Note: Patients with the status "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patients

		Outo	come at disch	arge		**30-day			***6-month			****1-year	
Year	*Outcome	Young	Middle- aged	Elderly									
		No. (%)	No. (%)	No. (%)									
∎ of	Death	5 (0.5)	148 (1.1)	218 (2.2)	10 (1.0)	196 (1.5)	293 (2.9)	15 (1.4)	286 (2.1)	414 (4.1)	22 (2.1)	376 (2.8)	550 (5.5)
)7 – 20 tal no. ntients 24459	Alive	1037 (99.5)	13280 (98.9)	9771 (97.8)	1032 (99.0)	13232 (98.5)	9696 (97.1)	1027 (98.6)	13142 (97.9)	9575 (95.9)	1020 (97.9)	13052 (97.2)	9439 (94.5)
0013 2007 10 no. of Total ients = patic ients = 24 ients = 24 ients	Total	1042 (100.0)	13428 (100.0)	9989 (100.0)									
2013 Total no. of patients = 6353 G	Death	4 (1.3)	48 (1.4)	84 (3.3)	5 (1.6)	61 (1.8)	106 (4.1)	6 (1.9)	73 (2.1)	132 (5.1)	9 (2.8)	89 (2.6)	152 (5.9)
	Alive	315 (98.7)	3414 (98.6)	2488 (96.7)	314 (98.4)	3401 (98.2)	2466 (95.9)	313 (98.1)	3389 (97.9)	2440 (94.9)	310 (97.2)	3373 (97.4)	2420 (94.1)
	Total	319 (100.0)	3462 (100.0)	2572 (100.0)									
of =	Death	5 (1.2)	78 (1.9)	101 (3.1)	6 (1.5)	87 (2.1)	117 (3.6)	6 (1.5)	96 (2.3)	136 (4.2)	7 (1.7)	100 (2.4)	143 (4.4)
2014 tal no. ttients 7783	Alive	405 (98.8)	4024 (98.1)	3170 (96.9)	404 (98.5)	4015 (97.9)	3154 (96.4)	404 (98.5)	4006 (97.7)	3135 (95.8)	403 (98.3)	4002 (97.6)	3128 (95.6)
To p:	Total	410 (100.0)	4102 (100.0)	3271 (100.0)									
14 of =	Death	9 (1.2)	126 (1.7)	185 (3.2)	11 (1.5)	148 (2.0)	223 (3.8)	12 (1.6)	169 (2.2)	268 (4.6)	16 (2.2)	189 (2.5)	295 (5.0)
(13 – 2014 tal no. of tients = 14136	Alive	720 (98.8)	7438 (98.3)	5658 (96.8)	718 (98.5)	7416 (98.0)	5620 (96.2)	717 (98.4)	7395 (97.8)	5575 (95.4)	713 (97.8)	7375 (97.5)	5548 (95.0)
20 To p	Total	729 (100.0)	7564 (100.0)	5843 (100.0)									

Table 5.3 Overall outcome for patients who underwent PCI, by age group (years), NCVD-PCI Registry, 2007 - 2014

\*The outcome data was derived based on National Death Register data

\*\*Including patients who died in-hospital, \*\*\* Including patients who died in-hospital and at 30 days, \*\*\*\*Including patients who died in-hospital, at 30 days and at six months Young is defined as age from 20 to less than 40 years, middle-aged is defined as age between 40 to less than 60 years, and elderly is defined as 60 years and above

Note: Patients with the status of "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patients

Year		0	utcome a	t dischar	ge		**30	-day			***6-1	nonth			****1	-year	
Year	*Outcome	Ma	ale	Fen	nale	Ma	ale	Fen	nale	Ma	ale	Fen	nale	Ma	ale	Fen	nale
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
12 of 4459	Death	281	1.4	90	2.1	370	1.8	129	2.9	524	2.6	191	4.4	694	3.5	254	5.8
07 – 20 tal no. nts = 2	Alive	19792	98.6	4296	97.9	19703	98.2	4257	97.1	19549	97.4	4195	95.6	19379	96.5	4132	94.2
200 To patie	Total	20073	100.0	4386	100.0	20073	100.0	4386	100.0	20073	100.0	4386	100.0	20073	100.0	4386	100.0
of 6353	Death	95	1.8	41	3.9	126	2.4	46	4.3	156	2.9	55	5.2	189	3.6	61	5.7
2013 Total no. patients = 6	Alive	5195	98.2	1022	96.1	5164	97.6	1017	95.7	5134	97.1	1008	94.8	5101	96.4	1002	94.3
	Total	5290	100.0	1063	100.0	5290	100.0	1063	100.0	5290	100.0	1063	100.0	5290	100.0	1063	100.0
of 7783	Death	154	2.4	30	2.4	176	2.7	34	2.7	199	3.0	39	3.1	209	3.2	41	3.3
2014 tal no. ents = '	Alive	6374	97.6	1225	97.6	6352	97.3	1221	97.3	6329	97.0	1216	96.9	6319	96.8	1214	96.7
To patié	Total	6528	100.0	1255	100.0	6528	100.0	1255	100.0	6528	100.0	1255	100.0	6528	100.0	1255	100.0
14 of 4136	Death	249	2.1	71	3.1	302	2.6	80	3.5	14	3.0	94	4.1	398	3.4	102	4.4
$13 - 201^{4}$ tal no. of nts = 141	Alive	11569	97.9	2247	96.9	11516	97.4	2238	96.5	11463	97.0	2224	95.9	11420	96.6	2216	95.6
20 To patie	Total	11818	100.0	2318	100.0	11818	100.0	2318	100.0	11818	100.0	2318	100.0	11818	100.0	2318	100.0

Table 5.4 Overall outcome of patients who underwent PCI, by gender, NCVD-PCI Registry, 2007 – 2014

\*The outcome data was derived based on National Death Register data \*\*Including patients who died in-hospital, \*\*\*Including patients who died in-hospital and at 30 days, \*\*\*\*Including patients who died inhospital, at 30 days, and at six months Note: Patients with the status of "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patient

2014 2013 2013 2013 2013 2014 2013 2013 2013 2013 2013 2013 2013 2014 2014 2014 2014 2014 2014 2014 2014		Outo	come at disch	arge		**30-day			***6-month			****1-year	
Year	*Outcome	Diabetic	Non- diabetic	Not known									
		No. (%)	No. (%)	No. (%)									
2013 Total no. of patients = 6353	Death	73 (2.7)	42 (1.3)	21 (5.4)	91 (3.3)	60 (1.9)	21 (5.4)	113 (4.1)	76 (2.4)	22 (5.7)	134 (4.9)	94 (2.9)	22 (5.7)
	Alive	2681 (97.3)	3171 (98.7)	365 (94.6)	2663 (96.7)	3153 (98.1)	365 (94.6)	2641 (95.9)	3137 (97.6)	364 (94.3)	2620 (95.1)	3119 (97.1)	364 (94.3)
	Total	2754 (100.0)	3213 (100.0)	386 (100.0)									
2014 of patients = 7783 Total	Death	79 (2.3)	69 (1.8)	36 (6.5)	90 (2.6)	80 (2.1	40 (7.2)	103 (3.0)	93 (2.4)	42 (7.6)	109 (3.2)	98 (2.6)	43 (7.8)
	Alive	3325 (97.7)	3756 (98.2)	518 (93.5)	3314 (97.4)	3745 (97.9)	514 (92.8)	3301 (97.0)	3732 (97.6)	512 (92.4)	3295 (96.8)	3727 (97.4)	511 (92.2)
Total no.	Total	3404 (100.0)	3825 (100.0)	554 (100.0)									

Table 5.5 Overall outcome of patients who underwent PCI, by pre-morbid diabetes, NCVD-PCI Registry, 2007 – 2014

		C	)utcome a	t discharg	je		**30	-day			***6-1	month			****1	-year	
Year	*Outcome	Diabetic	Non- diabetic	Not known	Missing												
		No. (%)	No. (%)	No. (%)	No. (%)												
2007 – 2012 tal no. of patients = 24459	Death	189 (1.7)	129 (1.0)	52 (8.4)	1 (4.5)	268 (2.4)	175 (1.4)	55 (8.9)	1 (4.5)	413 (3.7)	243 (1.9)	58 (9.4)	1 (4.5)	556 (5.0)	329 (2.6)	62 (10.1)	1 (4.5)
	Alive	10981 (98.3)	12522 (99.0)	564 (91.6)	21 (95.5)	10902 (97.6)	12476 (98.6)	561 (91.1)	21 (95.5)	10757 (96.3)	12408 (98.1)	558 (90.6)	21 (95.5)	10614 (95.0)	12322 (97.4)	554 (89.9)	21 (95.5)
2 Total I	Total	11170 (100.0)	12651 (100.0)	616 (100.0)	22 (100.0)												
4 .ents =	Death	152 (2.5)	111 (1.6)	57 (6.1)	0 (0)	181 (2.9)	140 (2.0)	61 (6.5)	0 (0)	216 (3.5)	169 (2.4)	64 (6.8)	0 (0)	243 (3.9)	192 (2.7)	65 (6.9)	0 (0)
013 – 2014 no. of patients 14136	Alive	6006 (97.5)	6927 (98.4)	883 (93.9)	0 (0)	5977 (97.1)	6898 (98.0)	879 (93.5)	0 (0)	5942 (96.5)	6869 (97.6)	876 (93.2)	0 (0)	5915 (96.1)	6846 (97.3)	875 (93.1)	0 (0)
2 Total I	Total	6158 (100.0)	7038 (100.0)	940 (100.0)	0 (0)												

\*The outcome data was derived based on National Death Register data \*\* Including patients who died in-hospital, \*\*\* Including patients who died in-hospital and at 30 days, \*\*\*\*Including patients who died in-hospital, at 30 days, and at six months Note: Patients with the status of "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patients

20142013Total no. of patients2013 $= 7783$ $= 6353$ $= 0.0533$ $= 6353$		Outo	come at discha	arge		**30-day			***6-month			****1-year	
Year	*Outcome	Hypertensive	Non- hypertensive	Not known									
		No. (%)	No. (%)	No. (%)									
2013 Total no. of patients = 6353	Death	93 (2.2)	25 (1.4)	18 (5.5)	122 (2.8)	32 (1.8)	18 (5.5)	152 (3.5)	39 (2.3)	20 (6.2)	183 (4.3)	46 (2.7)	21 (6.5)
	Alive	4202 (97.8)	1708 (98.6)	307 (94.5)	4173 (97.2)	1701 (98.2)	307 (94.5)	4143 (96.5)	1694 (97.7)	305 (93.8)	4112 (95.7)	1687 (97.3)	304 (93.5)
	Total	4295 (100.0)	1733 (100.0)	325 (100.0)									
2014 no. of patients = 7783	Death	101 (1.9)	42 (2.0)	41 (8.6)	119 (2.3)	48 (2.3)	43 (9.1)	142 (2.7)	53 (2.5)	43 (9.1)	149 (2.9)	58 (2.7)	43 (9.1)
	Alive	5083 (98.1)	2082 (98.0)	434 (91.4)	5065 (97.7)	2076 (97.7)	432 (90.9)	5042 (97.3)	2071 (97.5)	432 (90.9)	5035 (97.1)	2066 (97.3)	432 (90.9)
Total	Total	5184 (100.0)	2124 (100.0)	475 (100.0)									

Table 5.6 Overall outcome of patients who underwent PCI, by pre-morbid hypertension, NCVD-PCI Registry, 2007 – 2014

		C	Outcome a	t discharg	e		**30	-day			***6-1	nonth			****1	-year	
Year	*Outcome	Hypertensive	Non- hypertensive	Not known	Missing	Hypertensive	Non- hypertensive	Not known	Missing	Hypertensive	Non- hypertensive	Not known	Missing	Hypertensive	Non- hypertensive	Not known	Missing
		No. (%)	No. (%)	No. (%)	No. (%)												
2 ients =	Death	250 (1.4)	74 (1.2)	47 (9.2)	0 (0)	347 (1.9)	104 (1.7)	48 (9.4)	0 (0)	527 (2.9)	139 (2.3)	49 (9.6)	0 (0)	717 (4.0)	180 (3.0)	51 (10.0)	0 (0)
2007 – 2012 al no. of patien 24459	Alive	17647 (98.6)	5960 (98.8)	462 (90.8)	19 ( <b>100.0</b> )	17550 (98.1)	5930 (98.3)	461 (90.6)	19 ( <b>100.0</b> )	17370 (97.1)	5895 (97.7)	460 (90.4)	19 ( <b>100.0</b> )	17180 (96.0)	5854 (97.0)	458 (90.0)	19 ( <b>100.0</b> )
2 Total 1	Total	17897 (100.0)	6034 (100.0)	509 (100.0)	19 (100.0)												
4 ients =	Death	194 (2.0)	67 (1.7)	59 (7.4)	0 (0)	241 (2.5)	80 (2.1)	61 (7.6)	0 (0)	294 (3.1)	92 (2.4)	63 (7.9)	0 (0)	332 (3.5)	104 (2.7)	64 (8.0)	0 (0)
2013 – 2014 no. of patients 14136	Alive	9285 (98.0)	3790 (98.3)	741 (92.6)	0 (0)	9238 (97.5)	3777 (97.9)	739 (92.4)	0 (0)	9185 (96.9)	3765 (97.6)	737 (92.1)	0 (0)	9147 (96.5)	3753 (97.3)	736 (92.0)	0 (0)
2 Total	Total	9479 (100.0)	3857 (100.0)	800 (100.0)	0 (0)												

\*The outcome data was derived based on National Death Register data \*\*Including patients who died in-hospital, \*\*\*Including patients who died in-hospital and at 30 days, \*\*\*\*Including patients who died in-hospital, at 30 days, and at six months Note: Patients with the status of "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patients

2014 2013 2013 2013 2013 2013 2013 2013 2013		Outo	come at disch	arge		**30-day			***6-month			****1-year	
Year	*Outcome	Dyslipidaemic	Non- Dyslipidaemic	Not known									
		No. (%)	No. (%)	No. (%)									
2013 Total no. of patients = 6353 <u>L</u>	Death	47 (1.2)	54 (2.8)	35 (6.0)	74 (1.9)	62 (3.2)	36 (6.2)	100 (2.6)	74 (3.9)	37 (6.4)	125 (3.2)	87 (4.5)	38 (6.5)
	Alive	3807 (98.8)	1864 (97.2)	546 (94.0)	3780 (98.1)	1856 (96.8)	545 (93.8)	3754 (97.4)	1844 (96.1)	544 (93.6)	3729 (96.8)	1831 (95.5)	543 (93.5)
	Total	3854 (100.0)	1918 (100.0)	581 (100.0)									
2014 of patients = 7783 Total n	Death	63 (1.4)	67 (2.8)	54 (7.4)	75 (1.6)	79 (3.2)	56 (7.7)	92 (2.0)	90 (3.7)	56 (7.7)	98 (2.1)	96 (3.9)	56 (7.7)
	Alive	4557 (98.6)	2366 (97.2)	676 (92.6)	4545 (98.4)	2354 (96.8)	674 (92.3)	4528 (98.0)	2343 (96.3)	674 (92.3)	4522 (97.9)	2337 (96.1)	674 (92.3)
Total no.	Total	4620 (100.0)	2433 (100.0)	730 (100.0)									

Table 5.7 Overall outcome of patients who underwent PCI, by pre-morbid dyslipidaemia, NCVD-PCI Registry, 2007 – 2014

		0	Outcome a	t discharg	e		**30	-day			***6-1	month			****]	-year	
Year	*Outcome	Dyslipidaemic	Non- dyslipidaemic	Not known	Missing	Dyslipidaemic	Non- dyslipidaemic	Not known	Missing	Dyslipidaemic	Non- Dyslipidaemic	Not known	Missing	Dyslipidaemic	Non- dyslipidaemic	Not known	Missing
		No. (%)	No. (%)	No. (%)	No. (%)												
2 ients =	Death	193 (1.1)	96 (1.7)	80 (7.0)	2 (5.0)	287 (1.6)	119 (2.1)	91 (8.0)	2 (5.0)	443 (2.5)	168 (3.0)	102 (8.9)	2 (5.0)	620 (3.5)	216 (3.8)	110 (9.6)	2 (5.0)
<u>007 – 201</u> no. of pati 24459	Alive	17425 (98.9)	5562 (98.3)	1063 (93.0)	38 (95.0)	17331 (98.4)	5539 (97.9)	1052 (92.0)	38 (95.0)	17175 (97.5)	5490 (97.0)	1041 (91.1)	38 (95.0)	16998 (96.5)	5442 (96.2)	1033 (90.4)	38 (95.0)
2 Total	Total	17618 ( <b>100.0</b> )	5658 ( <b>100.0</b> )	1143 ( <b>100.0</b> )	40 ( <b>100.0</b> )	17618 ( <b>100.0</b> )	5658 ( <b>100.0</b> )	1143 ( <b>100.0</b> )	40 ( <b>100.0</b> )	17618 ( <b>100.0</b> )	5658 ( <b>100.0</b> )	1143 ( <b>100.0</b> )	40 ( <b>100.0</b> )	17618 ( <b>100.0</b> )	5658 ( <b>100.0</b> )	1143 ( <b>100.0</b> )	40 ( <b>100.0</b> )
4 ients =	Death	110 (1.3)	121 (2.8)	89 (6.8)	0 (0)	149 (1.8)	141 (3.2)	92 (7.0)	0 (0)	192 (2.3)	164 (3.8)	93 (7.1)	0 (0)	223 (2.6)	183 (4.2)	94 (7.2)	0 (0)
<u>013 – 201</u> no. of pati 14136	Alive	8364 (98.7)	4230 (97.2)	1222 (93.2)	0 (0)	8325 (98.2)	4210 (96.8)	1219 (93.0)	0 (0)	8282 (97.7)	4187 (96.2)	1218 (92.9)	0 (0)	8251 (97.4)	4168 (95.8)	1217 (92.8)	0 (0)
2 Total 1	Total	8474 ( <b>100.0</b> )	4351 ( <b>100.0</b> )	1311 ( <b>100.0</b> )	0 (0)	8474 ( <b>100.0</b> )	4351 ( <b>100.0</b> )	1311 ( <b>100.0</b> )	0 (0)	8474 ( <b>100.0</b> )	4351 ( <b>100.0</b> )	1311 ( <b>100.0</b> )	0 (0)	8474 ( <b>100.0</b> )	4351 ( <b>100.0</b> )	1311 ( <b>100.0</b> )	0 (0)

\*The outcome data was derived based on National Death Register data \*\*Including patients who died in-hospital, \*\*\* Including patients who died in-hospital and at 30 days, \*\*\*\*Including patients who died in-hospital, at 30 days, and at six months Note: Patients with the status of "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patients

		C	Outcome a	t discharg	e		**30	-day			***6-1	nonth			****1	-year	
Year	*Outcome	Elective	Non-elective	Not available	Missing												
		No. (%)	No. (%)	No. (%)	No. (%)												
ts = 6353	Death	26 (0.6)	110 (6.6)	0 (0)	0 (0)	49 (1.0)	123 (7.4)	0 (0)	0 (0)	77 (1.6)	134 (8.0)	0 (0)	0 (0)	103 (2.2)	147 (8.8)	0 (0)	0 (0)
2013 . of patien	Alive	4656 (99.4)	1561 (93.4)	0 (0)	0 (0)	4633 (99.0)	1548 (92.6)	0 (0)	0 (0)	4605 (98.4)	1537 (92.0)	0 (0)	0 (0)	4579 (97.8)	1524 (91.2)	0 (0)	0 (0)
Total no.	Total	4682 (100.0)	1671 (100.0)	0 (0)	0 (0)												
ts = 7783	Death	25 (0.4)	159 (8.3)	0 (0)	0 (0)	38 (0.6)	172 (9.0)	0 (0)	0 (0)	55 (0.9)	183 (9.6)	0 (0)	0 (0)	61 (1.0)	189 (9.9)	0 (0)	0 (0)
2014 of patien	Alive	5847 (99.6)	1752 (91.7)	0 (0)	0 (0)	5834 (99.4)	1739 (91.0)	0 (0)	0 (0)	5817 (99.1)	1728 (90.4)	0 (0)	0 (0)	5811 (99.0)	1722 (90.1)	0 (0)	0 (0)
Total no.	Total	5872 (100.0)	1911 (100.0)	0 (0)	0 (0)												

Table 5.8 Overall outcome of patients who underwent PCI, by PCI status, NCVD-PCI Registry, 2007 – 2014

		Out	come at d	ischarge			**30	-day			***6-]	month			****1	-year	
Year	*Outcome	Elective	Non- elective	Not available	Missing												
		No. (%)	No. (%)	No. (%)	No. (%)												
2 ients =	Death	96 (0.5)	273 (8.8)	0 (0)	2 (14.3)	201 (0.9)	296 (9.5)	0 (0)	2 (14.3)	391 (1.8)	322 (10.3)	0 (0)	2 (14.3)	595 (2.8)	351 (11.3)	0 (0)	2 (14.3)
<u>007 – 201</u> no. of pati 24459	Alive	21213 (99.5)	2839 (91.2)	24 (100)	12 (85.7)	21108 (99.1)	2816 (90.5)	24 (100)	12 (85.7)	20918 (98.2)	2790 89.7	24 (10)0	12 (85.7)	20714 (97.2(	2761 (88.7)	24 (100)	12 (85.7)
2 Total	Total	21309 (100.0)	3112 (100.0)	24 (100.0)	14 (100.0)												
4 ients =	Death	51 (0.5)	269 (7.5)	0 (0)	0 (0)	87 (0.8)	295 (8.2)	0 (0)	0 (0)	132 (1.3)	317 8.8	0 (0)	0 (0)	164 (1.6)	336 (9.4)	0 (0)	0 (0)
<u>013 – 201</u> no. of pati 14136	Alive	10503 (99.5)	3313 (92.5)	0 (0)	0 (0)	10467 (99.2)	3287 (91.8)	0 (0)	0 (0)	10422 (98.7)	3265 91.2	0 (0)	0 (0)	10390 (98.4)	3246 (90.6)	0 (0)	0 (0)
2 Total	Total	10554 (100.0)	3582 (100.0)	0 (0)	0 (0)												

\*The outcome data was derived based on National Death Register data

\*\*Including patients who died in-hospital, \*\*\*Including patients who died in-hospital and at 30 days, \*\*\*\*Including patients who died in-hospital, at 30 days, and at six months Note: Patients with the status of "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patients

		(	Outcome a	t discharg	e		**30	-day			***6-1	nonth			****1	-year	
Year	*Outcome	STEMI	NSTEMI	UA	Not available/ Missing												
		No. (%)	No. (%)	No. (%)	No. (%)												
ts = 6353	Death	87 (7.0)	18 (3.9)	6 (1.4)	1 (4.5)	98 (7.9)	21 (4.6)	12 (2.9)	1 (4.5)	106 (8.6)	23 (5.0)	16 (3.8)	1 (4.5)	120 (9.7)	23 (5.0)	17 (4.1)	1 (4.5)
2013 . of patient	Alive	1150 (93.0)	439 (96.1)	412 (98.6)	21 (95.5)	1139 (92.1)	436 (95.4)	406 (97.1)	21 (95.5)	1131 (91.4)	434 (95.0)	402 (96.2)	21 (95.5)	1117 (90.3)	434 (95.0)	401 (95.9)	21 (95.5)
Total no	Total	1237 (100.0)	457 (100.0)	418 (100.0)	22 (100.0)												
s = 7783	Death	139 (8.9)	21 (3.1)	4 (0.9)	0 (0)	148 (9.5)	26 (3.8)	4 (0.9)	0 (0)	156 (10.0)	32 (4.7)	6 (1.4)	0 (0)	161 (10.3)	34 (5.0)	8 (1.8)	0 (0)
2014 . of patient	Alive	1418 (91.1)	660 (96.9)	438 (99.1)	51 (100)	1409 (90.5)	655 (96.2)	438 (99.1)	51 (100)	1401 (90.0)	649 (95.3)	436 (98.6)	51 (100)	1396 (89.7)	647 (95.0)	434 (98.2)	51 (100.0)
Total no.	Total	1557 (100.0)	681 (100.0)	442 (100.0)	51 (100.0)												

Table 5.9 Overall outcome of patients who underwent PCI, by acute coronary syndrome, NCVD-PCI Registry, 2007 – 2014

		(	Outcome a	t discharg	e		**30	-day			***6-1	nonth			****1	-year	
Year	*Outcome	STEMI	NSTEMI	UA	Not available/ Missing	STEMI	INSTEMI	NA	Not available/ Missing	STEMI	INSTEMI	NA	Not available/ Missing	STEMI	NSTEMI	NA	Not available/ Missing
		No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)
s = 9416	Death	243 (4.6)	49 (1.6)	12 (1.1)	6 (7.2)	277 (5.3)	70 (2.3)	16 (1.5)	6 (7.2)	321 (6.1)	110 (3.6)	26 (2.5)	6 (7.2)	373 (7.1)	148 (4.9)	37 (3.5)	6 (7.2)
2007 – 2012	Alive	5004	2989	1036	77	4970	2968	1032	77	4926	2928	1022	77	4874	2890	1011	77
. of patient		(95.4)	(98.4)	(98.9)	(95.8)	(94.7)	(97.7)	(98.5)	(95.8)	(93.9)	(96.4)	(97.5)	(95.8)	(92.9)	(95.1)	(96.5)	(95.8)
2	Total	5247	3038	1048	83	5247	3038	1048	83	5247	3038	1048	83	5247	3038	1048	83
Total no		(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)
t	Death	226	39	10	1	246	47	16	1	262	55	22	1	281	57	25	1
s = 14136		(8.1)	(3.4)	(1.2)	(1.4)	(8.8)	(4.1)	(1.9)	(1.4)	(9.4)	(4.8)	(2.6)	(1.4)	(10.1)	(5.0)	(2.9)	(1.4)
2013 – 2014	Alive	2568	1099	850	72	2548	1091	844	72	2532	1083	838	72	2513	1081	835	72
of patients		(91.9)	(96.6)	(98.8)	(98.6)	(91.2)	(95.9)	(98.1)	(98.6)	(90.6)	(95.2)	(97.4)	(98.6)	(89.9)	(95.0)	(97.1)	(98.6)
2	Total	2794	1138	860	73	2794	1138	860	73	2794	1138	860	73	2794	1138	860	73
Total no.		(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)

\*The outcome data was derived based on National Death Register data

\*\* Including patients who died in-hospital, \*\*\* Including patients who died in-hospital and at 30 days, \*\*\*\*Including patients who died in-hospital, at 30 days, and at six months Note: Patients with status of "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patients

Year	#*Medication	Outco disch	me at arge	30-0	day	6-me	onth	1-у	ear
		No.	%	No.	%	No.	%	No.	%
15	Aspirin	22241	92.4	12954	86.5	10149	81.5	8357	77.0
400	Clopidogrel	22295	92.6	12263	81.9	8727	70.1	6232	57.5
<b>7</b>	Ticlopidine	857	3.6	592	4.0	556	4.5	466	4.3
nts	**Dual antiplatelet	21556	89.5	11899	79.4	8324	66.9	5741	52.9
112 tier	Statin	21458	89.1	7010	46.8	10178	81.8	8604	79.3
- 2( pa	Beta blocker	16518	68.6	5093	34.0	7642	61.4	6453	59.5
- 7 ive	ACE inhibitor	12326	51.2	3743	25.0	5369	43.1	4395	40.5
200 [al	ARB	3012	12.5	1206	8.1	2101	16.9	1988	18.3
6	Warfarin	266	1.1	63	0.4	89	0.7	67	0.6
no	Prasugrel								
tal	Ticagrelor								
$T_0$	Others	16501	68.5	11379	76.0	8349	67.1	7271	67.0
2	Aspirin	5522	88.8	1866	81.9	1544	78.2	1114	68.6
521	Clopidogrel	5162	83.0	1698	74.5	1310	66.3	750	46.2
"	Ticlopidine	81	1.3	25	1.1	12	0.6	16	1.0
nts	**Dual antiplatelet	5049	81.2	1666	73.1	1281	64.9	711	43.8
itie	Statin	5325	85.7	1738	76.3	1500	75.9	1111	68.4
13 pa	Beta blocker	4158	66.9	1361	59.7	1198	60.7	895	55.1
20 20	ACE inhibitor	3001	48.3	856	37.6	809	41.0	566	34.9
fal	ARB	607	9.8	197	8.6	171	8.7	167	10.3
0.0	Warfarin	74	1.2	18	0.8	6	0.3	9	0.6
nc	Prasugrel	32	0.5	8	0.4	5	0.3	3	0.2
otal	Ticagrelor	354	5.7	42	1.8	25	1.3	23	1.4
Ľ	Others	3430	55.2	1074	47.1	754	38.2	525	32.3
6	Aspirin	6890	90.7	1348	72	894	64.2	597	61.4
159	Clopidogrel	6168	81.2	1288	68.8	782	56.1	417	42.9
1	Ticlopidine	75	1.0	3	0.2	2	0.1	3	0.3
nts	**Dual antiplatelet	5946	78.2	1224	65.4	758	54.4	402	41.4
tie	Statin	6650	87.5	1291	69.0	858	61.6	594	61.1
14 pa	Beta blocker	5182	68.2	970	51.8	673	48.3	464	47.7
20 20 ive	ACE inhibitor	3633	47.8	679	36.3	471	33.8	345	35.5
fal	ARB	680	8.9	75	4.0	70	5.0	62	6.4
0.0	Warfarin	72	0.9	20	1.1	12	0.9	7	0.7
nc	Prasugrel	73	1.0	7	0.4	3	0.2	0	0
ota	Ticagrelor	923	12.1	79	4.2	27	1.9	8	0.8
Ĕ	Others	4100	54.0	431	23.0	237	17.0	168	17.3
9	Aspirin	12412	89.8	3214	77.4	2438	72.4	1711	65.9
38]	Clopidogrel	11330	82.0	2986	71.9	2092	62.1	1167	45.0
	Ticlopidine	156	1.1	28	0.7	14	0.4	19	0.7
its	**Dual antiplatelet	10995	79.6	2890	69.6	2039	60.5	1113	42.9
14 tien	Statin	11975	86.7	3029	73.0	2358	70.0	1705	65.7
-20 pat	Beta blocker	9340	67.6	2331	56.2	1871	55.6	1359	52.3
3- ve	ACE inhibitor	6634	48.0	1535	37.0	1280	38.0	911	35.1
201 ali	ARB	1287	9.3	272	6.6	241	7.2	229	8.8
. of	Warfarin	146	1.1	38	0.9	18	0.5	16	0.6
no	Prasugrel	105	0.8	15	0.4	8	0.2	3	0.1
tal	Ticagrelor	1277	9.2	121	2.9	52	1.5	31	1.2
To	Others	7530	54.5	1505	36.3	991	29.4	693	26.7

Table 5.10 Medication for patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014

\*Available for those who were alive \*Dual antiplatelet is combination of aspirin and clopidorel or ticlopidine #Patients were allowed to be in more than one type of category

Year	*Death cause	Outco disch	ome at arge	**30	-day	***6-1	nonth	****1	-year
I cai	Death cause	No.	%	No.	%	No.	%	No.	%
	Cardiac	290	78.2	330	66.1	378	52.9	423	44.6
1	Renal	2	0.6	2	0.4	2	0.3	2	0.2
э Э	Other	15	4.0	18	3.6	21	2.9	31	3.3
tts :	Infection	9	2.4	9	1.8	9	1.3	9	0.9
201 tier	Neurological	3	0.8	3	0.6	3	0.4	3	0.3
pai	Vascular	1	0.2	1	0.2	1	0.1	1	0.1
007 . of	Pulmonary	2	0.6	2	0.4	2	0.3	2	0.2
00. 20	Non-cardiac	0	0	8	1.6	18	2.5	30	3.2
tal	Not available	12	3.2	24	4.8	83	11.6	140	14.8
To	Missing	37	10.0	102	20.4	198	27.7	307	32.4
	Total	371	100.0	499	100.0	715	100.0	948	100.0
	Cardiac	107	78.7	113	65.7	116	55.0	120	48.0
36	Renal	0	0	0	0	0	0	0	0
, , , , , , , , , , , , , , , , , , ,	Other	8	5.9	9	5.2	11	5.2	11	4.4
nts	Infection	1	0.7	1	0.6	1	0.5	1	0.4
3 Itie	Neurological	0	0	0	0	0	0	0	0
010 pa	Vascular	0	0	0	0	0	0	0	0
. of	Pulmonary	3	2.2	3	1.7	3	1.4	3	1.2
ou	Non-cardiac	0	0	0	0	2	0.9	6	2.4
tal	Not available	3	2.2	6	3.5	8	3.8	9	3.6
$T_0$	Missing	14	10.3	40	23.3	70	33.2	100	40.0
	Total	136	100.0	172	100.0	211	100.0	250	100.0
_	Cardiac	140	76.1	145	69.0	152	63.9	153	61.2
184	Renal	4	2.2	4	1.9	4	1.7	4	1.6
П	Other	5	2.7	5	2.4	5	2.1	5	2.0
nts	Infection	3	1.6	3	1.4	3	1.3	3	1.2
4 atie	Neurological	0	0	0	0	0	0	0	0
201 f p:	Vascular	0	0	0	0	0	0	0	0
0	Pulmonary	1	0.5	1	0.5	1	0.4	1	0.4
nc	Non-cardiac	0	0	1	0.5	6	2.5	7	2.8
otal	Not available	2	1.1	3	1.4	6	2.5	8	3.2
Ľ	Missing	29	15.8	48	22.9	61	25.6	69	27.6
	Total	184	100.0	210	100.0	238	100.0	250	100.0
_	Cardiac	247	77.1	258	67.5	268	59.6	273	54.6
32(	Renal	4	1.3	4	1.0	4	0.9	4	0.8
	Other	13	4.1	14	3.7	16	3.6	16	3.2
14 ents	Infection	4	1.3	4	1.0	4	0.9	4	0.8
atio	Neurological	0	0	0	0	0	0	0	0
13 -	Vascular	0	0	0	0	0	0	0	0
201	Pulmonary	4	1.3	4	1.0	4	0.9	4	0.8
l n 🤇	Non-cardiac	0	0	1	0.3	8	1.8	13	2.6
ota	Not available	5	1.6	9	2.4	14	3.1	17	3.4
Ĕ	Missing	43	13.3	88	23.1	131	29.2	169	33.8
	Total	320	100.0	382	100.0	449	100.0	500	100.0

 \*The outcome data was derived based on National Death Register data

 \*\*Including patients who died in-hospital, \*\*\* Including patients who died in-hospital and at 30 days, \*\*\*\*Including patients who died in-hospital, at 30 days, and at six months

Year	2007 - Total no. ( = 3	– 2012 of patients 371	20 Total procedu	13 no. of res = 136	20 Total procedur	14 no. of res = 184	2013 - Total procedu	- 2014 no. of res = 320
Location of death	No.	%	No.	%	No.	%	No.	%
In lab	34	9.2	16	11.8	17	9.2	33	10.3
Out of lab	287	77.4	98	72.1	134	72.9	232	72.5
Not available	10	2.7	2	1.5	3	1.6	5	1.6
Missing	40	10.7	20	14.6	30	16.3	50	15.6
Total	371	100.0	136	100.0	184	100.0	320	100.0

Table 5.12 Location of death of patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014

Table 5.13 Outcome at discharge of patients who developed cardiogenic shock peri-procedure, NCVD-PCI Registry, 2007 – 2014

			Car	diogenic shoc	k peri-proce	dure	
Year	*Outcome	Y	es	Ň	lo	Mis	sing
		No.	%	No.	%	No.	%
012 . of s =	Death	75	69.4	295	1.2	1	1.1
7 – 2 al no tients 24459	Alive	33	30.6	23967	98.8	88	98.9
2007 Tot pa	Total	108	100.0	24262	100.0	89	100.0
• of s =	Death	33	80.5	103	1.6	0	0
2013 al no tients 6353	Alive	8	19.5	6161	98.4	48	100
Tot	Total	41	100.0	6264	100.0	48	100.0
. of 5 =	Death	43	89.6	139	1.8	2	3.7
2014 al no tients 7783	Alive	5	10.4	7542	98.2	52	96.3
Tot	Total	48	100.0	7681	100.0	54	100.0
014 • of s =	Death	76	85.4	242	1.7	2	2.0
3 – 2 al no tients [4136	Alive	13	14.6	13703	98.3	100	98.0
201 Tot Jai	Total	89	100.0	13945	100.0	102	100.0

\*The outcome data was derived based on National Death Register data

Note: Patients with the status of "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patients

				Post PCI	TIMI flow		
Year	*Outc ome	0	1	2	3	Not available	Missing
		No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)
12 esions	Death	25 (3.8)	16 (12.4)	37 (10.5)	341 (1.1)	8 (2.3)	31 (1.3)
07 – 20 no. of l = 34873	Alive	631 (96.2)	113 (87.6)	314 (89.5)	30709 (98.9)	346 (97.7)	2302 (98.7)
20 Total	Total	656 (100.0)	129 (100.0)	351 (100.0)	31050 (100.0)	354 (100.0)	2333 (100.0)
of	Death	8 (5.2)	1 (2.2)	6 (4.0)	142 (1.9)	9 (4.5)	7 (1.7)
2013 tal no. oatients = 6353	Alive	146 (94.8)	44 (97.8)	143 (96.0)	7404 (98.1)	190 (95.5)	417 (98.3)
L To	Total	154 (100.0)	45 (100.0)	149 (100.0)	7546 (100.0)	199 (100.0)	424 (100.0)
of	Death	9 (4.7)	7 (17.5)	22 (12.4)	155 (1.7)	8 (4.2)	21 (2.5)
2014 tal no. atients = 7783	Alive	181 (95.3)	33 (82.5)	155 (87.6)	9206 (98.3)	181 (95.8)	834 (97.5)
D L	Total	190 (100.0)	40 (100.0)	177 (100.0)	9361 (100.0)	189 (100.0)	855 (100.0)
14 of	Death	17 (4.9)	8 (9.4)	28 (8.6)	297 (1.8)	17 (4.4)	28 (2.2)
13 – 20 otal no. patients = 14136	Alive	327 (95.1)	77 (90.6)	298 (91.4)	16610 (98.2)	371 (95.6)	1251 (97.8)
10 10 11	Total	344 (100.0)	85 (100.0)	326 (100.0)	16907 (100.0)	388 (100.0)	1279 (100.0)

Table 5.14 Outcome at discharge, by post PCI TIMI flow, NCVD-PCI Registry, 2007 – 2014

\*The outcome data was derived based on National Death Register data Note: Patients with status of "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patients

	Total n	2007 – 2012 o. of patients :	= 24459	Total 1	2013 10. of patients	= 6353	Total 1	2014 10. of patients	= 7783	Total n	2013 – 2014 o. of patients	= 14136
Contrast volume, ml	*Death	Alive	Total	*Death	Alive	Total	*Death	Alive	Total	*Death	Alive	Total
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
≥ 300	38	1570	1608	12	295	307	7	381	388	19	676	695
	(2.4)	(97.6)	(100.0)	(3.9)	(96.1)	(100.0)	(1.8)	(98.2)	(100.0)	(2.7)	(97.3)	(100.0)
< 300	286	19959	20245	98	5059	5157	133	6302	6435	231	11361	11592
	(1.4)	(98.6)	(100.0)	(1.9)	(98.1)	(100.0)	(2.1)	(97.9)	(100.0)	(2.0)	(98.0)	(100.0)
Not available	32	1702	1734	12	466	478	25	455	480	37	921	958
	(1.8)	(98.2)	(100.0)	(2.5)	(97.5)	(100.0)	(5.2)	(94.8)	(100.0)	(3.9)	(96.1)	(100.0)
Missing	15 (1.7)	857 (98.3)	872 (100.0)	14 (3.4)	397 (96.6)	411 (100.0)	19 (4.0)	461 (96.0)	480 (100.0)	33 (3.7)	858 (96.3)	891 (100.0)

Table 5.15 Outcome at discharge, by contrast volume used, NCVD-PCI Registry, 2007 – 2014

\*The outcome data was derived based on National Death Register data Note: Patients with the status of "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patients

	2007 -	- 2012	20	13	20	14	2013 -	- 2014
	Total no. of procedures = 16329Total no. of procedures = 2No.%			no. of es = 2500	Total procedur	no. of es = 2070	Total procedur	no. of es = 4570
Readmission	No.	%	No.	%	No.	%	No.	%
Yes	910	5.6	112	4.5	122	5.9	234	5.1
No	15370	94.1	2231	89.2	1772	85.6	4003	87.6
Missing	49	0.3	157	6.3	176	8.5	333	7.3
Readmission reason, No. (%)								
Non-cardiac			10	8.9	16	13.1	26	11.1
CHF	17	1.9	6	5.4	3	2.5	9	3.8
Recurrent angina	107	11.8	8	7.1	10	8.2	18	7.7
Arrhythmia	1	0.1	0	0	0	0	0	0
ACS			7	6.3	9	7.4	16	6.8
STEMI			2	33.3	4	57.1	6	46.2
NSTEMI			3	50	1	14.3	4	30.8
UA			1	16.7	2	28.6	3	23.1
Not available			0	•	2	•	2	•
Missing			1	•	0	•	1	•
Staged revascularisation			39	34.8	57	46.7	96	41.1
PCI			36	97.3	51	96.2	87	96.7
CABG			1	2.7	2	3.8	3	3.3
Not available			1	•	0	•	1	•
Missing			1		4		5	•
PCI-planned	505	55.5	16	14.4	0	0	16	6.8
PCI-unplanned	15	1.6	0	0	0	0	0	0
CABG	12	1.3	0	0	0	0	0	0
AMI	16	1.8	0	0	0	0	0	0
Others	181	19.8	8	7.1	0	0	8	3.4
Not available	18	2.0	9	8.0	14	11.4	23	9.9
Missing	38	4.2	9	8.0	13	10.7	22	9.4
Total	910	100.0	112	99.9	122	100.0	234	100.0

Table 5.16 Summary of 30-day readmission status of patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014 (N = total no. of procedures for 30-day follow- up)

					20	13									20	14				
*Complications and clinical				Total 1	10. of p	atients	= 6353							<b>Total</b>	no. of pa	atients	= 7783			
outcomes	Elec	tive	NSTI U	EMI/ A	AN	MI	N avai	ot lable	Mis	sing	Elec	tive	NSTE A	MI/U	AN	ΛI	N avai	ot lable	Mis	sing
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Procedural complications																				1
Periprocedural MI/Significant periprocedural MI	15	0.3	4	0.7	14	1.3	0	0	0	0	23	0.4	11	1.7	28	2.2	0	0	0	0
Emergency reintervention/PCI	22	0.5	5	0.9	15	1.4	0	0	0	0	19	0.3	12	1.9	34	2.7	0	0	0	0
Stent thrombosis	4	0.1	0	0	1	0.1	0	0	0	0	4	0.1	1	0.2	4	0.3	0	0	0	0
Dissection	0	0	0	0	1	0.1	0	0	0	0	1	0.0	0	0	0	0	0	0	0	0
Cardiac perforation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Coronary perforation	1	0.0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
New ischaemia	1	0.0	0	0	1	0.1	0	0	0	0	2	0.0	1	0.2	3	0.2	0	0	0	0
Reinfarction	0	0	1	0.2	1	0.1	0	0	0	0	1	0.0	1	0.2	0	0	0	0	0	0
Cardiac tamponade	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Bail-out CABG	1	0.0	0	0	0	0	0	0	0	0	1	0.0	0	0	0	0	0	0	0	0
Cardiogenic shock	9	0.2	2	0.3	30	2.7	0	0	0	0	4	0.1	3	0.5	41	3.2	0	0	0	0
Arrhythmia	13	0.3	4	0.7	45	4.1	0	0	0	0	8	0.1	4	0.6	37	2.9	0	0	0	0
TIA/stroke	3	0.1	0	0	2	0.2	0	0	0	0	0	0	0	0	2	0.2	0	0	0	0
Tamponade	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0.2	0	0	0	0
Contrast reaction	6	0.1	1	0.2	0	0	0	0	0	0	3	0.1	0	0	0	0	0	0	0	0
New onset/worsen heart failure	3	0.1	1	0.2	8	0.7	0	0	0	0	1	0.0	0	0	9	0.7	0	0	0	0
New renal impairment	20	0.4	10	1.7	15	1.4	0	0	0	0	19	0.3	2	0.3	9	0.7	0	0	0	0
Bleeding	7	0.1	4	0.7	5	0.5	0	0	0	0	5	0.1	1	0.2	4	0.3	0	0	0	0
Access site occlusion	0	0	0	0	0	0	0	0	0	0	1	0.0	0	0	0	0	0	0	0	0
Loss of distal/radial pulse	0	0	0	0	0	0	0	0	0	0	1	0.0	0	0	0	0	0	0	0	0
Dissection	1	0.0	1	0.2	1	0.1	0	0	0	0	3	0.1	0	0	0	0	0	0	0	0
Pseudoaneurysm	2	0.0	0	0	0	0	0	0	0	0	5	0.1	0	0	1	0.1	0	0	0	0
Vascular perforation	1	0.0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

# Table 5.17 Procedural complications and clinical outcomes, according to PCI status, NCVD-PCI Registry, 2007 – 2014

\*Results are only presented for patients who had the complications or clinical outcomes

					2007 -	- 2012									2013 -	- 2014				
*Complications and clinical				Total n	o. of pa	tients =	= 24459							Total r	10. of pa	atients =	=14136			
outcomes	Elec	ctive	NSTI U	EMI/ A	AI	MI	N avai	ot lable	Mis	sing	Elec	tive	NSTE A	CMI/U A	AN	MI	N avail	ot lable	Mis	sing
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Procedural complications																				<u> </u>
Periprocedural MI/Significant																				
periprocedural MI	70	0.3	9	0.7	18	1.0	0	0	1	7.1	38	0.4	15	1.2	42	1.8	0	0	0	0
Emergency reintervention/PCI	34	0.2	9	0.7	17	0.9	0	0	1	7.1	41	0.4	17	1.4	49	2.1	0	0	0	0
Stent thrombosis	13	0.1	1	0.1	5	0.3	0	0	0	0	8	0.1	1	0.1	5	0.2	0	0	0	0
Dissection	11	0.1	2	0.2	1	0.1	0	0	0	0	1	0.0	0	0	1	0.0	0	0	0	0
Cardiac perforation											0	0	0	0	0	0	0	0	0	0
Coronary perforation											1	0.0	0	0	0	0	0	0	0	0
New ischaemia											3	0.0	1	0.1	4	0.2	0	0	0	0
Reinfarction											1	0.0	2	0.2	1	0.0	0	0	0	0
Cardiac tamponade											0	0	0	0	0	0	0	0	0	0
Bail-out CABG	5	0.0	0	0	3	0.2	0	0	0	0	2	0.0	0	0	0	0	0	0	0	0
Cardiogenic shock	37	0.2	15	1.2	56	3.1	0	0	0	0	13	0.1	5	0.4	71	3.0	0	0	0	0
Arrhythmia	66	0.3	17	1.3	57	3.1	0	0	1	7.1	21	0.2	8	0.7	82	3.5	0	0	0	0
TIA/stroke	6	0.0	2	0.2	2	0.1	0	0	0	0	3	0.0	0	0	4	0.2	0	0	0	0
Tamponade	12	0.1	2	0.2	2	0.1	0	0	0	0	0	0	0	0	2	0.1	0	0	0	0
Contrast reaction	11	0.1	0	0	4	0.2	0	0	0	0	9	0.1	1	0.1	0	0	0	0	0	0
New onset/worsen heart failure	10	0.0	2	0.2	8	0.4	0	0	0	0	4	0	1	0.1	17	0.7	0	0	0	0
New renal impairment	9	0.0	4	0.3	34	1.9	0	0	0	0	39	0.4	12	1.0	24	1.0	0	0	0	0
Bleeding	84	0.4	19	1.5	24	1.3	0	0	1	7.1	12	0.1	5	0.4	9	0.4	0	0	0	0
Access site occlusion	8	0.0	3	0.2	0	0	0	0	0	0	1	0.0	0	0	0	0	0	0	0	0
Loss of distal/radial pulse	2	0.0	0	0	0	0	0	0	0	0	1	0.0	0	0	0	0	0	0	0	0
Dissection	29	0.1	0	0	5	0.3	0	0	0	0	4	0.0	1	0.1	1	0.0	0	0	0	0
Pseudoaneurysm	16	0.1	1	0.1	0	0	0	0	0	0	7	0.1	0	0	1	0.0	0	0	0	0
Vascular perforation											1	0.0	0	0	0	0	0	0	0	0

\*Results were only presented for patients who had the complications or clinical outcomes

Heart rate at	Tota	- 2007 al no. of pa	- 2012 ntients = 24	1459	Tot	20 al no. of pa	13 atients = 6	353	Tot	20 al no. of pa	14 atients = 7	783	Tota	- 2013 1 no. of pa	- 2014 tients = 14	136
presentation	*De	eath	Ali	ive	*De	eath	Ali	ive	*De	eath	Ali	ive	*De	ath	Ali	ive
(beats/initiate)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
< 90	153	41.2	19467	80.8	49	36.1	4604	74.1	65	35.3	5724	75.3	114	35.6	10328	74.8
$\geq 90$	165	44.5	2457	10.2	63	46.3	780	12.5	86	46.8	1057	13.9	149	46.6	1837	13.3
Missing	53	14.3	2164	9.0	24	17.6	833	13.4	33	17.9	818	10.8	57	17.8	1651	11.9
Total	371	100.0	24088	100.0	136	100.0	6217	100.0	184	100.0	7599	100.0	320	100.0	13816	100.0

Table 5.18 Heart rate at presentation versus outcome, NCVD-PCI Registry, 2007 – 2014

\*The outcome data was derived based on National Death Register data Note: Patients with the status of "transferred to other centre", "lost to follow-up", "not available" and "missing" were categorised as "alive" patients

# Table 5.19 Heart rate at presentation versus length of stay, NCVD-PCI Registry, 2007 – 2014

	]	Fotal n	2007 - o. of pa	- 2012 ntients :	= 24088	8		Total r	20 10. of p	13 atients	= 6217	,		Total 1	20 10. of p	)14 atients	= 7599	)	ŗ	Fotal n	2013 - o. of pa	– 2014 atients	= 13816	6
Length of stay	v	90	٨١	90	animi M	BIIISSIIA	~	90	۸I	90		MISSIN	v	90	۸I	90		MISSIN	v	90	۸I	90	Missing	BIIIGSTIAI
Ν	189	985	23	95	21	01	46	04	73	80	8.	33	57	/21	10	57	8	18	10.	325	18	37	16	51
Mean (SD)	4.4 (	16.1)	6.8 (	28.4)	6.1 (2	29.5)	4.9 (	15.8)	6.2 (	20.4)	4.5 (	13.5)	4.8 (	(14.0)	5.8 (	13.0)	4.9 (	14.0)	4.9 (	14.8)	6.0 (	16.6)	4.7 (	13.7)
Median, (min, max)	3. (1 109	.0 .0, 8.0)	3 (1 734	.0 .0, 4.0)	3. (1 736	.0 .0, 5.0)	3 (1 375	.0 .0, 5.0)	4 (1 513	.0 .0, 3.0)	3 (1 37	.0 .0, 1.0)	3 (1 369	.0 .0, 9.0)	4 (1 368	.0 .0, 8.0)	3 (1 36	.0 .0, 7.0)	3 (1 37:	.0 .0, 5.0)	4 (1 513	.0 .0, 3.0)	3. (1. 371	.0 .0, .0)
Negative/zero, No. (%)	268	1.4	30	1.2	12	0.6	0	0	0	0	0	0	3	0.1	0	0	0	0	3	0.0	0	0	0	0
Missing, No. (%)	214	1.1	32	1.3	51	2.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

\*Alive included patients transferred to another centres

					2013 - 2014					
Factor		Total n	o. of patients	= 23843			Total n	o. of patients	= 14133	1
	Ν	Hazard ratio	95%	∕₀ CI	*p-value	Ν	Hazard ratio	95%	6 CI	*p-value
Age^	23843	1.12	1.03	1.22	0.007					
Gender										
Male (ref)						11816	1.00			
Female						2317	1.66	0.79	3.48	0.177
PCI status										
Elective (ref)	20801	1.00				10551	1.00			
NSTEMI/UA	1227	2.13	0.88	5.18	0.096	1221	3.04	1.09	8.52	0.034
AMI/STEMI	1780	3.98	2.02	7.85	< 0.001	2361	4.20	1.64	10.77	0.003
**Diabetes mellitus										
No (ref)										
Yes										
**Hypertension										
No (ref)	6383	1.00								
Yes	17443	0.59	0.35	0.99	0.047					
Killip class <sup>\$</sup>										
I (ref)	6234	1.00								
II	2936	2.36	1.13	4.93	0.022					
III	200	2.41	0.87	6.67	0.090					
IV	393	3.63	1.58	8.32	0.002					
Killip class										
I & II (ref)						5939	1.00			
III & IV						550	2.97	1.47	6.02	0.002

Table 5.20 Prognostic factors for in-hospital mortality among patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014

\* using Cox regression with backward stepwise variable selection \*\*The "No" category for these variables included "Not known" category

^Variables were not included in the variables' selection method for 2013 – 2014 analysis

\$Variables were recategorised for 2013 – 2014 analysis

Fastar		Total n	2007 – 2012 o. of patients	= 23843			Total n	2013 – 2014 o. of patients	= 14133	
ractor	Ν	Hazard ratio	95%	% CI	*p-value	Ν	Hazard ratio	95%	% CI	*p-value
Smoking status										
Never (ref)										
Former smokers										
Current smokers										
Left ventricular ejection										
fraction										
< 30	386	2.77	1.11	6.93	0.029	259	4.21	1.47	12.01	0.007
30 - 50	3549	1.37	0.61	3.09	0.448	2105	1.68	0.66	4.30	0.278
> 50 (ref)	4649	1.00				2675	1.00			
NYHA dyspnoea $\geq$ 3 or										
congestive heart failure^										
No (ref)	22265	1.00								
Yes	1557	2.01	1.18	3.43	0.010					
Cardiogenic shock <sup>^</sup>										
No (ref)	23683	1.00								
Yes	105	4.80	2.40	9.63	< 0.001					
IABP^										
No (ref)	22902	1.00								
Yes	604	2.53	1.27	5.05	0.009					
Serum creatinine (> 200										
µmol/L)										
No (ref)	20590	1.00				11447	1.00			
Yes	1116	1.88	1.06	3.34	0.03	616.00	3.42	1.64	7.11	0.001

\*using Cox regression with backward stepwise variable selection \*\*The "No" category for these variables included the "Not known" category ^Variables were not included in the variables selection method for 2013 – 2014 analysis \$Variables were recategorised for the 2013 – 2014 analysis

Factor		Total n	2007 – 2012 o. of patients :	= 15169			Total no	2013 – 2014 5. of patients :	= 14133	
Factor	Ν	Hazard ratio	95% CI		*p-value	Ν	Hazard ratio	95%	% CI	*p-value
Killip class <sup>\$</sup>										
I & II (ref)						2120	1.00			
III & IV						114	5.98	2.69	13.27	< 0.001

# Table 5.21a Prognostic factors for 30-days mortality among patients who underwent PCI, NCVD-PCI Registry, 2007 – 2014 (Multivariate analysis)

<sup>s</sup>Variables were recategorised for 2013 – 2014 analysis

Table 5.21b Prognostic factors for 30-da	vs mortality among patients y	who underwent PCI. NCVD-PO	CI Registry, 2007 –	2014 (Forced model analysis)
	/~			

Fastor		Total no	2007 – 2009 5. of patients =	= 10516			Total no	2013 – 2014 5. of patients =	= 14133	
Factor	Ν	Hazard ratio	95%	6 CI	*p-value	Ν	Hazard ratio	95%	6 CI	*p-value
Age group <sup>\$</sup>										
20 – < 30 (ref)										
30 - < 40										
40 - < 50										
50 - < 60										
60 - < 70										
70 - < 80										
$\geq 80$										
Age group <sup>\$</sup>										
20 – < 40 (ref)						235	1.00			
40 - < 60						2327	0.71	0.16	3.21	0.653
$\geq 60$						1651	1.52	0.34	6.79	0.584
Gender										
Male (ref)	12496	1.00								
Female	2673	2.36	1.35	4.12	0.003					

_		Total no	2007 – 2009 , of patients =	= 10516			Total no	2013 – 2014 ), of patients =	= 14133	
Factor	Ν	Hazard ratio	95%	- CI	*p-value	Ν	Hazard ratio	95%	o CI	*p-value
PCI status										
Elective (ref)	13672	1.00				3189	1.00			
NSTEMI/UA	675	1.61	0.57	4.54	0.370	307	2.33	0.84	6.47	0.103
AMI/STEMI	803	1.11	0.27	4.64	0.885	717	1.52	0.63	3.65	0.352
**Myocardial infarction history										
No (ref)						2638	1.00			
Yes						1575	0.44	0.18	1.05	0.066
Killip class <sup>\$</sup>										
I (ref)										
II										
III										
IV										
Killip class <sup>\$</sup>										
I & II (ref)						2120	1.00			
III & IV						114	4.22	1.69	10.55	0.002
Heart rate										
< 40										
40 - < 60										
60 – < 80 (ref)										
80 - < 100										
$\geq 100$										
Extent of coronary artery										
disease										
Single vessel disease (ref)						2832	1.00			
Multi vessels disease						1189	1.76	0.83	3.73	0.137
Left main/LMS^^						128	2.02	0.44	9.32	0.369
Graft^^						31	20.64	2.39	178.01	0.006

Factor		Total no	2007 – 2009 . of patients =	= 10516			Total no	2013 – 2014 . of patients :	= 14133	
Factor	Ν	Hazard ratio	95%	, CI	*p-value	Ν	Hazard ratio	95%	6 CI	*p-value
Left ventricular ejection										
fraction										
< 30	255	5.26	2.34	11.81	< 0.001					
30 - 50	2535	1.50	0.85	2.64	0.157					
> 50 (ref)	3420	1.00								
Serum creatinine > 200 $\mu$ mol/L										
No (ref)	13303	1.00								
Yes	678	3.19	1.65	6.18	0.001					
**Cerebrovascular disease										
No (ref)						4068	1.00			
Yes						145	1.14	0.25	5.10	0.865
Previous PCI										
No (ref)						3238	1.00			
Yes						975	0.85	0.29	2.50	0.771

\*using Cox regression

\*\*The "No" category for these variables included the "Not known" category ^Variables were not included in the variables selection method for the 2013 – 2014 analysis

^Variables were not included in the 2007 - 2012 analysis \$Variables were recategorised for 2013 - 2014 analysis

# APPENDIX A: DATA MANAGEMENT

The National Cardiovascular Disease Database (NCVD) Registry maintains two different databases for cardiovascular diseases, i.e. for Acute Coronary Syndrome and Percutaneous Coronary Intervention. Data is stored in SQL Server due to the high volume of data accumulated throughout the years.

## Data sources

Source Data Providers (SDPs) of NCVD-PCI registry comprise all major hospitals who participated in the registry, throughout Malaysia.

## Data Flow Process

This section describes the data management flow process of the National Cardiovascular Disease Database.



## SDP data reporting, data correction and submission tracking

Data reporting by SDP is done via web applications e-Case report forms.

There were a number of data security features that were designed into the NCVD web application (eCRF) such as web owner authentication, 2-level user authentication (user name and password authentication and a short messaging system (SMS) authorisation code for mobile phone authentication), access control, data encryption, session management to automatically log off the application, audit trail and data backup and disaster recovery plan.

For PCI, SDP submits NCVD-PCI notification form on an ad-hoc basis whenever a procedure is performed. SDP also submits follow-up data at 30-day, 6-month and 12-month post notification date intervals. An alert page containing all the overdue submissions for follow-up at 30-day, 6-month and 12-month post notification date is available to users to facilitate submissions tracking.

Prior to registering a patient record, a verification process is done by using the search functionality to search if the patient already exists in the entire registry. The application will still detect a duplicate record if the same MyKad number is keyed in, should this step be missed. This step is done to avoid duplicate records. For patients' whose records already exist in the database, SDP needs only to add a

new PCI notification with basic patient particulars pre-filled, based on existing patient information in the database. The PCI and ACS registries share the same patient list.

There were a few in-built functionalities at the data entry page that serve to improve data quality. One such function is auto calculation to reduce human error, in calculations. There is also an inconsistency check functionality that disables certain fields and prompts the user, if the value entered is out of range.

A real-time data query page is also available via the web application to enable users to check which non-compulsory data is missing, out of range, and inconsistent. A link is provided on the data query page for users to click to resolve the query for the particular patient.

Real time reports were also provided in the web application. The aggregated data reports are presented in tables and graphs. The aggregated data reports are typically presented in two manners, one as centre's own data aggregated data report and another as the registry's overall aggregated data report. In this way, the centre is able to compare itself against the overall registry's average.

Data download function is also available in the web application to allow users to download their own centre's data from all the forms entered, for their own further analyses. The data are downloadable in Text-tab delimited (.txt) format, Microsoft excel workbook (.xls) and as Comma separated value (.csv) format.

#### Edit checks run and data cleaning

Edit checks is performed periodically by the registry manager to identify missing compulsory data, outof-range values, inconsistency of data, invalid values, and errors with de-duplication. Data cleaning is then performed based on the results of edit checks. Data update and data checking of the dataset were performed when there is a query of certain fields as and when necessary. It could be due to request by user, correction of data based on checking via data query in eCRF or after receiving results for preliminary data analysis. During data standardisation, missing data were handled based on derivation from existing data. Data de-duplication is also performed to identify duplicate records in the database that might have been missed out by SDPs. Finally, matching the record against the National Death Register (*Jabatan Pendaftaran Negara*) database is performed to verify the mortality status of the patient.

#### Final query resolution/data cleaning/database lock

A final edit check run is performed to ensure that the data is clean. All queries will be resolved before the database is locked, to ensure data quality and integrity. The final dataset is subsequently locked and exported to the statistician for analysis.

#### Data analysis

Please refer to the Statistical Analysis Method section for further details.

#### Data release policy

One of the primary objectives of the Registry is to make data available to the cardiovascular healthcare providers, policy makers and researchers. The Registry would appreciate that users acknowledge the Registry for the use of the data. Any request for data that requires a computer run must be made in writing (by e-mail, fax, or registered mail) accompanied with a Data Release Application Form and signed Data Release Agreement Form. These requests need prior approval by the Advisory Board before data can be released.

#### **Registry ICT infrastructure and data centre**

The operation of the NCVD is supported by an extensive ICT infrastructure to ensure operational efficiency and effectiveness.

NCVD subscribes to co-location service with a high availability and highly secured Internet Data Centre at Cyberjaya in order to provide NCVD with quality assured internet hosting services and stateof-the-art physical and logical security features without having to invest in costly data centre setup internally. Physical security features implemented includes state-of-the-art security features such as anti-static raised flooring, fire protection with smoke and heat alarm warning system, biometric security access, video camera surveillance system, uninterrupted power supply, environmental control, etc.

Other managed security services include patch management of the servers, antivirus signature monitoring and update, firewall traffic monitoring and intrusion detection, security incidence response, data backup service done on a daily, weekly and monthly basis, data recovery simulation to verify that the backup works, which is done at least once yearly, network security scan and penetration test done on a half-yearly basis, security policy maintenance, maintenance and monitoring of audit trail of user access, etc. Managed system services such as usage and performance report, operating system maintenance and monitoring, bandwidth monitoring and systems health monitoring were also provided.

# **APPENDIX B: STATISTICAL METHODS**

The analysis described below was conducted on data collected in the NCVD-PCI registry for 2013 and 2014. Inclusion criteria were all patients who had PCI procedures performed in 2013 or 2014 and were aged 20 years and above. In general, the unit of analysis was PCI procedures performed or treated lesions. However, for some results, a patient level analysis was conducted.

Regarding the CRFs used for data collection: Data on some of the patients with PCI procedure in 2013 was collected using an earlier version of the CRF (version 1.4). Whereas other patient data was collected using the new CRF (version 1.5). In the new CRF, certain variables such as IABP, PCI status for STEMI, functional ischaemia, were collected in a different format and categorisation. Therefore, in the data preparation process, we combined the information for these variables in order that the data could be analysed appropriately.

Statistical methods used mainly descriptive analysis. For discrete data, we calculated frequency and percentages; while for continuous data, the mean, standard deviation (SD), median, minimum and maximum values were calculated. The only exception to this was regression analysis performed to evaluate prognostic factors for in-hospital mortality and 30-day mortality.

Missing data was reported for both discrete and continuous data. No statistical imputation was applied to replace any missing data. Acceptable ranges for different characteristics are presented in the table below:-

Name of the field	Acceptable range
Age	$\geq$ 20 years old
Height	130 – 250 cm
Weight	40 – 200 kg
Body mass index (BMI)	$14 - 50 \text{ kgm}^{-2}$
Heart rate	25 – 200 beats/min
Systolic blood pressure	60 – 230 mmHg
Diastolic blood pressure	10 – 120 mmHg
Creatinine	44 – 2000 micromol/L
Total cholesterol (TC)	2.0 - 5.0  mmol/L
Low-density lipoprotein (LDL)	0.7 – 20.0 mmol/L
Ejection fraction status	10-80 %
Fluoroscopy time	2.0 - 180.0 minutes
Contrast volume	15.0 – 500.0 mL
Pre-stenosis	0 – 100 %
Post-stenosis	0 – 100 %
Estimated lesion length	1.0 – 150.0 mm
Stent length	8.0 – 80.0 mm
Stent diameter	2.0 – 7.0 mm
Maximum balloon size used	1.0 – 6.0 mm
Maximum stent/balloon deploy pressure	1.0 – 40.0 mm
HbA1c	4.0 - 32.0 %

Analysis performed for each report chapter is described below:

## 1. Chapter 1: Patient characteristics

Patient characteristics were summarised in Chapter 1. Numbers of patients in each year were determined based on their PCI procedure year. The results presented the patients' age, gender, ethnicity, coronary risk factors, comorbidities, lab investigations, previous interventions, and other variables contained in the CRF.

#### 2. Chapter 2: Clinical presentations and investigations

Chapter 2 included an analysis of clinical presentation, baseline investigations, cardiac status such as NYHA and Killip class, Canadian Cardiovascular Score and IABP use at PCI procedure. An analysis of STEMI time-to-treatment was performed in which we excluded any illogical values for time-to-treatment (such as negative values for symptom-to-door and door-to-balloon time).

## 3. Chapter 3: Procedural setting

Chapter 3 included an analysis of the procedural details and treatment received by the patients. This chapter includes results for PCI procedure characteristics, duration of thienopyridine use, PCI and access site.

#### 4. Chapter 4: Lesion characteristics

Lesion characteristics were summarised in Chapter 4. This chapter included location of lesion, types of lesion, types of stent, types of intracoronary devices used, stent diameter, stent length and TIMI flow. Sub-group analyses were performed for PCI to left main stem, in-stent restenosis and graft lesion and CTO. In this chapter, numbers of lesions in each year were used as the denominator in the results. This was unlike other chapters where numbers of patients was the denominator.

#### 5. Chapter 5: Outcome

The overall in-hospital mortality, all-cause mortality, post-procedural complications, medications and patient outcome at discharge and follow-up (30-days, six months, and one year) are presented in Chapter 5. In order to evaluate the status of patients (whether alive or deceased), individual patients were matched against the status provided by the Malaysian National Registration Department (NRD). Patients were considered as alive at the time of follow-up if the death date was not provided in the NRD dataset.

## APPENDIX C: PARTICIPATING CENTRE DIRECTORY

**SDP Code: 1001 Pusat Perubatan Universiti Malaya** Department of Medicine, Lembah Pantai, 59100 KUALA LUMPUR

**SDP Code: 1004 Hospital Pulau Pinang** Department of Cardiology, Jalan Residensi, 10990 PULAU PINANG

**SDP Code: 1006 Hospital Sultanah Aminah** Department of Cardiology, Jalan Skudai, 80100 Johor Bahru, JOHOR

**SDP Code: 1012 Hospital Raja Permaisuri Bainun** Department of Cardiology, 145 Jalan Tun Razak, 50400 KUALA LUMPUR

**SDP Code: 1014 Hospital Raja Perempuan Zainab II** Department of Cardiology, 145 Jalan Tun Razak, 50400 KUALA LUMPUR

**SDP Code: 1020 Hospital Serdang** *Department of Cardiology, Jalan Puchong, 43000 Kajang, SELANGOR* 

SDP Code: 1028 Hospital Queen Elizabeth II Department of Cardiology, Lorong Bersatu, Off Jalan Damai, 88300 Luyang, Kota Kinabalu, SABAH

SDP Code: 1033 UiTM Sg. Buloh Campus Jalan Hospital, 47000 Sungai Buloh, SELANGOR **SDP Code: 1002 Institut Jantung Negara** Department of Cardiology, 145 Jalan Tun Razak, 50400 KUALA LUMPUR

**SDP Code: 1005 Pusat Jantung Hospital Umum Sarawak** *Kota Samarahan Expressway, 94300 Kuching, SARAWAK* 

**SDP Code: 1009 Hospital Sultanah Bahiyah** Department of Cardiology, KM 6, Jalan Langgar, 05460 Alor Setar, KEDAH

**SDP Code: 1013 Hospital Sultanah Nur Zahirah** *Department of Cardiology, Jalan Sultan Mahmud,* 20400 Kuala Terengganu, TERENGGANU

**SDP Code: 1016 Hospital Tengku Ampuan Afzan** Department of Cardiology, Jalan Tanah Putih, 25100 Kuantan, PAHANG

SDP Code: 1024 Subang Jaya Medical Centre 1, Jalan SS 12/1A, 47500 Subang Jaya, SELANGOR

SDP Code: 1030 Pantai Hospital Ipoh Jalan Tambun, 31400 Ipoh, PERAK

## **APPENDIX D: NOTE OF APPRECIATION**

A heart-felt appreciation is extended to all who had contributed to the successful publication of this report.

#### <u>PUSAT PERUBATAN UNIVERSITI</u> MALAYA

Dr Wan Azman Wan Ahmad Dr Alexander Loch Dr Imran Zainal Abidin Dr Chee Kok Han Dr Ramesh Singh Arjan Singh Dr Timothy James Watson Dr Muhammad Dzafir Ismail Dr Ahmad Syadi Mahmood Zuhdi Dr Ganiga Srinivasaiah Sridhar Dr Nor Ashikin Md Sari Dr Lee Zhen-Vin Dr Mohd Firdaus Hadi Dr Muhammad Imran Abdul Hafidz Dr Mon Myat Oo Yusliati Ahmad Zairani Abidin Chong Kun Jin Nur Azilah Abdul Rahman Mohd Zaki Mohd Ariff Mohd Saiful Lazmi Mohammad Fauzi Azrul Hisyam Yahaya Muhammad Khalini Abdul Halim Atikah Rossli Sthuwaibah Aslamiah Ahmad Najdi Mohd Suhairi Mohamad Amierul Ameen Rosli Hani Kamarudin Nur Yuhana Sarikat Sukanya Subramaniam Nor Fairuz Husna Alias Sinthu Bairavi Tharamalingam Noor Fatin Izzati Abu Hashim Nur Hafizah Mohd Nawi Midah Abas Normi Yusuf Ruziah Khalib Noranizah Sukarman Erfa Emarina A. Rahman Selva Rani G. Krishnan Yew Lee Khoon Siti Aminah Che Abdul Manan Kartini Abd Wahid Sabariah Hashim Norziah Abu Bakar Norhayati Saji Norzihawati Sireahni Fazilah Suib Teepa Rani Velayutham Siti Zulia Zulkifli Husna Sulman Fadhilah Abd Aziz Kalalarasi Karuppusamy Norasiah Awang Dolah

## HOSPITAL SULTANAH AMINAH

Dr Lee Chuey Yan Dr Benjamin Leo Cheang Leng Dr Gunasegaran Ramasamy Dr Kam Ji Yen Dr Ang Kai Ping Joriah Rosni Norliza Abd Rahman Siti Fatimah Abdullah Sangguro

#### **HOSPITAL SULTANAH BAHIYAH**

Dr Saravanan Krishinan Dr Abd Syukur Bin Abdullah Dr Billy Chng Seng Keat Dr Ahmad Shukri b. Md Saad Dr Wan Faizal Wan Rahimi Dr Hasmannizar Abd Manap Napisah Shafie Che Kalsom Md Saad Rashida Omar Zarina Abdul Hamid Khodijah Mat Isa Survati Md Derus Salina Samsudin Noor Hafiza Sharmila Ismail Khairul Faizal Rashida Omar Aminah Yaakop

#### **HOSPITAL PANTAI IPOH**

Dr Kevin Louis Joseph Martin Joseph Dr Philip Ho Yew Choong Dr Chan Chong Guan Dr Inderjit Singh Bagher Singh Lily Theresa Pritham Koor

#### **HOSPITAL PULAU PINANG**

Dr Omar Ismail Dr Ainol Shareha Sahar Dr Muhamad Ali Sheikh Abdul Kader Dr Kong Poi Keong Dr Saravanan Krishinan Dr Mohamed Jahangir Abdul Wahab Dr Shahul Hamid Ahmad Sha Dr Goh Chong Aik Dr Ng Jit Beng Dr Mohd Nazrulhisham Naser Nik Romizi Nik Mat Teh Tang Tong Gunachandran Veloo Firdaus Mohd Ali Kanabathy Ng Ghim Keow
Syarwani Yusuf Menaka Govindankuty Saraswathy Munusamy Norafiza Abdullah Rusdi Idrus Muniswari Rati Arumugam

#### <u>PUSAT JANTUNG HOSPITAL UMUM</u> SARAWAK

Dr Sim Kui Hian Dr Ong Tiong Kiam Dr Alan Fong Yean Yip Dr Nor Hanim Mohd Amin Dr Yew Kuan Leong Dr Khiew Ning Zan Dr Tan Sian Kong Dr Cham Yee Ling Dr Chua Seng Keong Dr Asri Said Zalina Mat Danny Day Dudu Lily Dunstan Muda Cynthia Nobert Meriter Choo Siew Yin Syamsukinah Abdullah Ritem Gundek Willson Johan Rosnani Yusri Zukhairi Bek Tarmizi Tukimin Felicia Limah John Ahad Elizabeth Jong Hui Yen Tan Ah Hong Juriah Sulehan Felicia Chin Elizabeth Jega Jenggut

#### HOSPITAL QUEEN ELIZABETH II

Dr Liew Houng Bang Dr Chu Chong Mow Dr Jeremy Robert Dr Mohd Khairi Othman Dr Sahrin Saharudin Dr Beh Boon Cong Dr Lee Yu Wei Dr Yen Chia How Dr Prem Nathan Arumuganathan Dr Tan Nee Hooi Siti Rahmah Idris Litta Jacob Juinie Minin Angie Anthony Siti Ainsah Razali Fakri Hamzie Muhamad Yusof Jovce Hiew Nanthini Vijaykumaran Maria Sofyana Mursin Licina Chai @ Mohd Ridzuan Leon Irwin Stephen

Dyann Viviann Jonius

## INSTITUT JANTUNG NEGARA

Dr Robaayah Zambahari Dr Azhari Rosman Dr Rosli Mohd Ali Dr David Chew Soon Ping Dr Razali Omar Dr Mohd Nasir Muda Dr Aizai Azan Abd Rahim Dr Amin Ariff Nuruddin Dr Azlan Hussin Dr Ahmad Khairuddin Mohamed Yusof Dr Shaiful Azmi Yahaya Dr K Balachandran Dr Sanjiv Joshi Hari Chand Dr Surinder Kaur Khelae Dr Lim Bee Chian Dr Syahidah Syed Tamin Dr Emily Tan Lay Koon Dr Al Fazir Omar Dr Mahmood Sabrudin Zulkifli Dr Azmee Mohd Ghazi Dr Shamruz Khan Akerem Khan Dr Lau Gin Choy Dr Jaideep Singh Sidhu Dr Shahrul Zuraidi Idris Dr Tee Chee Hian Dr Zulkeflee Muhammad Dr Shakeel Ahmed Memon Dr Hafidz Abd Hadi Dr Akmal Hakim Arshad Dr Teoh Chee Kiang Dr Kumara Gurupparan Ganesan Dr Koh Kok Wei Dr Beni Isman Rusani Dr Ika Faizura Mohd Nor Dr Shahrol Anuar Mohd Yasin Dr Dhanan Umadevan Dr Alan Koay Choon Chern Dr Mohan Ramachandran Dr Barveen Aisya Abu Baker Dr Yap Lok Bin Dr Navin Sukilan Dr Jayakhanthan Kolanthai Velu Dr Yap Swee Hien Dr Rafidah Abu Bakar Dr Nandakumar Ramakrishnan Dr Rubenthiran Navaratnam Dr Ng Yau Piow Siti Nurzaliana Mohd Safari Zulaikha Zainal Nur Khalilah Abdul Hakim Nor Faiqah Ahmad Nabilah Huda Mohd Ismail Noor Bashiroh Md Said Akmashatila Mohamad Tan Nor Amira Baharudin

and Other members of Clinical Research Department (indirectly involved, i.e.: follow up call)

## HOSPITAL SERDANG

Dr Abdul Kahar Abdul Ghapar Dr Koh Hui Beng Dr Diana Shahida Dr Norfaziela Jaafar Siti Salmor Talib Juliana Nyadong Suhaila Abu Bakar Norziliana Nordin

# HOSPITAL TENGKU AMPUAN AFZAN

Dr Siti Khairani Zainal Abidin Dr Anwar Irawan Ruhani Dr Shahidi Jamaludin Dr Norhalwani Habizal Dr Noor Darinah Chooi Lee Ling Zuhaini Ismail Hasnah Hamat Noor Fauziah Muhammad Wan Norfaizah Wan Abdullah Issa Norhafizza Tajuddin Siti Nor Ashraf Ahmad Nori Marina Mohd Nawi Roslan Azali Mohammad Azhar Mat Saman Mohd Saiful Izad Shafuddin Syed Yusri Saiyed Ibrahim Wan Norazlees Wan Majid Nor Suriana Abdulla Mohd Shahazrie Mohd Yusof Mohd Rasmanizam Seman Hamizan Zakaria Mohammad Khodori Shafiei

# HOSPITAL SULTANAH NUR ZAHIRAH

Dr Mohd Sapawi Mohamad Dr Zulkifli Mustapha Dr Ahmad Wazi Ramli Hidayah Omar Rina Muhamad Nafisah Othman

#### SUBANG JAYA MEDICAL CENTRE

Dr Choo Gim Hooi Dr Hj Nik Ishak Wan Abdullah Dr Jeyamalar Rajadurai D. Kannan Pasamanickam Dr Lawrence Chan Hon Wah Dr Betty Teh Bee Tee Yen Sze Whey Chee Ai Lieng Divinashini Manogeran Yusniza Noor Farizan Mohd

## HOSPITAL RAJA PERMAISURI BAINUN

Dr Asri Ranga Abdullah Dr Vijay Vengkat Sivanesan Seevagan Nor Azura Tamlaha Suriati Che Ros Norliyana Mat Yusof Idayu Mohd Din Huslinawati Hussin Mohamad Al-Walid Ramlee Hazleena Mohamed Hasnan Sharifah Noor Hidayah Mohd Zamani Katrine Julie Iruthayam Mahboob Jailani Rahumat Ali Chan Tze Ming

#### **UITM SG. BULOH**

Dr Sazzli Shahlan Kasim Dr Zubin Othman Ibrahim Dr Mohd Kamal Mohd Arshad Dr Johan Rizwal Ismail Dr Effarezan Abdul Rahman Dr Lim Chiao Wen Dr Hafisyatul Aiza Zainal Abidin Dr Nicholas Chua Yul Chye Dr Rizmy Najme Khir Roseerviyana Ahmad Noorlizah @ Wendy Usul Mohd Harfizzaq Anuar Rosazelah Bt Mansor Nurdivana Md Hassan Salehah Ab Rahim Siti Syailiza Ismail Mohd Naqiuddin Abd Rahman Nurnadiah Bahari

#### HOSPITAL RAJA PEREMPUAN ZAINAB II

Dr Mansor Yahya Dr Azerin Othman Wan Ruzita Wan Hassan Faridah Ab Rahman Che Roselina Ab Rahman Norna Zura Saidinal Ali Norzubaidah Bedin

## ALTUS SOLUTIONS SDN BHD

Lim Jie Ying Sebastian Thoo Amy R Porle Abdul Malik Tanjeng

## AZMI BURHANI CONSULTING SDN BHD

Siti Haryanie Abdul Aziz Yee Siau Lin

# **APPENDIX E: GLOSSARY**

Access site occlusion	Indicates whether an access site occlusion occurred at the site of percutaneous entry during the procedure or after the laboratory visit, but before any subsequent laboratory visits. This is defined as total obstruction of the artery usually by thrombus (but may have other causes) usually at the site of access, requiring surgical repair. Occlusions may be accompanied by absence of palpable pulse or Doppler.
Acute Coronary Syndrome (ACS)	Indicates if the patient is suffering from an ACS event. ACS encompasses clinical features comprising chest pain or overwhelming shortness of breath, defined by accompanying clinical, ECG, and biochemical features. ACS comprises the following: - Unstable Angina Pectoris (UAP) - NSTEMI - STEMI
Bail-out CABG	Urgent/emergent CABG as a complication related to the index PCI (e.g. secondary to stent thrombosis, left main or TVR dissection, coronary perforation, unsuccessful INDEX PCI). This also applies to where the CABG was precipitated due to worsening, sudden chest pain, CHF, AMI, or anatomy.
Bleeding	The person's episode of bleeding as described by the thrombolysis in myocardial infarction (TIMI) criteria. Indicate if bleeding occurred during or after the cath. lab visit until discharge. The bleeding should require a transfusion and/or prolong the hospital stay and/or cause a drop in haemoglobin $> 3.0$ gm/dl.
Body Mass Index (BMI)	A measurement of the relative percentages of fat and muscle mass in the human body, in which weight in kilograms is divided by height in metres and the result used as an index of obesity (kgm <sup>-2</sup> ). This will be autocalculated by the system.
Canadian Cardiovascular Score (CCS)	<ul> <li>Indicates the Canadian Cardiovascular Angina Classification Score (CCS) of a patient which is categorised as:</li> <li>Class 0: Asymptomatic</li> <li>Class 1: Ordinary physical activity, such as walking or climbing the stairs does not cause angina. Angina may occur with strenuous, rapid or prolonged exertion at work or recreation.</li> <li>Class 2: There is a slight limitation to ordinary activity. Angina may occur with moderate activity such as walking or climbing stairs rapidly, walking uphill, walking or climbing stairs after meals, in the cold, in the wind, or under emotional stress, or walking more than two blocks on the level, and climbing more than one flight of stairs at normal pace under normal conditions.</li> <li>Class 3: There is marked limitation to ordinary physical activity. Angina may occur after walking one or two blocks on the level or climbing one flight of stairs under normal conditions at a normal pace.</li> <li>Class 4: There is inability to carry on any physical activity without discomfort; angina may be present at rest.</li> </ul>

Cardiogenic shock	<ul> <li>Indicates if the patient fulfilled the clinical criteria for cardiogenic shock as follows:</li> <li>a. hypotension (a systolic BP of &lt; 90 mmHg for at least 30 minutes or the need for supportive measures to maintain a systolic BP of &gt; 90 mmHg).</li> <li>b. end-organ hypoperfusion (cool extremities or a urine output of less than 30 ml/h, and a heart rate &gt; 60 beats per minute).</li> <li>c. the haemodynamic criteria are a cardiac index of no more than 2.2 l/min per square meter of body-surface area and a pulmonary-capillary wedge pressure of at least 15 mmHg.</li> </ul>
Chronic renal failure	Indicates if the patient has a history and/or documented evidence and/or have undergone treatment for chronic renal failure. Includes all patients with creatinine 200 micromol/L.
Contralateral Injections	Injection of contrast injected in the opposite non-occluded vessel.
Current smoker	Patient who regularly smokes a tobacco product/products one or more times per day or has smoked within the 30 days prior to this admission.
Diabetes	Indicates if the patient has diabetes as documented by the following: 1. A history of diabetes, regardless of duration of disease, or need for antidiabetic agents, or 2. Fasting blood glucose > 7.0 mmol/L, or 3. HbA1c > 6.5 mmol/L
Direct stenting	Stent deployment without prior treatment of stenotic segment.
Dissection (post procedure)	Indicates for the treated segment (or for a significant side branch) if a dissection $> 5$ mm was observed during the PCI procedure. Dissection is defined as the appearance of contrast materials outside of the expected luminal dimensions of the target vessel and extending longitudinally beyond the length of the lesion.
Dissection (vascular)	Indicates whether a dissection occurred at the site of percutaneous entry during the procedure or after lab visit but before any subsequent lab visits. A dissection is defined as a disruption of an arterial wall resulting in splitting and separation of the intimal (subintimal) layers.
Documented CAD	Indicates if the patient has angiographically-proven coronary disease (stenosis $> 50\%$ ) or has undergone percutaneous angioplasty (PCI) or coronary artery bypass graft (CABG) prior to this admission to the hospital.
Door to balloon time	The duration between time patient presented to the reporting centre to time of first intracoronary device used performed by the same centre. Applicable only to patients with STEMI undergoing urgent PCI.
Door to needle time	The duration between time patients presented to the reporting centre to time intravenous fibrinolytic therapy was administered or initiated by that same centre. Applicable only to STEMI patients receiving thrombolysis at the reporting centre.
Elective PCI	PCI performed for patients with stable CAD.
Emergency Reintervention/PCI	Indicates if the patient required an UNPLANNED PCI during hospitalisation and prior to discharge that occurs as a complication related to the index PCI e.g., – stent thrombosis, dissection with target vessel occlusion).
French size	The French size of the guiding catheter or guiding sheath used to cannulate the ostium of the coronary artery. The largest size used should be indicated.

Functional ischaemia	Indicates if the patient has functional ischaemia as indicated by a non- invasive test such as exercise or pharmacological stress test, radionuclide, echo, CT scan done to rule out ischaemia. The test could be performed at admission (prior to the PCI), or it could be a test that resulted in the admission.
Glomerular Filtration Rate (MDRD)	Glomerular filtration rate (GFR) is the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time calculated using the Modification of Diet in Renal Disease (MDRD) formula. GFR MDRD = 186 x (serum creatinine ( $\mu$ mol/L) / 88.4) -1.154 x AGE-0.203 x (0.742 if female). The unit is mL/min/1.73m <sup>2</sup> .
Intra Aortic Balloon Pump (IABP)	Indicates if an Intra Aortic Balloon Pump has been used during the procedure.
Killip classification	Identifies the Killip class, as a measure of haemodynamics compromise, of the person at the time of presentation <b>Class I</b> includes individuals with no clinical signs of heart failure <b>Class II</b> includes individuals with rales in the lungs, an S3 gallop, and elevated jugular venous pressure <b>Class III</b> describes individuals with frank pulmonary oedema <b>Class IV</b> describes individuals in cardiogenic shock
Lesion code	Indicates the sites of lesion treated by PCI.
Lesion result	Indicates for the treated lesion whether the treatment was successful or unsuccessful.
Lesion type	The lesion type according to ACC/AHA guidelines that determines the complexity of the lesions thus determining the success rate and complication rates following PCI.
Loss of radial pulse	Indicates whether an acute loss of the pulse radial to the arterial access site occurred either by dissection, thrombus, or distal embolisation.
LVEF	The left ventricular ejection fraction as measured by the percentage of the blood emptied from the left ventricle at the end of the contraction. Indicates the EF status at the time of PCI procedure. The most recent test within the last six months, including the current procedure and up to discharge following the procedure.
Medina Classification	It involves assigning a binary value $(1, 0)$ to each of the three components of a bifurcation (proximal region of main branch, distal region of main branch, and the side branch) depending whether there is more than $(1)$ or less than $(0)$ fifty percent lesion stenosis. If only proximal segment of the main branch has a significant lesion, it becomes Medina 1 ,0, 0. If distal segment of main branch alone is involved, it becomes 0, 1, 0. Sole involvement of side branch is designated 0, 0, 1 and involvement of all the three is designated 1, 1, 1 and so on.
No Reflow	Indicates for the treated segment if there was a period where no flow was noted during the PCI procedure.

New York Heart Association	<ul> <li>Indicates the patient's NYHA classification as follows:</li> <li>I. Patient has cardiac disease but without resulting limitations to ordinary physical activity; ordinary physical activity (e.g. walking several blocks or climbing stairs) does not cause undue fatigue or dyspnoea. Limiting symptoms may occur with marked exertion.</li> <li>II. Patient has cardiac disease resulting in slight limitation to ordinary physical activity. Patient is comfortable at rest. Ordinary physical activity such as walking more than two blocks or climbing more than one flight of stairs results in limiting symptoms (e.g., fatigue or dyspnoea).</li> <li>III. Patient has cardiac disease resulting in marked limitation of physical activity. Patient is comfortable at rest. Less than ordinary physical activity (e.g., walking one to two level blocks or climbing one flight of stairs) causes fatigue or dyspnoea.</li> <li>IV. Patient has dyspnoea at rest that increases with any physical activity. Patient has cardiac disease resulting in inability to perform any physical activity without discomfort. Symptoms may be present even at rest. If any physical activity is undertaken, discomfort is increased.</li> </ul>
Percutaneous entry	Indicates the percutaneous entry location used to provide vascular access for the procedure.
Perforation	Indicates for the treated segment if a perforation occurred during the procedure.
Pre-stenosis	Indicates the % of most severe pre-procedure stenosis assessed. This does not include collateral circulation.
Pseudoaneurysm	Indicates whether a pseudoaneurysm occurred at the site of percutaneous entry during the procedure or after the laboratory visit but before any subsequent laboratory visits. This does not account for pseudoaneurysms noted after discharge. Pseudoaneurysm is defined as the occurrence of a disruption and dilation of the arterial wall without identification of the arterial wall layers at the site of the catheter entry, as demonstrated by arteriography or ultrasound.
Smoking status	Indicates if the patient has a history confirming any form of tobacco use in the past. This includes the use of cigarettes/cigars/pipes/ tobacco chewing.
Status - Elective	PCI performed in patient with stable CAD either planned/staged PCI following coronary angiogram done earlier or PCI performed during the time of angiogram (ad-hoc).
Status - NSTEMI/UA	PCI for patients admitted with NSTEMI/UA.
Status - STEMI	PCI for patient admitted with STEMI following different treatment strategies.
TIA / Stroke	Indicates if the patient experienced a cerebrovascular accident (CVA) noted during the cath lab visit or after lab visit until discharge (or before any subsequent lab visits), as documented by CT/MRI confirmation.
Time of first balloon inflation / stent / aspiration	Indicates the time of the intracoronary treatment device deployment.
TIMI Flow (Post)	Indicates the post-procedure TIMI flow down the treated vessel.
TIMI Flow (Pre)	Indicates the pre-procedure TIMI flow down the treated vessel.
Vascular perforation	Perforation of the peripheral vessel where the catheter/sheath/wire is being tracked.

**APPENDIX F: CASE REPORT FORM**